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ABSTRACT 
Introduction: Tuberculosis (TB) is major scourge for human history and causes 
profound economic burden. Bangladesh is a high burden TB country with 12% of its 
annual death is caused and 362 thousand people are infected by TB. DS-TB is the most 
prominent type of TB found in Bangladesh and a 6 month drug regimen (2 month 
intensive and 4 month continuation phase) is followed. But the directly observed 
treatment short-course (DOTS) differ in delivery through community health workers 
(CHW) and community members (CM). Bangladesh has also experienced surge in the 
number of MDR-TB cases with a 29% of MDR-TB cases were found among the re-
treatment of pulmonary TB cases in 2015. In Bangladesh, two MDR-TB treatment 
regimens (9 month and 20-24 month) are practiced. This dissertation aims to estimates 
the economic burden of TB on the afflicted Bangladeshi population and conducts 
economic evaluation among different programs for DS-TB and MDR-TB in Bangladesh. 
Methods: This study collects direct and indirect cost for TB care data from 1,000 
drug sensitive TB (DS-TB) and 145 multi-drug resistant (MDR-TB) patients from all 
over Bangladesh. Provider cost for TB care was also collected from the health facilities. 
Costs for DS-TB and MDR-TB patients were estimated using Generalized Linear Model 
and summed up with per patient provider level costs to get the total costs per TB patients.   
The incremental cost-effectiveness ratio (ICER) of treating DS-TB and MDR-TB 
patients, CM versus CHW model for DS-TB and 9-month vs. 20-24 month regimen for
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MDR-TB were compared using a Markov model with life-time horizon. The measure of 
effectiveness, Quality adjusted life year (QALY) and cost of treatment was collected 
from 1,000 DS-TB and 145 MDR-TB patients (598 for CM model and 402 from CHW 
model; 58 undergone 9 month treatment and 87 from 20-24 month regimen) in 
Bangladesh. Transition probabilities between Markov states were estimated from 
quarterly outcomes report collected from health facilities and cost and QALY both were 
discounted at a rate of 3%. Both deterministic and probabilistic sensitivity analyses were 
conducted in a Monte Carlo Simulation using R.  
Results: Mean age of DS-TB patients under the study was 45.2 years while mean 
age of MDR-TB patients were 35.5 years. In aggregate, DS-TB patients incurred total 
average costs of BDT 21,235 (USD 265) for TB illness; while MDR-TB patients’ 
average costs were BDT 34,975 (USD 437). Including provider costs for each patient 
(USD 9 for DSTB and USD 2,006 for MDR-TB patients) total average costs for each DS-
TB patient was BDT 22,003 (USD 275) and for each MDR-TB patient was BDT 
1,95,449 (USD 2443).  
Assuming 57% case notification rate, the actual costs for treating TB patients in 
2015 was USD 55.6 million. If all DS-TB patients were treated the cost would have been 
1 billion USD.  For MDR-TB treatment, total cost was USD 12.5 million; treating all 
MDR-TB patients would have costed USD 23 million. 
Results show that each DS-TB patient under CM treatment model gains 3.61 
QALYs with a cost of BDT 131,555. For the DS-TB patients under the CHW model the 
cost is 81,650 and the QALY gain is 3.12. The Incremental Cost-Effectiveness Ratio 
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(ICER) is 103,454, i.e., the CM model is cost-effective if per QALY gain if willingness-
to-pay is set to the per capita GDP of Bangladesh (BDT 107,360 in 2015). 
Based on the study data, each patient under 9 month regimen gained 6.21 QALY 
with a total cost of BDT 987,418. Whereas, each patient under CHW model gained 5.74 
QALY by incurring costs of BDT 1,501,221. Therefore, 9 month regimen is clearly 
dominating over the 20-24 month regimen because it costs less while it gains more 
QALY.  
Conclusions: Results show that DS-TB patients incurred about 50% of their 
household annual income for treatment while that goes up to 66% for the MDR-TB 
patients. Pre-diagnosis cost constitutes about 63% of total costs for DS-TB patients and 
42% of MDR-TB patient costs. This figures show the significant economic burden posed 
by TB and early diagnosis of the disease can reduce the burden in great extent.  
Our study results demonstrate that community based model of DS-TB treatment is 
cost-effective even with changed costs and utility values in probabilistic sensitivity 
analysis. Community members as DOTS provider are more capable of reducing stigma 
related to TB, enhancing patient adherence and thereby reduce costs and increase utility 
from the treatment. Community members should also be involved in contact tracing and 
prevention activities to increase the effect of the involvement in TB control. 
Our study results also suggest that shorter regimen remains cost-effective in 
Bangladesh setting with changing costs and utility parameters changed in the 
probabilistic sensitivity analysis. MDR-TB treatment is itself cost-effective in developed 
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countries and with cost-effective shorter regimen both treatment adherence and efficacy 
of the treatment will be improved.  
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PREFACE 
American Psychological Association, 6th edition was used in the dissertation. 
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CHAPTER 1 
INTRODUCTION 
1.1 STATEMENT OF THE PROBLEM AND RATIONALE 
In 2015, Tuberculosis (TB) ranked 18th among the highest burden diseases 
globally and it constituted 47% of the global burden attributable to communicable, 
maternal, neonatal, and nutritional disorders (Kassebaum et al., 2016). In 2015, 10 
million new cases of TB were reported and almost two million people died from TB 
worldwide (World Health Organization (WHO), 2016a).  In 2015, TB became the top 
infectious disease killer by claiming With the me1.1 million lives by matching the death 
tolls by HIV/AIDS (Kassebaum et al., 2016). 
Almost 85% of all new cases of TB and multi-drug resistant TB (MDR-TB) occur 
in 30 high burden TB countries and Bangladesh is one them (World Health Organization 
(WHO), 2015b). In 2015, 362,000 Bangladeshis developed TB and 73,000 died from it. 
TB accounted for 12% of all deaths (609,800) that occurred in 2015 in Bangladesh 
(Institute for Health Metrics and Evaluation (IHME), 2016). Although case notification 
rate is only 57%, success of the treatment is high (93%) among DS-TB patients. 
However, the success rate is 75% among MDR-TB patients which signifies how difficult 
to treat drug resistant strains (World Health Organization (WHO), 2016a). 
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Despite having effective treatment, patient adherence to TB treatment remains 
poor because of long duration of the regimen (six months for newly diagnosed cases) and 
the need for daily dosing.  Failure to adhere to the regimen results in MDR-TB (Gandy & 
Zumla, 2002). The emergence of drug resistant TB strains has slowed down the progress 
in global TB epidemic control over the last two decades. Bangladesh has also 
experienced surge in the number of MDR-TB cases with a 1.6% of new cases are drug 
resistant and 29% of MDR-TB cases were found among the re-treatment of pulmonary 
TB cases in 2015 (World Health Organization (WHO), 2016a).  
World has experienced a slow progress in TB control. TB incidence has fallen by 
an average of 1.5% per year since 2000. However, this needs to accelerate to 4-5% 
annual reduction to reach 2035 milestones of “End TB Strategy” (World Health 
Organization (WHO), 2016b). End TB Strategy has set ambitious targets of 95% 
reduction in TB deaths and 90% reductions in TB incidence by 2035 (Uplekar et al., 
2015).Bangladesh is also experiencing a slow reduction in TB incidence (360,000 in 
2015 from 362,000 in 2014) and incidence rate (225 per 100,000 population in 2015 from 
227 per 100,000 population in 2014) (World Health Organization (WHO), 2015a, 2016a). 
Economic burden of TB in Bangladesh is a great concern, since it affects a sizable 
number of people each year and causes 12% of the total death. Both disability and death 
have grave economic implications in the form of lost income to the persons and their 
families and lost Gross Domestic Product (GDP) for the country. Expensive treatment of 
the disease also put burden on the patients, families, and the health system of the country.    
The most affected group is the working age group persons, that also increases the costs 
associated with the disease (World Health Organization (WHO), 2016b). Moreover, 
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almost half (43%) of the patients in Bangladesh is not reported under the national 
registries and goes untreated (World Health Organization (WHO), 2016a); this makes the 
control and elimination of the disease extremely hard and expensive. Emergence of drug 
resistant strain also contributes in escalating costs because of high death rates, costly 
treatments, and poor outcomes (Fitzpatrick & Floyd, 2012). 
Directly Observed Treatment, Short Course (DOTS) strategy for treating drug 
sensitive TB (DS-TB) has been implemented in Bangladesh since 1993 and all the 
Upazila Health Complexes (UHCs) have been brought under the purview of the service 
from where TB detection and treatment services are given free of cost. The essence of the 
strategy is the diagnosed TB patient has to go to the facility every day for taking the 
drugs, thus treatment discontinuity and subsequently MDR-TB cases can be averted 
(World Health Organization (WHO), 2013b). 
Menacing drug resistant strains is a growing concern as discontinuity in treatment 
often results into MDR-TB or XDR-TB. Treatment for both the conditions are costly and 
also more time consuming as the shortest effective MDR-TB treatment regimen spans 
over nine months (Deun et al., 2010).  Therefore, this prolonged treatment schedule may 
result into more incidence of treatment discontinuation. WHO in partnership with STOP 
TB Partnership came up with the response plan in 2007-2008 and Bangladesh is one of 
the seven countries using the shorter treatment regimens for MDR-TB in June 2013 
(World Health Organization (WHO), 2013b). 
Given the extent of the incidence and death rate of TB patients worldwide and in 
Bangladesh, its overwhelming economic impact is of great importance. Few studies have 
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been conducted to elucidate the social and economic costs of TB (Murrat, Styblo, & 
Roullion, 1993). Recently few studies have been carried out in this regard (Muniyandi, 
Ramachandran, Balasubramanian, & Narayanan, 2006; Rajeswari et al., 1999; Russell, 
2004) but very few in the context of Bangladesh (Croft & Croft, 1998; Gospodarevskaya 
et al., 2014; Islam, Wakai, Ishikawa, Chowdhury, & Vaughan, 2002). There is also 
paucity of evidence on cost-effectiveness of the TB programs. One study compared cost-
effectiveness between an NGO and government intervention and found that NGO-driven 
program is more cost-effective (Islam et al., 2002), however, no study has been 
conducted after the advent of PPP model or using the cost-utility method.   
The costs can be incurred on the patient directly (direct costs) or indirectly 
(indirect costs) and most of the studies do not capture the whole picture as they often 
concentrate on pre-diagnosis, pre-treatment or treatment costs (KNCV Tuberculosis 
Foundation, 2008) only. Besides this the study will also capture the provider’s cost of 
delivery health care services to the TB patients which is often absent in other studies. 
This research proposal intends to contribute to the body of TB literature by 
illustrating the cost associated with different types of TB and to estimate the total 
economic burden of tuberculosis in Bangladesh. This dissertation also covers the 
economic evaluation of ongoing treatments approaches for both DS-TB and MDR-TB. 
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1.2 CURRENT TB CARE APPROACHES IN BANGLADESH 
Bangladesh National TB control program (NTP) adopted the Directly Observed 
Treatment, Short Course (DOTs) strategy in November 1993. By 2007 the DOTS 
services were available throughout the country including metropolitan areas (National 
Tuberculosis Control Program (NTP), 2015).  
NTP follows a PPP model where NGOs are working in collaboration with the 
MOHFW. There are about 12 NGOs working in different areas of Bangladesh. Among 
these BRAC, the largest NGO in the world and Damien Foundation Bangladesh, an 
affiliate of the Belgian NGO running TB control programs worldwide is the principal 
NGOs who get fund from Global Fund for Tuberculosis and Malaria (GFTAM) directly. 
BRAC gives away the funds to number of NGOs as the sub-recipient to work in different 
areas in Bangladesh. MOHFW also gets funding from the same source and equip the 
National Institute of Diseases of the Chest and Hospital (NIDCH) and number of Medical 
College Hospitals with diagnostic and treatment facilities for TB patients infected with 
both drug sensitive and drug resistant strains(National Tuberculosis Control Program 
(NTP), 2015). 
For the drug sensitive TB patients, standard 6 months’ regimen is followed by all 
participating NGOs. However, the mode of delivery is different for different NGOs. 
BRAC has employed Community Health Workers (CHWs) besides the DOTs centers to 
ensure patient compliance, while Damien Foundation (DF) trained and employed 
influential community members to help the patients to be adhered to the treatment 
protocol. Another NGO, Salvation Army Bangladesh, is using drug sellers at the 
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pharmacies as the counselor and drug distributors for the TB patients. Since involving 
different people, e.g., family members, neighbors, pharmacists falls under common 
strategy of involving community members. This study will conduct economic evaluation 
between these two different modes of DS-TB treatment delivery.  
National Tuberculosis Control Program (NTP) in Bangladesh follows the 20-24 
months treatment regimen for MDR-TB patients. It follows the Programmatic 
Management of Drug-resistant TB (PMDT) guideline (Falzon et al., 2011). The patients 
are admitted in the hospitals for first 6-8 months, after the intensive phase they are 
released to go to their respective home. From then on their treatment is supervised and 
administered by assigned CHWs (MOHFW, 2012). Intensive phase treatment for MDR-
TB patients are provided in NIDCH, which is situated in Dhaka, and Chest Disease 
Hospitals (CDH) in Chittagong, Sylhet and Khulna. 
 Damien Foundation (DF) runs shorter protocol of treatment for MDR-TB 
patients, which span over 9 months. DF generally admits the MDR-TB patients in one of 
their three hospitals situated at Jalchatra of Madhupur, Tangail, Shomvuganj, 
Mymensingh and at Netrakona for the intensive phase of treatment which spans over four 
months followed by five months of continuation phase for which drugs are administered 
at patients’ home (Damien Foundation, 2008). Rajshahi Chest Disease Hospital also 
provides 9 months treatment. DF also follows the strategy of involving the community 
members (Sharma, 2002) while BRAC programs deploy community health workers 
(CHWs) to reach the patients (Liu, Sullivan, Khan, Sachs, & Singh, 2011). This study 
will assess the cost-effectiveness of the two MDR-TB programs run by NTP and DF in 
Bangladesh.    
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1.3 RESEARCH OBJECTIVES 
The study will focus on the following general objective: 
To assess economic burden of drug sensitive and drug resistant tuberculosis on 
the afflicted population of Bangladesh and to investigate economic evaluation of the 
current approaches of Tuberculosis control in Bangladesh. 
The specific objectives of the study are as follows: 
1. To analyze the direct and indirect cost of diagnosis and treatment of drug-
sensitive TB and MDR-TB in Bangladesh.  
2. To estimate the health system cost of diagnosis and treatment of drug-sensitive 
TB and MDR-TB in Bangladesh.  
3. To measure effects as quality-adjusted life-years (QALYs) gained and 
disability-adjusted life-years (DALYs) averted. 
4. To conduct a cost effectiveness analysis with QALYs and DALYs as the health 
outcomes.  
1.4 STRUCTURE OF THE DISSERTATION 
This dissertation proposal is divided into introduction, literature review, methods 
which are followed by three sections depicting the three studies conducted under the 
purview of the dissertation. Three studies are namely economic burden of TB in 
Bangladesh, economic evaluation of DS-TB treatment approaches and economic 
evaluation of MDR-TB treatment approaches in Bangladesh.
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CHAPTER 2 
LITERATURE REVIEW 
2.1 INTRODUCTION AND SCOPE OF REVIEW 
This chapter reviews the theoretical concepts of illness with tuberculosis and its 
impact on individuals, families/households, and society as a whole.  Following that the 
chapter includes literature review of existing studies on economic burden of tuberculosis 
studies as well as the studies on cost-effectiveness of both drug sensitive and drug 
resistant TB treatments all around the globe. 
2.2 ECONOMIC BURDEN OF TUBERCULOSIS 
2.2.1 THEORETICAL CONCEPTS OF ECONOMIC BURDEN OF TUBERCULOSIS 
In cost analysis three types of costs are taken into account, direct costs, indirect 
costs and intangible costs due to illness. Direct costs include healthcare costs (hospital, 
medication, emergency transportation, outpatient visit charges) and family costs (out-of-
pocket payment (OOP), medication, transportation of families etc.). Indirect costs include 
the opportunity costs of work-loss days, lost productivity/income on the part of both the 
patients and his/her relatives. Intangible costs can arise from the functional limitations, 
pains acquired in the process and cannot be quantified and highly subjective in nature 
(Centers for Disease Control and Prevention (CDC), 2013).  
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Besides these costs, there is another important cost incurred by the households through 
coping strategies, which includes sale of assets, taking up debt, saving on food or other 
items, taking a child out of school to care for the patient or taking up another job 
(Russell, 2004). 
The costs of communicable diseases fall on the households in three distinct phases: 
1. Pre-diagnosis 
2. During Diagnosis/Pre-treatment 
3. During Treatment 
The causal linkages of these factors are depicted by Russell (2004): 
 
 
  
Figure 2.1 Conceptual Framework for analyzing the economic burden of illness for 
households (Russell, 2004) 
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At the stage of boxes 1 and 2, decisions are made whether and how treatment is 
sought as a response to the event of illness. The health system is captured in Box 6. 
Direct costs capture expenditures related to seeking treatment while indirect costs are loss 
of labor time for patients and their caregivers. The severity of illness and characteristics 
of health services affect direct and indirect costs and influence access to and choice of 
provider. The cost burden and coping strategies of struggling with this burden 
(mobilizing resources outside the household such as credit) determine household assets 
and impoverishing processes, hence the link between illness and poverty (Russell, 2014). 
McIntyre et al. (McIntyre et al., 2006) provided a flow-chart on economic 
consequences of TB illness and payment for healthcare (Figure 2.2). According to 
McIntyre there are four stages of tuberculosis treatment, e.g., illness experience, 
treatment seeking behavior, economic consequences, and coping strategies and social 
resources. In preliminary stages, perception of illness and treatment seeking can be 
affected by the economic status of the person. If the patient with TB does not seek 
treatment then only indirect costs is incurred in form of lost productivity, while if the 
patient goes for treatment then direct costs also incurred on top of indirect costs. Indirect 
costs further subdivided into productivity loss of the patient and the caregiver, whereas 
direct cost is categorized into financial costs of healthcare (services and medicines) and 
other financial costs. 
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Based on conceptual model of McIntyre et al. (McIntyre et al., 2006) Laokri et al. 
(Laokri et al., 2014) (2014) provided an extended conceptual framework incorporating 
intangible costs, e.g., pain and suffering, and social stigma; elaborating coping costs and 
social burdens due to illness; and includes societal economic loss along with illness 
poverty trap ensued due to illness (Figure 2.3). This extended model also includes 
forgone activities of the informal caregivers as well as those of guardians accompanying 
the TB patients for treatment. These foregone activities can culminate into labor 
substitution, withdrawal of children from school, and informal caregiving activities of the 
family members. Guardians lose time and income. Direct costs have been subdivided into 
subsidized healthcare costs, non-subsidized healthcare costs, and non-healthcare costs. 
Non-subsidized healthcare costs and non-healthcare costs along with income loss of the 
guardian can result in (1) Financial resource mobilization, e.g., borrowing, selling assets, 
Figure 2.2 Simplified flow-chart of key issues relating to the economic consequences 
of illness (McIntyre, Thiede, Dahlgren, & Whitehead, 2006) 
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pledging, extra-earnings etc.; (2) Resource reallocation, e.g., dissaving, budget cuts, 
deprivation, delayed investment etc. Non-subsidized healthcare costs and non-healthcare 
costs can also lead to erratic care pathways which include redundant care visits, 
alternative care seeking, diagnosis and treatment delays, and care interruption.  
Intangible costs like pain and sufferings and social stigma can impose social 
consequences like (1) Low awareness: low awareness of disease, denial of illness status, 
bad living conditions, fear of losing position, social isolation, lack of family support, 
patient-related delays; (2) Social exclusion: exclusion from services including public 
healthcare services, from income and from participation. 
Between McIntyre’s and Laokri’s conceptual frameworks, both of which are built 
upon the framework proposed by Russell (2004), simpler McIntyre’s framework will be 
adopted for this study. Both frameworks are more or less similar, while Laokri’s one is 
more detailed and includes pain and suffering, and social stigma. It is difficult to assign 
monetary value to intangible costs like pain and stigma. On the other hand, these 
intangible phenomena affect the quality of life of the patients. In our adopted quality of 
life measurement tool pain and stigma have included to offset their absence in the costs 
estimation. It also prevents double counting; once included in costs and again take into 
account while measuring quality of life.  
There are four approaches to measure the cost of illness, e.g., human capital 
method, willingness to pay method, production cost and friction cost method (Jo, 2014; 
Malaney, 2003). Out of these human capital and willingness to pay methods are best 
suited for calculating the costs of illness from the patient perspective (KNCV 
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Tuberculosis Foundation, 2008). This study intends to employ both the method to capture 
different dimensions of costs. As Human Capital method (HCM) captures the valuation 
of forgone income and productivity and willingness to pay (WTP) captures the subjective 
reporting of actual costs accrued to the household and the perceived costs of the illness. It 
is argued that the HCM underestimates the total cost of illness than the WTP method, 
since it fails to capture the costs which are difficult to measure in numeric terms, e.g., 
costs associated with pains and sufferings.    
The study will estimate the cost to society in the form of lost future productivity 
discounted to the present.  The calculations aim at a sum of future earnings of the 
premature dead by looking at life expectancy, labor force participation and average salary 
data. This is sometimes called the ‘top-down-approach’. It includes direct and indirect 
costs. Indirect costs are productivity losses, measured by estimating income foregone due 
to morbidity and mortality. The cost of morbidity is the value of lost workdays. Future 
earnings are discounted to assess the present value of lost income.  
The study will measure the total cost of illness including the costs of illness in the 
past and present along with the future projection of the costs based on the collected data. 
The future projection of the costs is important in the sense that the debilitating disease 
may accrue a long-term costs burden on the family and the society as a whole and these 
costs can be quite high, even though often not considered explicitly in cost of illness 
analysis. As in the case of Measles vaccination, it is found that although measles 
vaccination prevents deaths within a short time frame (preventing measles death) it also 
has longer term impact on child survival. In other words, mortality rate among measles 
vaccinated children were lower than comparable children without vaccination (Koenig et 
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al., 1990). Productivity effect of malaria persists for many years after the control of 
malaria outbreaks in an area and imposes huge economic burden in the long run (Breman, 
Egan, & Keusch, 2001). It is also likely that TB has these indirect long-term effects and 
this study will try to get a handle on these longer-term outcomes.  
From the institutions like DOTS centers, hospitals treating TB patients etc. data 
will be collected for the variable costs, which is the direct function of number of patients 
treated and includes costs such as drugs, reagents, and food during hospitalization. Then 
the fixed costs like personnel salaries, costs of vehicles and their maintenance and other 
administrative costs will also be enumerated to estimate programmatic costs (Murrat et 
al., 1993). 
 
2.2.1 EXISTING EVIDENCE ON ECONOMIC BURDEN OF TUBERCULOSIS 
Islam et al. (Islam et al., 2002) conducted a cost-effectiveness study comparing 
between community health workers (CHW) model adopted by BRAC and government 
run TB program which did not include CHWs. As part of the study the authors estimated 
the cost of delivering TB treatment from both patient and provider perspectives.  From 
the study areas they collected the costs of all health workers and administrative staff, 
BRAC capital costs (including building costs) derived from accounting books and 
financial reports and in the absence of government report on capital costs those were 
estimated based on the local market price and current replacement costs. Capital costs 
were annuitized by using 10 years lifetime for furniture, 5 years for vehicles and 
equipment and were discounted at 5% per annum rate.  Training costs were excluded 
assuming the costs equal across the two types of programs. 
 
 
1
5
 
Figure 2.3 Conceptual framework to assess multidimensional economic burden of illness in a user’s perspective 
(adapted from McIntyre et al., 2006) (Laokri, Dramaix‐Wilmet, Kassa, Anagonou, & Dujardin, 2014) 
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Recurrent costs were collected from accounting books and financial reports from both 
programs and overhead costs for TB programs were calculated to be 10% in BRAC 
facilities and 5% in government run facilities. Patient’s costs were elicited by 
interviewing 18 BRAC and 20 government patients. Time and travel costs associated 
with patients visits to health facilities for diagnosis, drug collection, and follow-up tests 
as well as costs of people accompanying the patients in each visit was included in 
patient’s costs.  It was calculated that the total cost was about $10 (422 BDT in 1996-
1997) in BRAC areas while the cost was US$19 (802 BDT in 1996-1997) in government 
facilities (Islam et al., 2002). Using the Consumer Price Index (CPI) reported in the 
World Bank website we get that the costs was in 1,392 in 2015 BDT in BRAC areas, 
while the costs in government areas were 2,646 in 2015 BDT (The World Bank, 2017a). 
Another study estimated the patient costs during TB treatment in Bangladesh and 
Tanzania (Gospodarevskaya et al., 2014). Total 96 patients were interviewed to find out 
the patient costs for six months DSTB treatment. The study sample includes 67 patients 
from BRAC, 22 from Damien Foundation, and 7 from Population Services and Training 
Centers. Total costs incurred during the six-month treatment regimen was estimated by 
combining the cost incurred during two months of intensive phase plus twice the costs 
incurred during two months of continuation phase. Total cost includes travel costs, 
guardian/accompanying person costs, caregiver cost, as well as treatment costs, e.g., 
laboratory tests, administration fees, hospital admission charges, medicines and 
supplements costs.  Income lost due to TB for the patients and the guardians who would 
otherwise be paid through employment was calculated to determine the indirect costs. 
Indirect costs for students, prisoners, and those who were unemployed before the TB 
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illness were not estimated assuming that these groups of people had no foregone costs. 
But for those who do housework, their foregone wage at the rate paid for maid service 
was calculated and added to the patient costs. Total patient costs in Bangladesh was $224 
in 2012, which is equivalent to 16,690 in 2012 BDT and 20,720 in 2015 BDT. 
Interestingly both of these studies excluded the costs incurred by patients before 
reaching the treatment facilities. This constitutes a major source of costs for the patients. 
Since the TB treatment is almost free except for traveling, this cost constitutes a major 
portion of the total costs. A study conducted by Croft et al. (Croft & Croft, 1998) among 
TB patients in Nilphamari, Bangladesh showed that a mean financial cost to the patients 
due to foregone income and payments for doctors’ consultation and medicines were $245 
in 1996 which is equal to $808 in 2015 and BDT 64,663 in 2015 (1 Dollar=80 BDT). 
There are several systematic reviews on TB patient and health system costs have 
been done. Laurence et al. (Laurence, Griffiths, & Vassall, 2015) searched for cost and 
economic evaluation studies on both DS-TB and MDR-TB between January 1990 and 
February 2015. The authors found mean DS-TB treatment costs were $273 in lower 
middle-income countries (LMICs) and $258 in low income countries (LICs), whereas the 
MDR-TB treatment costs were $6,313 and $1,218 respectively. Tanimura et al. 
(Tanimura, Jaramillo, Weil, Raviglione, & Lönnroth, 2014) focused only on LMICs and 
searched the database from inception to March 31, 2013. Mean total costs ranged from 
$55 to $8,198, with an unweighted average of $847. Half of the total costs were reported 
before treatment started, while the composition of costs was 20% to direct non-medical 
costs, 20% to direct medical care costs, 60% to income loss due to TB illness. In a study 
conducted with published literature on African countries showed that mean pre-
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diagnostic costs were between $36 and $196, while post-diagnostic costs were between 
$17 and $448. 
2.3 HEALTH RELATED QUALITY OF LIFE (HRQOL) 
In this section studies on health related quality of life (HRQoL) of TB patients is 
reviewed. Main focus is on different measurements of HRQoL, e.g., Quality Adjusted 
Life Year (QALY) and Disability Adjusted Life Year (DALY). Then different 
measurement scales used for eliciting HRQoL measures for TB patients is explored.  
Quality of life measurement uses utility theory to identify the degree of health 
concerns related to any disease or health conditions. Quality adjusted life year (QALY) 
and Disability adjusted life year (DALY) are the two summary estimates widely used in 
health economic evaluations. While QALY views health outcomes from the perspective 
of “healthiness”, DALY views health outcomes in terms of loss of life years due to 
disabilities. 
 𝑄𝐴𝐿𝑌𝑠 𝑔𝑎𝑖𝑛𝑒𝑑 =  𝑄𝑖
1−𝑒−𝑟𝐿
𝑖
𝑟
−  𝑄
1−𝑒−𝑟𝐿
𝑟
    (1) 
where 𝐿𝑖 and 𝑄𝑖 are, respectively, the period over which treatment affects the 
individual’s quality of life, and the quality of life weight with treatment; while L and Q 
are the corresponding parameters without treatment.  
The formula for calculating the number of QALYs gained through an intervention 
i is as follows: 
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𝑄𝐴𝐿𝑌𝑠 𝑔𝑎𝑖𝑛𝑒𝑑 =  ∑ 𝑄𝑝
𝑖𝑝
𝑝=1
𝑒−𝑟(𝑡𝑝
𝑖 −𝑎)− 𝑒
−𝑟−𝑟(𝑡𝑝−1
𝑖 −𝑎)
𝑟
−
 ∑ 𝑄𝑚
𝑖𝑁
𝑚=1
𝑒−𝑟(𝑡𝑚
𝑖 −𝑎)− 𝑒−𝑟−𝑟(𝑡𝑚−1
𝑖 −𝑎)
𝑟
    (2) 
here the life expectancy with the intervention (𝐿𝑖) at age a is divided into P time 
periods 𝑛𝑝, and 𝑄𝑝
𝑖  is a vector of health-related quality of life weights predicted (or 
observed) for each time period 𝑛𝑝 following the intervention. While 𝑄𝑚
𝑖  is weight 
associated with the health state before intervention and individual’s residual life 
expectancy is divided into N time periods 𝑛𝑚.  Here 𝑡𝑝 𝑎𝑛𝑑 𝑡𝑚 are the of individual years 
within the life expectancy.  
On the other hand, Disability Adjusted Life Year (DALY) is the sum of the Years 
of Life Lost (YLL) due to premature mortality and the Years Lost due to Disability 
(YLD) for people living with the health condition or its consequence (World Health 
Organization (WHO), 2013a).  
DALY = YLL + YLD    (3) 
We can derive the formula for YLL and YLD as follows (Diel et al., 2014): 
 
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   (5) 
Where, K = Age-weighting modulation constant (1.00), C= Age-weighting 
scaling constant, L= country-specific standard life expectancy at age of death (years), 
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DW = Disability Weight (0.333; 95% CI= 0.224-0.454) as per the Global Burden of 
Disease 2013 study weights (Salomon et al., 2015), T= treatment duration, and α = age of 
onset of disability. 
2.3.1. HEALTH RELATED QUALITY OF LIFE OF TUBERCULOSIS PATIENTS 
Although several studies have been conducted to assess the health-related quality-
of-life (HRQoL) for tuberculosis patients (Brown et al., 2015), there is no well-accepted 
tuberculosis-specific HRQoL measurement instrument available. Most studies use EQ-
5D, SF-36, SF-6D and other generic HRQoL instruments (Guo, Marra, & Marra, 2009). 
Only one study conducted in India used a TB-specific tool named DR-12, which has 12 
items each ranked on a scale of 1–3 (Dhingra & Rajpal, 2003). Recently a 
multidimensional TB-specific HRQoL instrument named Functional Assessment of 
Chronic Illness Therapy-Tuberculosis (FACIT-TB) was developed and psychometrically 
validated in Iraq (Dujaili et al., 2015). This FACIT-TB instrument includes physical, 
mental, social and economic, functional, as well as spiritual well-being of the TB 
patients. This instrument is unique in incorporating questions on adverse drug reaction 
(ADR), perception about social stigma, and spirituality related with TB.  
The scale comprises 45 items: 17 items covering physical well-being (possible 
score range 0–68), seven items covering social and economic well-being (possible score: 
range 0–28), 11 items covering emotional well-being/living with TB (possible score 
range 0–44), seven items covering functional well-being (possible score range 0–28), and 
three items covering spiritual well-being (possible score range 0–12). A 5-point Likert 
type scale ranging from 0 (not at all) to 4 (very much) is assigned to each item. 
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2.4 COST-EFFECTIVENESS OF TUBERCULOSIS PROGRAMS 
Till date, to our best knowledge, the only cost-effectiveness analysis between two 
TB control programs run by BRAC and government was conducted by Islam et al. 
(2002). It showed that the government program was 50% more expensive for similar 
outcomes. 
Many cost-effectiveness analyses have been done in order to determine the cost-
effective diagnostic techniques, e.g., sputum examination (Walker et al., 2000), 
serological tests vs. other diagnostic tests (Dowdy, Steingart, & Pai, 2011), dual or single 
test for detection of  latent tuberculosis infection (LTBI) (Pooran et al., 2010), . However, 
since the focus of this thesis is to compare between two TB control programs we restrict 
our review among those studies which conducted cost-effectiveness analyses between 
programs. 
Using Denver General Hospital data Burman et al. showed that although DOT is 
costly at the outset it turns to be cost-effective than Self-administered Therapy (SAT) 
because of higher cure rates (Burman, Dalton, Cohn, Butler, & Reves, 1997). The 
outcome variable for this study was cure rate per cost unit. 
Using published literature, records, and expert opinions Baltussen et al. showed 
that DOT as well as incremental programs like DOTS plus, Full combination of DS-TB 
and MDR-TB strategies all are cost-effective in terms of DALYs averted per cost unit in 
high burden TB countries in Africa and South-East Asia (Baltussen, Floyd, & Dye, 
2005). 
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Several other studies have been conducted in different countries, e.g., Thailand 
(Hunchangsith, Barendregt, Vos, & Bertram, 2012), Egypt and Syria (Vassall, Bagdadi, 
Bashour, Zaher, & Maaren, 2002), Botswana (Moalosi et al., 2003), Haiti (Jacquet et al., 
2006), Uganda (Okello, Floyd, Adatu, Odeke, & Gargioni, 2003), Brazil(Mohan, Bishai, 
Cavalcante, & Chaisson, 2007). These studies invariably documented that the DOTs 
strategy or involving the communities in the care process is cost-effective over SAT. 
In two studies conducted in South Africa (Sinanovic et al., 2003), and in India 
(Pantoja et al., 2009) the authored showed that PPP models were more cost-effective by 
virtue of reducing costs to patients by 64-100%in South Africa; while the patient cost fell 
from US$154 to US$132 over four-years period in India. 
A recent study shows that shortening of the DS-TB treatment from six-months to 
four-months remain cost-effective option for Brazil, South Africa, Bangladesh and 
Tanzania (Gomez et al., 2016). Another study results also support this finding in South 
Africa (Knight et al., 2015). 
Several studies have also been conducted to assess the cost-effectiveness of 
different MDR-TB treatment regimens. Fitzpatrick et al. (2012) conducted a systemic 
review of studies which used primary data and outcome which eventually includes only 
four studies conducted in Estonia, Peru, the Philippines, and Tomsk, Russia. Cost per 
DALY averted were $598, $163, $143, $745 respectively. The cost per DALY averted 
was lower than GDP per capita in all 14 WHO sub-regions considered.  
However, there was no study comparing between the shorter and longer regimen 
for MDR-TB treatment. Two separate studies conducted by DF scientists assessed the 
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effect of two regimes. One study which was conducted for the standardized regimen of 
21-24 months published in 2004 (Van Deun, Salim, Kumar Das, Bastian, & Portaels, 
2004)and another study on shorter regimen was published in 2010 (Deun et al., 2010). 
Both of the studies showed that both treatment strategies are successful in treating MDR-
TB patients; however, in absence of any comparative cost-effectiveness analysis between 
them we cannot tell which one is better. 
2.4.1 METHODS OF COST-EFFECTIVENESS OF TUBERCULOSIS PROGRAMS  
Cost-effectiveness analyses with DALY or QALY as outcome variable usually 
employs various models like population model PopMod (Baltussen et al., 2005), Monte 
Carlo simulation technique (Tupasi et al., 2003), dynamic state-transition model of TB 
(Resch, Salomon, Murray, & Weinstein, 2006) etc. In this study, to conduct the economic 
evaluations of different tuberculosis control programs, we shall use the Monte Carlo 
simulation technique. A probabilistic Markov Chain Monte Carlo (MCMC) simulation 
model will be fitted. The patient level data on treatment outcomes will help to get the 
transitional probabilities between states as well as we can use regression techniques to get 
the probabilities along with the uncertainties. That will help us to conduct the sensitivity 
analysis of the results. Finally, we will estimate the Incremental Cost-Effectiveness Ratio 
(ICER) between the different comparators and use the acceptability curves approach to 
find out the cost-effective TB control program in Bangladesh. 
Markov model has some unique characteristics which fit the progression of TB 
well. For example, in Markov model states are mutually exclusive, states are complete 
(i.e. no people are lost) and people remain in that state for a fixed period of time. Also, 
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Markov model is preferred over the decision trees when health event repeats over time, or 
have longer term health effects, effect of treatment either stops quickly after initial 
treatment or continue at an earlier level, and the risk of different health events does not 
depend on patient’s prior history (Briggs, Claxton, & Sculpher, 2006). 
Here we can represent the Markov model for TB as below: 
  
 
 
 
  
 
 
 
From the Markov model we can find that after starting of the treatment the MDR-
TB patient can move to any of the four states, e.g., cure/treatment complete, 
failure/relapse, default, and death. Here default and death are the absorbing states. If any 
patient is cured he/she can remain cured, relapse/reinfection may occur, or can be dead. 
On the other hand, the failed/relapsed patients undergo another cycle of treatment and can 
culminate into cure, remain failed, can default, or can be dead as well. 
Infectious disease often requires dynamic models which reflect the rate of 
transmission of disease among the population. The rate of infection is a function of the 
number of infected individuals in the community (Briggs et al., 2006). Epidemiology of 
an infectious disease is important to take into account because due to change in the 
  Cure 
Default 
    Fail 
 Death 
Death 
Figure 2.4 Simplified Markov Model for Outcomes of Illness with Tuberculosis 
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natural history of disease can affect the outcome of the disease and  thereby, the cost-
effectiveness analysis will be flawed (Jit & Brisson, 2011). 
TB is an infectious disease and have latent period and many latent cases which 
does not turn into a full blown disease. But these latent TB infection (LTBI) can be 
activated upon proper stimuli or absence of immunity, as in the case of HIV/AIDS. 
Therefore, many researchers included these aspects in the infectious disease modeling 
(Jacquet et al., 2006; Menzies, Cohen, Lin, Murray, & Salomon, 2012; Oxlade, Piatek, 
Vincent, & Menzies, 2015; White & Abubakar, 2016).  Dowdy et al. (2013) synthesized 
that a single model is unlikely meet all criteria for all studies and prepared a wish list for 
the TB modelers would love to have (Dowdy, Dye, & Cohen, 2013)
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CHAPTER 3 
METHODS 
3.1 INTRODUCTION 
Bangladesh National Tuberculosis control program (NTP) follows a PPP model 
where NGOs are working in collaboration with the MOHFW. There are about 12 NGOs 
working in different areas of Bangladesh. Among these the largest NGO in the world- 
BRAC and Damien Foundation Bangladesh, an affiliate of the Belgian NGO running TB 
control programs worldwide are the principal NGOs. These NGOs are recipients of the 
funds provided by Global Fund for Tuberculosis and Malaria (GFTAM) along with NTP 
being the principal recipient. BRAC gives away the funds to number of NGOs as the sub-
recipient to work in different areas in Bangladesh. NTP uses the fund for equipping the 
National Institute of Diseases of the Chest and Hospital (NIDCH) and number of Medical 
College Hospitals with diagnostic and treatment facilities for tuberculosis (TB) patients 
infected with both drug sensitive and drug resistant strains (MOHFW, 2014). 
For the drug sensitive TB patients standard 6 months regimen is followed by all 
participating NGOs. However, the mode of delivery is different for different NGOs. 
BRAC has employed Community Health Workers (CHWs) besides the DOTs centers to 
ensure patient compliance, while Damien Foundation (DF) trained and employed 
influential community members to help the patients to be adhered to the treatment 
protocol.  
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Another NGO, Salvation Army Bangladesh, is using drug sellers at the pharmacies as the 
counselor and drug distributors for the TB patients. This study will conduct economic 
evaluation between these two different programs.  
NTP in Bangladesh follows the 20-24 months treatment regimen for Multi-Drug 
Resistant TB (MDR-TB) patients. It follows the Programmatic Management of Drug-
resistant TB (PMDT) guideline (Falzon et al., 2011). Initially MDR-TB patients are 
admitted to designated hospitals for intensive phase of treatment which generally last for 
6-8 months. Then the patients are released to community and their treatment is supervised 
and administered by CHWs for another 14-16 months (MOHFW, 2012). Damien 
Foundation (DF) runs their own protocol of treatment for MDR-TB patients, which span 
over 9 months and differs in mode of treatment. DF generally admits the MDR-TB 
patients in one of their three hospitals situated at Jalchatra of Madhupur, Tangail, 
Shomvuganj, Mymensingh and at Netrakona for the continuation phase of the treatment 
which spans over four months followed by five months of continuation phase for which 
drugs are administered at patients’ home (Damien Foundation, 2008). DF also follows the 
strategy of involving the community members (Sharma, 2002) while BRAC programs 
deploy community health workers (CHWs) to reach the patients (Liu et al., 2011). This 
study will assess the cost-effectiveness of the two MDR-TB programs run by NTP and 
DF in Bangladesh. 
3.2 STUDY DESIGN 
The study follows a stratified random sampling method. From the 64 districts of 
Bangladesh nine districts from the eight divisions (at least one from each division) were 
selected based on the high and low burden of TB cases. Then from each district two 
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upazilas (sub-districts) will be selected randomly. From the registry of the DOTS center 
of the UHCs of these eighteen upazilas lists of TB patients currently undergoing 
treatment or recently finished will be collected.  
3.3 STUDY SITE 
3.3.1 DRUG SENSITIVE TB (DS-TB) 
For total representation at least one district from all eight divisions of Bangladesh 
was selected for the study. Since Dhaka division is bigger in size, three districts was 
selected from Dhaka division including an urban area of Dhaka city.  Selection was made 
based upon the high and low TB burden among all districts. Therefore, five high burden 
and four low burden districts have been selected under the purview of the study. Two 
upazilas (sub-districts) from each of the selected districts was selected randomly. 
Following is the list of all districts and upazilas covered under the study. From each 
upazila 50 DS-TB patients were selected randomly for interview. 
3.3.2 MULTI-DRUG SENSITIVE TB (MDR-TB) 
 For assessing economic burden of MDR-TB patients and the economic 
evaluation of comparator MDR-TB control programs about 175 MDR-TB patients will 
be selected purposively. According to the recent estimates in 2014 number of laboratory-
confirmed MDR-TB patients was 994 in Bangladesh (World Health Organization 
(WHO), 2015a) and the prevalence of MDR-TB is 5,100 in 2015 (World Health 
Organization (WHO), 2016a). In our study areas the number will be clearly significantly 
lower. Therefore, we collected the information of the MDR-TB patients from the TB 
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control programs and reach those who (Brazier, Roberts, & Deverill, 2002) were 
accessible. 
3.4 STUDY PARTICIPANTS 
The inclusion criteria for the study participants will be as follows: 
a) Older than 18 years of age, 
b) Suffering or recently suffered from pulmonary TB (DS-TB/MDR-TB), 
c) Undergoing treatment or finished treatment within last 6 months. 
3.5 SAMPLE SIZE 
Glick (H. A. Glick, 2011) proposed a sample size formula for cost-effectiveness 
evaluation of clinical trials. Although our study is not a typical clinical trial, given the 
nature of the intervention and the study design we can apply the formula for calculating 
the required sample size for our study.  The formula calculates the sample size for each of 
the two groups with similar standard deviation of costs and effect and same sample size: 
𝑛 =
2 (𝑍𝛼 + 𝑍𝛽)
2
[𝑠𝑑𝑐
2 +  (𝑊 ∗ 𝑠𝑑𝑞
2)
2
−  (2 𝑊𝜌 ∗ 𝑠𝑑𝑐 ∗ 𝑠𝑑𝑞)
(𝑊𝑄 − 𝐶)2
 
Where:  
Zα is the Z-statistic for the level of Type I error (set at 95%)  
Zβ is the Z-statistic for the level of Type II error (set at 80%) 
sdq, sdc are the std deviations for each group for treatment effect and cost respectively  
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W is the Maximum Willingness to Pay  
Q is the expected mean difference in treatment effectiveness  
C is the expected mean difference in treatment cost  
ρ is the expected correlation of the difference in cost (C) and effect (Q) 
This is a measure of the covariance of changes in effectiveness and changes in 
cost. Negative covariance, where cost decreases with increasing effectiveness result in a 
larger sample size. Positive covariance where cost increases with increasing effectiveness 
result in smaller sample sizes. 
DSTB: 
With 95% confidence interval and 80% power of the test, we assumed that the 
standard deviation of costs (sdc) is 400 USD, standard deviation of effect (sdq) is 0.2 
QALY, ρ, correlation of difference in cost (C) and effect (Q) is 0.4. The expected mean 
difference in treatment effectiveness (Q) is 0.4 QALY and expected mean difference in 
treatment cost (C) is 500 USD. We set the willingness-to-pay threshold (W) at the three 
times of GDP of Bangladesh which is 3942 USD (Macroeconomics, 2001). We found the 
sample size for both treatment groups is 405. 
MDR-TB: 
With 95% confidence interval and 80% power of the test, we assumed that the 
standard deviation of costs (sdc) is 100 USD, standard deviation of effect (sdq) is 0.25 
QALY, ρ, correlation of difference in cost (C) and effect (Q) is 0.5. The expected mean 
difference in treatment effectiveness (Q) is 0.15 QALY and expected mean difference in 
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treatment cost (C) is 1000 USD. We set the willingness-to-pay threshold (W) at the three 
times of GDP of Bangladesh which is 3942 USD (Macroeconomics, 2001). We found the 
sample size for one group is 70 and another is 104 with a 2:1 sample size ratio. 
Table 3.1 List of Districts and Sub-districts where the survey among DS-TB patients was 
conducted  
 
Division District Sub-District 
Number 
of 
Patients 
Surveyed 
Treatment 
Delivery  
Barisal Pirojpur 
Pirojpur Sadar 50 Community 
Health 
Worker Najirpur 
50 
Chittagong 
 
Laxmipur 
Laxmipur Sadar 50 Community 
Health 
Worker Ramganj 
50 
Dhaka 
Faridpur 
Faridpur Sadar 50 Community 
Member 
Nagarkanda 50 
Manikganj 
Manikganj Sadar 50 Community 
Health 
Worker Shingair 
50 
Dhaka Mirpur (Urban Area) 
100 DOTs 
center, 
Pharmacists 
Khulna Kushtia 
Kushtia Sadar 50 Community 
Health 
Worker Doulatpur 
50 
Mymensingh Netrokona 
Netrokona Sadar 50 Community 
Member 
Kendua 50 
Rajshahi ChapaiNawabganj 
ChapaiNawabganj Sadar 50 Community 
Member 
Shibganj 50 
Rangpur Panchangarh 
Panchagarh Sadar 50 Community 
Member 
Debiganj 49 
Sylhet Habiganj 
Habiganj Sadar 50 Community 
Member 
Bahubal 51 
Total  1,000  
 
  
32 
 
 
  
Figure 3.1 Study Sites (Sub-districts) where DS-TB patients were interviewed 
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Table 3.2 List of Districts where the survey among MDR-TB patients was conducted 
Division District 
Number of Patients 
Surveyed 
Treatment Regimen 
Chittagong 
 
Chittagong 
78 
20-24 Months Regimen 
Dhaka Dhaka 
23 
20-24 Months Regimen 
Mymensingh 
Mymensingh 
17 
9 Months Regimen 
Netrokona 
32 
9 Months Regimen 
Rajshahi Rajshahi 
18 
9 Months Regimen 
Total 
168 
 
 
3.6 ETHICAL CONSIDERATION 
The study has already got ethics approval from University of South Carolina in 
the USA where the PI is a PhD student. Institutional Board Review (IRB) approval will 
also be taken from Jahangirnagar University in Bangladesh. A third and final approval 
was obtained from WHO Research Ethics Review Committee (WHO ERC).  
The participants were approached at their households by the trained enumerators. 
At first the enumerators politely introduced themselves and asked pleasantries. After 
establishing rapport, the enumerators conveyed their purpose of the visit. 
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An informed consent was obtained from each participants of the study. At the 
beginning the enumerator read the introduction in comprehensible manner to the patient. 
In the introduction the name and whereabouts of the investigators, name of the funding 
agency, and the purpose of the study are furnished. It also attests the right of the 
Figure 3.2 Study Sites (Districts) where MDR-TB patients were interviewed 
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respondent to withdraw any time during the interview. The benefit of participating in the 
study is also described in that part.  
The data is kept in one laptop and under lock and key in the office of the principal 
investigator. No one except the investigator have access to the stored data. For data 
analysis the patient’s information is de-identified. Thus the data analysis and presentation 
in the report is completely anonymous and in any circumstances it will be kept 
confidential. 
3.7 DATA COLLECTION INSTRUMENTS 
3.7.1 PATIENT QUESTIONNAIRE 
Stop-TB questionnaire on patient’s cost has been adopted for the study. The 
patient questionnaire includes questions on the previous TB treatment costs including 
number of visits, tests, drugs, travel, food, accommodation, and out-of-pocket and 
insurance costs etc. The questionnaire also includes questions on the current or recent 
treatment for TB, which comprises of treatment costs, follow-up costs, costs borne by 
family or friends, hospitalization costs, food costs, other comorbidities cost, insurance, 
coping costs. Therefore, the cost instrument is a comprehensive tool to capture all costs 
incurred by the patients and their families for TB. The questionnaire was field tested 
among the TB patients and changes were made accordingly to make the question 
understandable and answerable. 
The patient questionnaire also includes the health-related quality of life questions. 
In this study Functional Assessment of Chronic Illness Therapy-TB (FACIT-TB) 
questionnaire (Dujaili et al., 2015), which includes 45 items under five sub-groups, will 
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be incorporated along with smaller generic instruments like EuroQol-5 Dimensions-5 
Levels (EQ-5D-5L) with visual analogue scale (VAS), and SF-6D, which is an abridged 
well-validated version from SF-36 (Brazier et al., 2002). These generic instruments will 
be used to assign utility scores for various components of the FACIT-TB instruments. 
Mapping function will be used to predict the utility values. This approach involves 
estimating the relation between a non-preference-based measure (like FACIT-TB) and 
generic preference-based measure using statistical association and this approach requires 
overlap between the two measures applied on the same population (Young, Mukuria, 
Rowen, Brazier, & Longworth, 2015). Multinomial logistic regression models will be 
estimated for each dimension, and the estimates from these regressions will be used to 
categorize respondents into five levels of each of the EQ-5D dimensions and thus predict 
the EQ- 5D health state for each respondent. A total of 1000 Monte Carlo simulations 
will be run to estimate EQ-5D health states. The standard set of UK general population 
values will be then applied to each predicted health state to obtain EQ-5D values. 
Mapping is usually performed using regression analysis and often preferred regressions 
are OLS or tobit. 
3.7.2 PROVIDER QUESTIONNAIRE 
Institutional level data was also collected for assessing the direct health system 
costs associated with TB treatment. From this secondary source the data on the number of 
patients diagnosed and treated and the outcome of the diseases in terms of complete cure, 
remission, relapse or death was collected. Another questionnaire for the program 
managers was used in the study to collect data on the facility and personnel level costs for 
the TB control programs (included in the Annexure). Market values of the TB drugs was 
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collected for estimating the drug costs for patients under various programs. Those who 
are involved in the TB control programs on honorary basis, their opportunity costs of the 
time were calculated using the average wage rates for service holders using secondary 
sources.  
3.8 DATA COLLECTION 
Given the extent of household level primary data collection in 10 randomly 
selected districts a total of two survey teams consisting of sixteen data collectors were 
formed with one supervisor, one back checker and six enumerators in each team. The 
questionnaires were prepared in consultation with my supervisor and mentors at USC. 
The questionnaires were pre-tested at the field level by the selected survey teams before 
the actual data collection began. 
3.8.1 QUALITY ASSURANCE 
The study employed multilevel quality assurance process for data collection.  
Researcher will execute a four-step scrutiny process to ensure the reliability and validity 
of the information. For each of the steps, certain team members will be given specific 
responsibility to manage the quality assurance process. 
3.8.2 CROSS CHECK 
Enumerators collected quantitative data directly from households. Later, 
enumerators went to the households with filled questionnaire where other enumerators 
had collected the answers. This cross check by other enumerators helped to recover any 
primary mistakes in collecting data.  
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3.8.3 ACCOMPANY CHECK AND SPOT CHECK  
Field team supervisor carried out next level data check through accompany check 
and spot check. Accompany check includes accompanying enumerators during data 
collection, validating the information provided by the respondents, throwing of questions, 
examining proper coding and collection of information.  Field team supervisor also 
scrutinized the information through spot check by going to the households after the 
enumerators leave the households. Such meticulous checking system ensured the quality 
of data effectively. 
3.8.4 Back Check  
The third level quality assurance was carried out by the team supervisors. Team 
supervisors visited households randomly with filled up questionnaires to examine the 
accuracy and reliability of information. Three-layer cross checking in the field ensured 
high quality data collection. 
3.8.5 OTHER QUALITY CHECK AND FEEDBACK  
After data compilation, the data set was sent to the PI for his feedbacks and other 
quality measures. The Principal Investigator travelled intensely during the period of data 
collection and ensured the quality of the data collection. 
3.9 DATA ANALYSIS 
Data analysis is primarily performed in STATA 14.2. Patient and provider level 
costs data are being managed and analyzed. Regression modelling for finding important 
predictors for patient costs.  
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For cost-effectiveness analysis R will be used for the ease of estimation. Markov 
simulation modeling will be performed in Winbugs and Just Another Gibbs Sampler 
(JAGS). Both of these softwares are open source and can easily be used from within R. R 
is also an open source software for which many packages are found suitable for cost-
effectiveness analysis (Sutton, Welton, Cooper, Ades, & Abrams, 2012). BCEA is one of 
those packages. It helps to analyze cost-effectiveness within a Bayesian framework 
(Baio, 2012) 
3.10 EXPECTED OUTCOME OF THE STUDY 
Tuberculosis is a deadly tropical disease affecting the people of developing 
countries and incurring huge cost on the economy. Thus economic evaluation of this 
disease in a developing country setting will provide the researchers, policy makers an 
empirical evidence of the extent of the cost burden. 
3.11 DISSEMINATION OF RESULTS AND PUBLICATION POLICY 
The results of the research will be disseminated to the global audience through 
presentations in conferences organized by World Health Organization (WHO), 
International Health Economics Association (iHEA), and American Public Health 
Association (APHA) etc. 
The results will also be communicated with the policy makers and program 
managers of TB programs in Bangladesh and abroad. Scientific research articles will be 
prepared after analyzing the data and will be published in reputed peer-reviewed journal. 
The Principal Investigator of the study, Mohammad Rifat Haider, will take lead in 
analyzing the data and writing the article and will be the first author. The supervisor of 
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PhD Study, M Mahmud Khan, PhD, and the mentor, Zaina P. Qureshi, PhD, committee 
members James W. Hardin, PhD and Md. Abdul Hamid Salim, MBBS will also be co-
authors for these studies. 
Contribution of other contributors in preparing the papers will also be 
acknowledged. The sponsorship of TDR, WHO will be acknowledged by quoting: “This 
investigation received financial support from TDR, the Special Programme for Research 
and Training in Tropical Diseases, co-sponsored by UNICEF, UNDP, the World Bank 
and WHO”.  
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CHAPTER 4 
STUDY I 
4.1 ECONOMIC BURDEN OF TUBERCULOSIS IN BANGLADESH1 
 
                                                          
1 Haider, M. R. To be submitted. 
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Abstract 
Background: Tuberculosis (TB) is major scourge for human-kind and causes profound 
economic burden. Bangladesh is a high burden TB country by which 12% of its annual 
deaths are caused and 362,000 people are infected by TB. This study estimates the 
economic burden of TB on the afflicted Bangladeshi population.  
Methods: Based on McIntyre’s framework on economic consequences of illness, this 
study collects direct and indirect cost for TB care data from 1,000 drug sensitive TB (DS-
TB) and 145 multi-drug resistant (MDR-TB) patients from all over Bangladesh. Provider 
cost for TB care was also collected from the health facilities. Costs for DS-TB and MDR-
TB patients were estimated using a Generalized Linear Model and summed up with per 
patient provider level costs to get the total costs per TB patients.   
Results: Mean age of DS-TB patients under the study was 45.2 years while mean age of 
MDR-TB patients were 35.5 years. In aggregate, DS-TB patients incurred total average 
costs of BDT 21,235 (USD 265) for TB illness; while MDR-TB patients’ average costs 
were BDT 34,975 (USD 437). Including provider costs for each patient (USD 9 for 
DSTB and USD 2,006 for MDR-TB patients) total average costs for each DS-TB patient 
was BDT 22,003 (USD 275) and for each MDR-TB patient was BDT 1,95,449 (USD 
2443).  
Assuming 57% case notification rate, the actual costs for treating TB patients in 2015 
was USD 55.6 million. If all DS-TB patients were treated the cost would have been 1 
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billion USD.  For MDR-TB treatment, total cost was USD 12.5 million; treating all 
MDR-TB patients would have costed USD 23 million. 
Conclusions: Results show that DS-TB patients incurred about 50% of their household 
annual income for treatment while that goes up to 66% for the MDR-TB patients. Pre-
diagnosis cost constitutes about 63% of total costs for DS-TB patients and 42% of MDR-
TB patient costs. This figures show the significant economic burden posed by TB and 
early diagnosis of the disease can reduce the burden in great extent.  
Keywords: Economic Burden, Tuberculosis, Bangladesh, Patient Costs, Provider Costs 
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Background 
Tuberculosis is an ancient disease and has claimed more life than any other 
microbial pathogens in human history (Daniel, 2006). Despite having effective treatment 
for TB for more than half a century and an effective vaccine for a century, TB still kills 
more people now than it ever has in the history of the world (McMillen, 2015). It is the 
human behavior, non-compliance to the relatively long regimen of drugs that provides the 
bacteria with opportunity of growing resistance against the anti-TB drugs. Tuberculosis is 
also a disease of poverty, that means the poor and congested living conditions facilitate 
the bacteria to strive (Davies, 2003, Gandy et al., 2002). Slow progress in control of a 
preventable and curable disease over last two decades calls for shift our focus from 
biomedical research of inventing new drugs with shorter regimen to community and 
patient-driven approach where a paradigm shift is urged for (Stop TB, 2015).  
In 2015, Tuberculosis (TB) ranked 18th among the highest burden diseases 
globally and it constituted 47% of the global burden attributable to communicable, 
maternal, neonatal, and nutritional disorders (Kassebaum et al., 2016). In 2015, 10 
million new cases of TB were reported and almost two million people died from TB 
worldwide (World Health Organization (WHO), 2016a).  In 2015, TB became the top 
infectious disease killer by claiming 1.1 million lives by matching the death tolls by 
HIV/AIDS (Kassebaum et al., 2016).  
Almost 85% of all new cases of Drug Sensitive TB (DS-TB) and multi-drug 
resistant TB (MDR-TB) occur in 30 high burden TB countries and Bangladesh is one 
them (World Health Organization (WHO), 2015b). In 2015, 362,000 Bangladeshis 
developed TB and 73,000 died from it. TB accounted for 12% of all deaths (609,800) that 
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occurred in 2015 in Bangladesh (Institute for Health Metrics and Evaluation (IHME), 
2016). 
The economic burden of TB in Bangladesh is a great concern, since it affects a 
sizable number of people each year and causes 12% of the total death. Both disability and 
death have grave economic implications in the form of lost income to the persons and 
their families and lost Gross Domestic Product (GDP) for the country. The working age 
group is more affected by the disease, that also increases the costs associated with the 
disease (World Health Organization (WHO), 2016b). Besides causing death TB causes 
significant disability among the afflicted population. Not only are older people more 
vulnerable to the disease, but their disease is more frequently complicated with adverse 
drug events which leads to reduced health related quality of life (Negin, Abimbola, & 
Marais, 2015).  
Expensive treatment of the disease also put burden on the patients, families, and 
the health system of the country. (World Health Organization (WHO), 2016b). Moreover, 
almost half (43%) of the affected in Bangladesh are not reported under the national 
registries and go untreated (World Health Organization (WHO), 2016a); this makes the 
control and elimination of the disease extremely hard and expensive. Emergence of drug 
resistant strain also contributes in escalating costs because of high death rates, costly 
treatments, and poor outcomes (Fitzpatrick & Floyd, 2012). 
This study intends to assess the patient-level costs for both DSTB and MDR-TB, 
and the provider-level costs for providing the TB diagnosis and treatment. 
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Methods 
Conceptual Framework 
In cost analysis three types of costs are taken into account, direct costs, indirect 
costs and intangible costs due to illness. Direct costs include healthcare costs (hospital, 
medication, emergency transportation, outpatient visit charges) and family costs (out-of-
pocket payment (OOP), medication, transportation of families etc.). Indirect costs include 
the opportunity costs of work-loss days, lost productivity/income on the part of both the 
patients and his/her relatives. Intangible costs can arise from the functional limitations, 
pains acquired in the process and cannot be quantified and highly subjective in nature 
(Centers for Disease Control and Prevention (CDC), 2013). Besides these costs, there is 
another important cost incurred by the households through coping strategies, which 
includes sale of assets, taking up debt, saving on food or other items, taking a child out of 
school to care for the patient or taking up another job (Russell, 2004). 
The costs of communicable diseases fall on the households in three distinct 
phases: Pre-diagnosis, During Diagnosis/Pre-treatment, and During Treatment. McIntyre 
et al. (McIntyre et al., 2006) provided a flow-chart on economic consequences of TB 
illness and payment for healthcare (Figure 2.2). According to McIntyre there are four 
stages of tuberculosis treatment, e.g., illness experience, treatment seeking behavior, 
economic consequences, and coping strategies and social resources. In preliminary 
stages, perception of illness and treatment seeking can be affected by the economic status 
of the person. If the patient with TB does not seek treatment then only indirect costs are 
incurred in form of lost productivity, while if the patient goes for treatment then direct 
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costs also incurred on top of indirect costs. Indirect costs further subdivided into 
productivity loss of the patient and the caregiver, whereas direct cost is categorized into 
financial costs of healthcare (services and medicines) and other financial costs. 
Based on the conceptual model of McIntyre et al. (McIntyre et al., 2006) Laokri et 
al. (Laokri et al., 2014) provided an extended conceptual framework incorporating 
intangible costs, e.g., pain and suffering, and social stigma; elaborating coping costs and 
social burdens due to illness; and includes societal economic loss along with illness 
poverty trap ensued due to illness (Figure 2.3). This extended model also includes 
forgone activities of the informal caregivers as well as those of guardians accompanying 
the TB patients for treatment. These foregone activities culminate into labor substitution, 
withdrawal of children from school, and informal caregiving activities of the family 
members. Guardians lose time and income. Direct costs have been subdivided into 
subsidized healthcare costs, non-subsidized healthcare costs, and non-healthcare costs. 
Non-subsidized healthcare costs and non-healthcare costs along with income loss of the 
guardian can result in (1) Financial resource mobilization, e.g., borrowing, selling assets, 
pledging, extra-earnings etc.; (2) Resource reallocation, e.g., dissaving, budget cuts, 
deprivation, delayed investment etc. Non-subsidized healthcare costs and non-healthcare 
costs can also lead to erratic care pathways which include redundant care visits, 
alternative care seeking, diagnosis and treatment delays, and care interruption.  
Intangible costs like pain and suffering and social stigma can impose social 
consequences like (1) Low awareness: low awareness of disease, denial of illness status, 
bad living conditions, fear of losing position, social isolation, lack of family support, 
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patient-related delays; (2) Social exclusion: exclusion from services including public 
healthcare services, from income and from participation. 
Between McIntyre’s and Laokri’s conceptual frameworks, both of which are built 
upon the framework proposed by Russell (2004), simpler McIntyre’s framework will be 
adopted for this study. Both frameworks are more or less similar, while Laokri’s one is 
more detailed and includes pain and suffering, and social stigma. It is difficult to assign 
monetary value to intangible costs like pain and stigma. On the other hand, these 
intangible phenomena affect the quality of life of the patients. In our adopted quality of 
life measurement tool pain and stigma have included to offset their absence in the costs 
estimation. It also prevents double counting; once included in costs and again take into 
account while measuring quality of life.  
Study Design 
The study follows a stratified random sampling method. From the 64 districts of 
Bangladesh nine districts from the eight divisions (at least one from each division) were 
selected based on the high and low burden of TB cases. Then from each district two 
upazilas (sub-districts) were selected randomly. From the registry of the Directly 
Observed Treatment-Short-course (DOTS) center of the UHCs of these eighteen sub-
districts lists of TB patients currently undergoing treatment or recently finished were 
collected. Following is the list of all districts and sub-districts covered under the study. 
From each sub-district 50 DS-TB patients were selected randomly for interview. 
For assessing economic burden of MDR-TB patients and the economic evaluation 
of comparator MDR-TB control programs about 168 MDR-TB patients was selected 
purposively. 
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Study Participants 
The inclusion criteria for the study participants were older than 18 years of age, 
suffering or recently suffered from pulmonary TB (DS-TB/MDR-TB), and undergoing 
treatment or finished treatment within the previous 6 months. 
Sample Size  
The sample size for estimation of the costs incurred by DS and MDR-TB treatment 
will be calculated using the following formula: 
𝑛 = (
𝑍 ∗ 𝑆𝐷
𝑑
)
2
 
Where, 
Z= 1.96, the right-tail quantile value of a standard normal variable Z at =0.05 
d= margin of error 
SD= Standard Deviation of the mean costs 
For DS TB in a recent study we find that the patient cost for the treatment was 
$224 (Tanzania). This cost does not include the cost for providing the treatment, i.e., 
health care delivery costs. If we guess that the total cost would be $400 including all 
other costs. We also assume that the standard deviation would be $400 and with the 
margin of error of $50 we get the sample size at 5% significance level is 246. However, 
1,000 DS-TB patients were interviewed under the study; out of them 404 undergone 
treatment under CHW model and 598 got treatment under CM model. 
NTP PMDT Expansion plan, Bangladesh (2013 – 2017) estimates the MDR-TB 
treatment cost is $6000. If we take the similar figure as the standard deviation and $1200 
as the margin of error, we get the sample size for MDR-TB patients at 5% significance 

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level is 96. Under this study, 145 MDR-TB patients were interviewed; 58 patients were 
treated with 9 month regimen while 87 patients were under 20-24 month regimen. 
Providers 
Under the purview of the study 16 DOTs center managers and 3 representatives 
from MDR-TB care providing hospitals were interviewed for collecting cost of providing 
treatment to DS-TB patients. In each of the TB treatment facilities the facility manger 
was interviewed using a pre-set questionnaire. 
Variables 
Patient Costs Provider Costs Patients’ Socio-economic 
Characteristics 
 Direct costs 
o Medical 
costs 
o Non-medical 
costs 
 Indirect 
(opportunity) costs 
• Coping costs 
• Costs made in the 
facility that were not 
obligatory to get the 
diagnosis and 
treatment (i.e., costs 
of food).  
• Other costs: 
(in)direct costs made 
by or for 
accompanying 
persons (attendants) 
 
• Prevention and 
Promotion Costs 
• Contact Tracing 
Costs 
• Diagnosis Costs 
• Drugs Costs 
• Treatment Costs 
• Other TB activities 
Costs 
• Human Resources 
Costs 
• Capital Costs 
 
• Age 
• Sex 
• Education 
• Occupation 
• Religion 
• Current health status 
• Location (Rural, 
urban, urban slum) 
• Wealth (asset) index 
• Type of TB patient 
(New, relapse, 
failure, transfer in) 
• Household 
income/number of 
earning members 
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Data Analysis 
Data analysis was performed by Stata 14.2 (StataCorp, 2015). Descriptive 
statistics like means, standard deviation, frequency, and percentages will be reported. 
Multivariable regression analysis will be performed for finding the important variables 
for treatment and access costs. 
Measurement of Average Total Direct Costs 
Average total direct costs will be measured by combining all the out-of-pocket 
medical and non-medical costs for TB treatment. Costs for DS-TB and MDR-TB patients 
will be separately calculated. These costs include drugs, diagnostic tests, fees, 
consultation fees, food costs, travel costs, accompanying person costs. That means direct 
costs include all costs incurred directly out-of-pocket for the treatment of TB patient. 
Costs incurred by each patient, e.g., both DS-TB and MDR-TB, have been 
calculated. Patients were interviewed on each and every visits they made to any type of 
provider for the TB illness were tried to track down. For each visit the patients reported 
their (including their accompanying persons) incurred direct costs.  
Measurement of Average Total Indirect Costs 
Average total indirect costs will be measured by foregone income due to inability 
to do normal daily activities. These activities can be formal or informal. Valuation of 
productivity losses has been done using per capita gross domestic product (GDP) of 
Bangladesh (USD 1342/year that means 294 BDT/day). Valuation using GDP is 
preferred because this approach gives same weight to rich and poor people’s income.  
Regression Analysis 
Multivariable regression analysis will be performed using socio-demographic 
variables as the predictors. The cost data for both DS-TB and MDR-TB patients were 
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skewed to the right with cost amounts concentrating near zero values. However, the costs 
are not exactly zeros because all TB patients incurred some costs. Given the distribution 
of the costs data, normality assumption for OLS regression has been checked using 
histogram and normal probability plot, and heteroscedasticity was tested using the 
Breusch-Pagan test. We found that the normality assumption was violated and there was 
evidence of heteroscedasticity (unequal variance). 
Although log transformation of the cost variable is a common way to deal with 
this skewness, it still suffers from the problem of heteroscedasticity and the 
transformation and retransformation would lead to biased estimate of cost. Therefore, 
estimation of a Generalized Linear Model (GLM) has been preferred because it is 
particularly helpful in avoiding the log retransformation problem and it does not require 
the normality assumption to hold true. For GLM one has to specify the correct link and 
variance (family) function. The modified Park test was used for selecting family, while 
the Pregibon link test (checking linearity of response on scale of estimation) was used to 
assess the choice of link function, The large sample Pearson correlation test and Modified 
Hosmer-Lemeshow test (checks for systematic bias in fit on raw scale) were used for 
specifying link. Based on these tests, a GLM model with identity link and inverse 
Gaussian family, in which variance is proportional to the cube of mean, was found best 
suited for both DS-TB and MDR-TB cost models. 
We can specify the model as below: 
𝑐𝑖,𝑗 = 𝛽0 + 𝛽1𝑥𝑖,𝑗1 + 𝛽2𝑥𝑖,𝑗2 + ∑ 𝛼𝑘𝑧𝑖,𝑗
𝑛
𝑘
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Here, 𝑐𝑖,𝑗is the patient cost patient (i=1 to N) and suffering from DS-TB or MDR-
TB (j=0 or 1). 𝑥𝑖,𝑗1, 𝑥𝑖,𝑗2 are dummy variables for treatment through CHW model and CM 
model for DS-TB treatment costs respectively; while these two represents 20-24 month 
regimen and 9 month regimen for MDR-TB treatment model, 𝑧𝑖,𝑗   represents different 
covariates to control for across individuals.  
Provider Costs 
These costs can be called as health system costs as it contains the costs from the 
health system perspective. It includes capital costs, personnel costs, drugs cost, laboratory 
costs, and programmatic costs. Total cost for each facility has been summed up and then 
was divided by the number of total TB patients served by each facilities to come up with 
the per patient costs incurred by the provider. In other words, the health system cost will 
be described as the cost from the provider side to treat each patient under each type of 
treatment modality. 
Estimating Economic Burden of TB in Bangladesh 
Finally, the total economic burden of TB in Bangladesh has been calculated using 
the TB prevalence data. This data was obtained from Global Tuberculosis Report 2015 
published by World Health Organization (WHO). Recently a TB prevalence survey has 
been conducted by Institute of Epidemiology, Disease Control, and Research (IEDCR) in 
Bangladesh. The preliminary findings of that survey found that the prevalence rate was 
lower (295 per 100,000 population) than WHO estimate of 362 per 100,000 in 2015. This 
rate has also been used to estimate a comparative economic burden of TB in Bangladesh. 
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Results 
Patient Characteristics 
Mean age of DS-TB patients under the study was 45.2 years while mean age of 
MDR-TB patients were 35.5 years. Most MDR-TB patients were under the age of 45 
years, whereas DS-TB patients were more dispersed among the age groups. In both DS-
TB and MDR-TB samples majority of the patients were male, had no education, did 
informal work or did not work before occurrence of TB, of Islamic faith, and resided in 
rural areas. Most of the DS-TB patients were newly diagnosed, while most MDR-TB 
patients suffered from relapse or treatment failure. In the same vein, most of the DS-TB 
patients had no previous history of TB treatment, but almost two-third of the MDR-TB 
patients had previous history of TB treatment and almost one-fifth of the total sample did 
not complete the treatment. Since, wealth index was calculated separately among two 
samples, one-fifth (20%) of each population belonged to each quintile except the poorest 
quintile contained more (22.4%) patient than the poorest one (17.6%) (Table 4.1). 
Table 4.1 DSTB and MDR-TB Patient characteristics under the study 
Characteristics DS-TB Patients MDR-TB Patients 
N 1,000 145 
 % (n) %(n) 
Age   
 18-25 Years 14.9 (149) 29.0 (42) 
 26-35 Years 18.4 (184) 33.8 (49) 
 36-45 Years 17.5 (175) 13.8 (20) 
 46-55 Years 20.6 (206) 9.6 (14) 
 56-65 Years 17.5 (175) 9.0 (13) 
 66+ Years 11.1 (111) 4.8 (7) 
Sex   
 Female 37.5 (375) 42.1 (61) 
 Male 62.5 (625) 57.9 (84) 
Education   
 No Education 42.1 (421) 33.1 (48) 
 Primary 31.7 (317) 31.0 (45) 
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 Secondary 20.6 (206) 29.0 (42) 
 Higher Secondary and 
Higher 
5.6 (56) 6.9 (10) 
Occupation before TB   
 Formal 11.6 (116) 21.4 (31) 
 Agriculture or Household 
Jobs 
13.4 (134) 8.3 (12) 
 Informal  37.6 (376) 33.1 (48) 
 Did not work 37.4 (374) 37.2 (54) 
Religion   
 Other 10.6 (106) 7.6 (11) 
 Islam 89.4 (894) 92.4 (134) 
Current Health Status 
(VAS) 
  
 0.-50 23.2 (232) 34.5 (50) 
 51-65 16.9 (169) 11.0 (16) 
 66-80 37.9 (379) 30.3 (44) 
 81-100 22.0 (220) 24.1 (35) 
Location   
 Urban 18.2 (182) 37.9 (55) 
 Rural 77.2 (772) 47.6 (69) 
 Urban Slum 4.6 (46) 14.5 (21) 
Type of TB Patient*   
 New 94.2 (909) 4.6 (6) 
 Relapse/Failure 4.9 (47) 87.7 (114) 
 Loss to Follow Up 0.9 (9) 7.7 (10) 
Household Income Before 
TB 
15,282 [24,916] 17,355 [11,307] 
Previous TB Treatment   
 No Previous Treatment 94.0 (940) 35.2 (51) 
 Not Completed 1.0 (10) 17.9 (26) 
 Completed 5.0 (50) 46.9 (68) 
DS-TB Program Model   
 Community Health Worker 40.3 (404) - 
 Community Member  59.7 (598) - 
MDR-TB Program 
Regimen 
  
 9 Month Regimen - 40.0 (58) 
 24 Month Regimen - 60.0 (87) 
Wealth Index   
 Poorest 22.4 (224) 20.0 (29) 
 Poorer 17.6 (176) 20.0 (29) 
 Middle 20.0 (200) 20.0 (29) 
 Richer 20.0 (200) 20.0 (29) 
 Richest 20.0 (200) 20.0 (29) 
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Total 100 (1,000) 100.0 (145) 
* 15 missing for MDR-TB 
Patient Level Average Costs 
Direct Costs 
In Table 4.2, average direct costs borne by DS-TB and MDR-TB patients have 
been illustrated. Direct costs include all the out-of-pocket medical and non-medical costs 
for TB treatment. Total average direct costs for DS-TB patients were BDT 20,154 (USD 
252) and for MDR-TB the amount was BDT 30,858 (USD 386). The highest costs were 
incurred by the patients during the pre-diagnosis phase of the illness. DS-TB patients 
spent BDT 13,287 (USD 166) and MDR-TB patients incurred BDT 14844 (USD 186) 
before the diagnosis of TB disease was confirmed. TB diagnosis was costly for DS-TB 
patients (BDT 1,107; USD 14) than MDR-TB patients (BDT 685; USD 9). Hospital costs 
were way higher for the MDR-TB patients (BDT 7,669; USD 96) than DS-TB patients 
(BDT 2,515; USD 31). Additional food costs were more or less same for both DS-TB and 
MDR-TB patients. Accompanying person’s costs was higher for MDR-TB patients (BDT 
2,114.70; USD 26) than DS-TB patients (BDT 380; USD 5). Costs for side-effects of TB 
drugs were higher for the MDR-TB patients (BDT 1,647; USD 21) than DS-TB patients 
(BDT 435; USD 5). Relocation costs was incurred by only the MDR-TB patients during 
hospitalization (initial incentive phase of treatment). On an average, the relocation cost 
was BDT 341.24/USD 4.      
Indirect Costs 
In table 4.2, average indirect costs borne by DS-TB and MDR-TB patients have 
also been shown. Indirect costs include the income loss by the patients as well as their 
accompanying persons. MDR-TB patients incurred more indirect costs (BDT 1,523; USD 
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19) than DS-TB patients (BDT 407; USD 5). Similarly, the persons accompanied MDR-
TB patients lost more income (BDT 2,594; USD 32) than persons accompanied DS-TB 
patients (BDT 674; USD 8). In total, MDR-TB patients incurred more indirect costs 
(BDT 4,117; USD 51) than DS-TB patients (BDT 1,081; USD 14). 
Total Average Patient Level Costs 
In aggregate, DS-TB patients incurred total average costs of BDT 21,235 (USD 
265) for TB illness; while MDR-TB patients’ average costs were BDT 34,975 (USD 
437). 
Table 4.2 Patient Level Average Costs (BDT) 
Costs DS-TB Patients MDR-TB Patients 
N 1,000 145 
 Mean [SD] Mean [SD] 
Direct Costs   
 Before Diagnosis Costs 13,287.16 [55002.53] 14,844.23 [25589.24] 
 TB Diagnosis Costs 1,106.69 [5725.75] 684.63 [2177.10] 
 Follow-up Costs 172.16 [640.63] 877.17 [1825.46] 
 Drug Collection Costs 14.6 [195.91] 1.17 [6.18] 
 Hospital Costs  2,515.23 [14813.86] 7,669.40 [10521.34] 
 Additional Food Costs 2,244.01 [1915.92] 2,678.39 [1595.63] 
 Accompanying Person 
Costs 
380.03 [739.85] 2,114.70 [5309.25] 
 MDR-TB Relocation Costs - 341.24 [1386.08] 
 Drug Side-effects Costs 4,34.58 [2998.73] 1,647.28 [5463.01] 
Sub-Total (Direct Costs) 20,154.43 [60241.68] 30,858.22 [39964.31] 
Indirect Costs   
 Patient Opportunity Costs 
(Income Loss) 
407.07 [378.39] 1,522.86 [942.80] 
 Accompanying Person 
Opportunity Costs 
673.57 [1952.26] 2,593.91 [6765.72] 
Sub-Total (Indirect Costs) 1,080.64 [2004.40] 4,116.76 [6887.64] 
Total Costs 21,235.10 [60841.03] 34,974.098 [43635.95] 
Provider Level Average Costs 
In Table 4.3, facility level data was used to illustrate the average per person health 
system costs to provide TB treatment. DS-TB treatment facilities did not report any costs 
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for prevention and promotional activities, e.g., contact tracing, health promotional 
activities, vaccination activities etc. In treating each DS-TB patients the health system 
incurred only BDT 768 (USD 9.60), for MDR-TB patients the cost rose to BDT 160,474 
(USD 2006). Drugs (BDT 59276; USD 741), human resources (BDT 51826; USD 648), 
and diagnostic (BDT 35554; USD 444) were the highest cost incurring areas for MDR-
TB patients. Similarly, for DS-TB patients the highest cost-incurring areas were drugs 
(BDT 439; USD 5), diagnostics cost (BDT 184; USD 2), and human resources (BDT 70; 
USD 1). 
Table 4.3 Provider Level Average Costs (Per Patient) 
Costs DS-TB Facilities MDR-TB Facilities 
N 5648 576 
 BDT BDT 
 Prevention and Promotion 
Costs 
0.00 524.78 
 Diagnostic Costs 183.51 35,554.08 
 Drug Costs 438.79 59,275.55 
 Training Costs 10.63 1,014.58 
 Meeting Costs 1.34 874.64 
 Incentive Payment 31.28 3,100.00 
 Human Resources Costs 69.86 51,825.73 
 Capital Costs 29.37 8,211.78 
 Other Costs 2.92 92.73 
Total Costs (BDT) 767.69 16,0473.86 
Total Costs (USD) 9.60 2,005.92 
Per Patient Total Average Costs 
Average per patient total costs including patient and provider level costs have 
been shown in Table 4.4. On an average, each DS-TB patient incurs BDT 22,003 (USD 
275) and each MDR-TB patient incurs BDT 1,95,449 (USD 2443). 
Table 4.4 Per Patient total average cost (Including patient and provider level costs) 
Costs DS-TB  MDR-TB  
 BDT BDT 
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Patient Level Costs 
(BDT) 
21,235.10  27,809.67  
Provider Level Costs 
(BDT) 
767.69 16,0473.86 
Total Costs (BDT) 22,002.79 19,5448.84 
Total Costs (USD) 275.03 2,443.11 
Bivariate Analysis of Patient Level Cost Data 
Table 4.5 shows the results from bivariate analysis of patient level cost for both 
DS-TB and MDR-TB patients.  For DS-TB costs only mean total costs of different 
wealth quintiles were significantly different. In case of MDR-TB patients, categories of 
previous history of TB treatment and MDR-TB regimen had significantly different mean 
total costs.  
Table 4.5 Bivariate Analysis of Patient Level Cost for DS-TB and MDR-TB patients 
Characteristics DS-TB Patients MDR-TB Patients 
N 1,000 145 
 Mean Median p-Value Mean Median p-
Value 
Age   0.056a   0.438 
 18-25 Years 15,178 9,529 0.813 
(kwallis) 
43,3348 26,616 0.269 
 26-35 Years 17,788 8,806  31,536 18,732  
 36-45 Years 23,763 8430  23,988 16,135  
 46-55 Years 22,795 8,887  25,703 14,609  
 56-65 Years 15,993 8,802  47,734 19,504  
 66+ Years 36,463 9,378  35,049 16,476  
Sex   0.206   0.179 
 Female 18,092 8,802 0.812 40,703 24,217 0.239 
 Male 23,121 8,849  30,816 17,816  
Education   0.107   0.289 
 No Education 16,888 7,130 0.000 25,946 14,923 0.075 
 Primary 21,531 8,646  36,153 27,196  
 Secondary 26,083 12,830  40,912 18,467  
 Higher Secondary 
and higher 
34,404 21,196  48,076 25,419  
Occupation   0.079   0.097 
 Did not work 2320 10,095 0.001 46,270 26,431 0.133 
 Formal 31,086 10,478  32,054 26,898  
 Agriculture or 
Household Jobs 
22,693 7,552  30,992 16,102  
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 Informal  15,602 7,533  25,150 16,201  
Religion   0.168   0.210 
 Other 13,532 7,234 0.110 19,083 14,428 0.058 
 Islam 22,148 9,194  36,280 18,665  
Location   0.205   0.141 
 Urban 26,814 10,416 0.0015 44,143 29,782 0.003 
 Rural 20,585 8,494  29,566 14,127  
 Urban Slum 10,071 8,319  28,737 17,709  
Previous TB 
Treatment 
  0.108   0.041 
 No 20,453 8,515 0.001 45,025 35,200 0.004 
 Yes 33,484 11,988 0.021 29,523 16,377  
DS-TB Program 
Model 
  0.069    
 Community Health 
Worker 
16,971 7,574 0.000 - -  
 Community 
Member  
24,102 9,519  - -  
MDR-TB 
Program Regimen 
     0.006 
 9 Month Regimen - -  22,975 13,406 0.000 
 20-24 Month 
Regimen 
- -  42,975 28,261  
Wealth Index   0.015   0.120 
 Poorest 12,375 7,267 0.000 30,846 16,542 0.071 
 Poorer 27,450 7,072  30,180 16,476  
 Middle 18,483 8,340  27,372 16,147  
 Richer 19,175 9,972  32,204 21,801  
 Richest 30,776 12,826  54,273 30,770  
Comorbidity   0.238   0.927 
 No 19,610 8,180 0.006 35,146 18,012 0.693 
 Yes 24,404 9,752  34,319 20,607  
a p-values are obtained from univariate analysis 
Multivariable Analysis of Patient Level Cost Data 
Two separate GLMs were estimated with the patient level cost data for DS-TB 
and MDR-TB patients (Table 4.6). The modified Park test showed that best the GLM 
model for DS-TB costs belonged utilized the inverse Gaussian family, but for MDR-TB 
costs the Gamma family was best suited. The log link was best for both models. Results 
from the GLM post-estimation for selecting best model are shown in table 4.7.  
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Results show that education is a significant cost driver for both DS-TB and MDR-
TB patients. With higher education the costs tend to become higher in both cases. 
Improved health status (measured by VAS) was associated with decreased expense on TB 
care for DS-TB patients. This effect of better health status did not hold true for MDR-TB 
patients. Similarly, while location of the patient had no effect in case of MDR-TB 
patients, DS-TB patients resided in the urban slums incurred less cost than their urban 
counterparts.  
Previous TB treatment had a negative effect on MDR-TB patients cost, but it had 
no effect on costs of DS-TB patients. Community member model incurred more cost than 
the community health care model in case of DS-TB treatment. On the other hand, 20-24 
month regimen incurred more cost on MDR-TB patients than 9 month regimen. 
Wealth has no effect on cost of MDR-TB patients, while DS-TB patients 
belonged to middle, richer, richest quintiles incurred more costs than the poorest patients.  
Table 4.6 Multivariable Analysis of Patient Level Cost with Generalized Linear Model 
Characteristics DS-TB Patients MDR-TB Patients 
N 1,000 145 
 Log Link Inverse 
Gaussian Family 
Log Link Gamma Family 
 Coefficient 95% CI Coefficient 95% CI 
Age     
 18-25 Years Ref. - Ref. - 
 26-35 Years 0.25 -0.19-0.68 0.05 -0.39-0.48 
 36-45 Years 0.30 -0.15-0.76 -0.30 -0.79-0.23 
 46-55 Years 0.42 -0.03-0.86 0.20 -0.46-0.87 
 56-65 Years 0.36 -0.14-0.85 0.28 -0.34-0.90 
 66+ Years 0.41 -0.18-1.00 0.16 -0.68-0.99 
Sex     
 Female Ref. - Ref. - 
 Male 0.18 -0.15-0.52 -0.10 -0.48-0.27 
Education     
 No Education Ref. - Ref. - 
 Primary 0.39* 0.08-0.70 0.57** 0.15-0.99 
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 Secondary 0.45* 0.07-0.84 0.59** 0.15-1.02 
 Higher Secondary and 
higher 
0.93* 0.07-1.80 0.30 -0.41-1.01 
Occupation     
 Did not work Ref. - Ref. - 
 Formal 0.09 -0.42-0.60 -0.33 -0.80-0.14 
 Agriculture or Household 
Jobs 
0.02 -0.50-0.54 0.28 -0.44-1.00 
 Informal  -0.31 -0.68- -0.07 -0.49 -0.92-0.07 
Religion     
 Other Ref.  Ref. - 
 Islam 0.28 -0.07-0.62 0.43 -0.20-1.05 
Current Health Status 
(VAS) 
-0.01* -0.02- -0.002 -0.004 -0.01-0.005 
Location     
 Urban Ref. - Ref. - 
 Rural -0.02 -0.46-0.41 0.42 -0.19-1.04 
 Urban Slum -1.07** -1.74- -0.40 -0.004 -0.58-0.58 
Previous TB Treatment     
 No Ref. - Ref. - 
 Yes 0.40 -0.23-1.03 -0.49** -0.83- -
0.15 
DS-TB Program Model     
 Community Health 
Worker 
Ref. - - - 
 Community Member  0.43** 0.18-0.69 - - 
MDR-TB Program 
Regimen 
    
 9 Month Regimen - - Ref. - 
 20-24 Month Regimen - - 1.17*** 0.60- 1.74 
Wealth Index     
 Poorest Ref. - Ref. - 
 Poorer 0.15 -0.18-0.48 -0.03 -0.52-0.46 
 Middle 0.38* 0.04-0.72 -0.37 -0.93-0.20 
 Richer 0.41* 0.04-0.78 -0.32 -0.95-0.31 
 Richest 0.54* 0.03-1.05 0.10 -0.63- 0.82 
Comorbidity     
 No Ref. - Ref. - 
 Yes 0.15 -0.13-0.44 0.02 -0.40-0.44 
AIC 29.30 22.91 
BIC -5958.78 -515.46 
Log Likelihood -13159.45 -1636.64 
 
Table 4.7 Results from GLM post-estimation for selecting best model 
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Test DS-TB Patients MDR-TB Patients 
 Test 
Statistic  
p-Value 
Decision Test 
Statistic  
p-Value 
Decision 
Modified Park Test 0.27 Inverse 
Gaussian 
Family  
0.15 Gamma 
Family 
Pearson Correlation 
Test 
0.83 Log Link 0.15 Log Link 
Pregibon Link Test 0.21 Log Link 0.12 Log Link 
Modified Hosmer-
Lemeshow Test 
0.57 Log Link 0.66 Log Link 
Economic Burden of TB Care in Bangladesh 
Based on the World TB Report 2016, total 209,438 DS-TB patients were under 
treatment in Bangladesh. Assuming 57% case notification rate, we get the actual number 
of TB patients in Bangladesh in 2015 was 367,435. Therefore, the actual costs incurred 
by Bangladesh have been calculated as USD 55.6 million. Whereas, if all DS-TB patients 
were treated the cost would have been 1 billion USD.  
For MDR-TB treatment, total USD 12.5 million was incurred in Bangladesh in 
2015. If all MDR-TB patients were treated the total cost would have been USD 23 
million (Table 4.8). 
Table 4.8 Economic Burden of TB care in Bangladesh in 2015 
Type of 
TB 
Patients 
Average 
cost  
  
Total TB 
patients 
under 
treatment 
in 2015 
Total actual costs 
for TB Care 
Total TB 
patients in 
2015 
  
Total costs 
required for TB 
Care 
BDT  USD BDT  USD 
DS-TB 22,003 209,438 4.45 
Billion 
55.59 
Million 
367,435 8.08 
Billion 
101.06 
Million 
MDR-
TB 
195,449 5,100 0.18 
Billion 
12.46 
Million 
9,700 1.90 
Billion 
23.70 
Million 
Total     4.63 
Billion 
68.05 
Million 
  9.98 
Billion 
124.76 
Million 
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Discussions 
Study results show that average per DS-TB patient costs were BDT 21,235 (USD 
265), which is almost similar to the findings of a recent study (BDT 20,720; USD 224) 
(Gospodarevskaya et al., 2014). However, the study reported only treatment cost and 
excluded the pre-diagnosis cost incurred by TB patients. Excluding the whooping $166 
for pre-diagnosis cost, the actual treatment level costs for DS-TB in Bangladesh from our 
study comes to $100. The main difference between the study and our result stems from 
the estimation of productivity losses by patients and guardians. That study used the 
household level income but we used per capita GDP as the basis for calculation of lost 
productivity. Given our sample size of 1,000 in comparison to their 96, we can 
confidently claim that our result is more authentic and does not differ significantly 
between different types of providers.   
 Both types of delivery modalities for DS-TB patients in Bangladesh, e.g., CHW 
and CM models, ensure patients can get their medicines at their doorsteps or very near to 
their houses supervised by community health workers and community members. MDR-
TB patients also get their medicines from assigned community DOTS providers. Yet, TB 
patients incur considerable expenditure for TB treatment. From the results we can see that 
a significant portion of the expenditure is incurred before TB diagnosis. It constitutes 
about 63% of total costs for DS-TB patients and 42% of MDR-TB patient costs. This 
shows that once the patient is diagnosed and under the treatment stream, patient level 
costs and health system costs constitute only one-third of the total cost. Delay in TB 
diagnosis is the major cost driver for the patients. Patients may visit number of providers 
from informal to formal, even are hospitalized in the course, and incur a great loss in 
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terms of medical and non-medical costs. This finding is similar to other studies where 
pre-diagnosis cost of TB treatment constituted more than half of the total costs (Tanimura 
et al., 2014). High pre-diagnosis cost of TB care is a phenomenon ubiquitous in LMICs, 
e.g., in Malawi the patients incur a significant pre-diagnosis cost which offset the free TB 
care and make the TB treatment unaffordable (Kemp, Mann, Simwaka, Salaniponi, & 
Squire, 2007). 
The study results slightly differ with the findings from a systematic review done 
by Laurence et al. The average provider level cost was $273 in that study (Laurence et 
al., 2015) in comparison to $9 per DS-TB patient in ours, since they included 
hospitalization cost ($215). But in Bangladesh, the DS-TB treatment protocol does not 
require hospitalization, therefore, our results do not include any hospitalization costs and 
that makes the two estimates very close.  For MDR-TB costs, provider level costs were 
calculated $6313 in LMICs and $1218 in LICs, and patient level costs were calculated 
$1616 total direct costs in LMICs and $1662 total costs in LICs (Laurence et al., 2015). 
In our study we found different results-  provider level costs were $2006 and patient level 
costs were $437. It may be due to their estimation of life-time productivity loss, which 
we confined within the period of illness only. 
We found that health system costs for providing treatment costs is nominal ($9 
per patient) in Bangladesh. But the high number of patients make the total burden high. 
For treating DS-TB patients Bangladesh incurred 55.6 million USD in 2015, and for 
MDR-TB patients USD 12.5 million. In total, expenditure for TB treatment in 
Bangladesh was 68 million USD. In Bangladesh, total health expenditure was 325,094 
million BDT (4,063 million USD) in 2012. Therefore, in 2015 the amount would have 
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been 4,545 million USD. So, TB care expenditure constitutes about 1.67% of total 
healthcare expenditure in Bangladesh. This figure does not look so ominous, but the 
potential of TB treatment is very high in terms of future benefits. In a recent study 
commissioned by the Copenhagen Consensus Group, Vassal showed that TB treatment 
was ranked first among all priorities because its huge potential in future befits. If one taka 
is spent for TB treatment, the economic return would be in the range of 29 to over 162 
BDT (Anna Vassal, 2016). 
TB also poses great financial hardship on the afflicted population. Often times 
poor people are the sufferer and their economic condition does not help them either. In 
our study results we see that DS-TB patients incurred about 50% of their household 
annual income for TB treatment while that goes up to 66% for the MDR-TB patients. 
This catastrophic health expenditure is multiplied in severity due to the absence of any 
health insurance or other healthcare financing mechanism in Bangladesh (Nazmul, Abul 
Quasem, Howlader, & Kabir, 2015). People tend to resort to sale of assets or savings and 
borrowing with or without interest to cope with this catastrophic cost, which, in the long 
run, make the household poorer (Khan, Ahmed, & Evans, 2017; Rahman, Gilmour, Saito, 
Sultana, & Shibuya, 2013). 
Data collected from the DS-TB health facilities show that no cost was incurred for 
health promotional and preventive activities in past year. That means there was no such 
activities in place. But contact tracing, promotional activities like making people aware of 
the signs and symptoms of TB illness, informing the people on the treatment availability 
and the successful cure is possible upon completion of treatment, the place where TB 
treatment is available etc. are deemed to be instrumental in combating TB in LMICs like 
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Bangladesh. There are some top-down promotional activities done from the central level, 
but that may not reach the grass-root level. Different means of behavioral change 
communication should be introduced; otherwise the ambitious target of reducing TB 
deaths by 95% and curbing new cases by 90% from 2015 to 2035 (World Health 
Organization (WHO), 2017) would not be achieved. 
Urban slum is another hot spot which can serve as the new foci of TB in 
Bangladesh. With highest urbanization rate in the world (6.5%) the capital Dhaka city 
experiencing a burgeoning urban slum population. This population often resides in the 
most inhuman condition and lack basic needs like health, education, and proper housing. 
This close proximity of people (200,000.people in 1 square kilometer in Bangladeshi 
slums (Angeles et al., 2009)) and poor living conditions facilitate transmission of the TB 
bacillus and containment of the disease makes so challenging. We find from our results 
that slum dwellers can spend much lower than their urban counterparts and still that 
lower spending leaves them as poverty-stricken for rest of their lives due to the long term 
effect on their income generating potentials. 
Conclusions 
Since the lion share of the total costs was incurred before diagnosis, it is 
imperative to strengthen the early diagnosis and treatment of TB disease in Bangladesh. 
CHW or CM who are involved with the DOTS treatment and act as a DOTS provider 
should also act as the counselor for the patients and their family members. DOTS 
supporter should also keep eyes open to find any potential TB cases and refer them to the 
nearest facility. 
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Contract tracing can be another useful way for detecting TB patients. Although it 
was a regular activity in the past, during the survey we did not find any such activities 
performed nowadays. It is a reminder that we should not move away from the basic 
prevention techniques of the public health. 
Although, treating DS-TB patients is more beneficial in the long-run, proper 
treatment of MDR-TB patient is very important in further spread of the deadly disease. 
MDR-TB needs special attention, because of the length of the treatment and potential for 
loss to follow up and relapse. Therefore, MDR-TB patients should also be given proper 
treatment and special arrangements, like tracking patients uptake of drugs by novel 
means, can be thought of. 
TB has been cited as the most effective health intervention in terms of cost-
benefit ratio (Anna Vassal, 2014).  It is high time to get all TB patients under treatment 
and thereby improve the economy of the country. It will also help us to reach the 
ambitious goal of the WHO End TB strategy by 2035. 
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CHAPTER 5 
STUDY II 
5.1 ECONOMIC EVALUATION OF DRUG-SENSITIVE TUBERCULOSIS (DS-TB) 
TREATMENT APPROACHES IN BANGLADESH2 
                                                          
2 Haider, M. R. To be submitted. 
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Abstract 
Introduction: Bangladesh is a high burden Tuberculosis (TB) country that experienced 
362,000 new TB patients and 73,000 TB deaths in 2015. Drug sensitive TB (DS-TB) is 
the most prominent type of TB found in Bangladesh and a 6-month drug regimen (2 
month intensive and 4 month continuation phase) is prescribed. However, the directly 
observed treatment short-course (DOTS) differs in delivery through community health 
workers (CHWs) and community members (CMs). This study compares these two 
delivery models and conducts a cost-effectiveness analysis.  
Methods: The incremental cost-effectiveness ratio (ICER) of treating DS-TB patients, 45 
years old on average, through CM versus CHW delivery was compared using a Markov 
model with life-time horizon (27 years). The measure of effectiveness, Quality adjusted 
life year (QALY) and cost of treatment was collected from 1,000 MDR-TB patients (598 
for CM model and 402 from CHW model) in Bangladesh. Transition probabilities 
between Markov states were estimated from quarterly outcomes report collected from 
health facilities and cost and QALY both were discounted at a rate of 3%. Both 
deterministic and probabilistic sensitivity analyses were conducted in a Monte Carlo 
Simulation using the R programming language.  
Results: Results show that each DS-TB patient under CM treatment model gains 3.61 
QALYs with a cost of BDT 131,555. For the DS-TB patients under the CHW model the 
cost is 81,650 and the QALY gain is 3.12. The Incremental Cost-Effectiveness Ratio 
(ICER) is 103,454, i.e., the CM model is cost-effective if per QALY gain if willingness-
to-pay is set to the per capita GDP of Bangladesh (BDT 107,360 in 2015). 
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Conclusions: Our study results suggest that a community-based model of DS-TB 
treatment is cost-effective even with changed costs and utility values in probabilistic 
sensitivity analysis. Community members as DOTS provider are more capable of 
reducing stigma related to TB, enhancing patient adherence and thereby reduce costs and 
increase utility from the treatment. Community members should also be involved in 
contact tracing and prevention activities to increase the effect of the involvement in TB 
control. 
Keywords: Economic Evaluation, Drug Sensitive Tuberculosis, Cost-effectiveness, Cost, 
QALY, Community Based Treatment, Bangladesh 
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Introduction 
In 2015, tuberculosis (TB) ranked 18th among the highest burden diseases 
globally and it constituted 47% of the global burden attributable to communicable, 
maternal, neonatal, and nutritional disorders (Kassebaum et al., 2016). During that year, 
10 million new cases of TB were reported and almost two million people died from TB 
worldwide (World Health Organization (WHO), 2016a).  In the same year, TB became 
the joint top infectious disease killer by claiming 1.1 million lives and matching the death 
tolls by HIV/AIDS (Kassebaum et al., 2016). 
Almost 85% of all new cases of TB and multi-drug resistant TB (MDR-TB) occur 
in 30 high burden TB countries including Bangladesh (World Health Organization 
(WHO), 2015b). According to one estimate in Bangladesh during the whole year of 2015, 
approximately 362,000 people developed TB and 73,000 died from it. In Bangladesh, TB 
accounted for 12% of all deaths (609,800) that occurred in 2015 (Institute for Health 
Metrics and Evaluation (IHME), 2016). Although case notification rate is only 57%, 
success of the treatment is high (93%) among DS-TB patients. However, the success rate 
is 75% among MDR-TB patients which signifies how difficult to treat drug resistant 
strains (World Health Organization (WHO), 2016a). Despite having effective treatment, 
patient adherence to TB treatment remains poor because of the long duration of the 
regimen (six months for newly diagnosed cases) and the need for daily dosing.  Failure to 
adhere to the regimen results in MDR-TB (Gandy & Zumla, 2002).  
The predominant method of detecting TB at the community level is examining the 
sputum sample with Acid Fast Bacilli (AFB) technique. In the case of detection of MDR-
TB, culture and sensitivity analyses are done in laboratories. Directly Observed 
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Treatment Short-Course (DOTS) strategy has been implemented in Bangladesh since 
1993 and all the Upazila Health Complexes (UHCs) have been brought under the 
purview of the service from where TB detection and treatment services are given free of 
cost. The essence of the strategy is the diagnosed TB patient has to go to the facility 
every day for taking the drugs, thus treatment discontinuity and subsequently MDR-TB 
cases can be averted (World Health Organization (WHO), 2013d).  
The vibrant presence of Non-governmental organizations (NGOs) in the health 
sector and TB control endeavor compels the National Tuberculosis Control Program 
(NTP) under Ministry of Health and Family Welfare (MoHFW) of Bangladesh to 
incorporate them into the public-private partnership (PPP) model of combating TB since 
2003. In the recent guideline the role of government and private sector partnership was 
reiterated again (Guideline). It was also found in different studies that this PPP model in 
TB control was effective in achieving relatively high case detection (Ullah et al., 2012; 
Ullah, Newell, Ahmed, Hyder, & Islam, 2006). 
For the drug sensitive TB patients, a standard 6-month regimen is followed by all 
participating NGOs. However, the mode of delivery is different for different NGOs. 
BRAC has employed Community Health Workers (CHWs) besides the DOTS centers to 
ensure patient compliance, while Damien Foundation (DF) trained and employed 
influential community members to help the patients to be adhered to the treatment 
protocol. Another NGO, Salvation Army Bangladesh, is using drug sellers at the 
pharmacies as the counselor and drug distributors for the TB patients. Since involving 
different people, e.g., family members, neighbors, pharmacists falls under common 
strategy of involving community members.  
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Using Denver General Hospital data Burman et al. showed that although DOTS is 
costly at the outset it turns to be cost-effective than Self-administered Therapy (SAT) 
because of higher cure rates (Burman et al., 1997). The outcome variable for this study 
was cure rate per cost unit. Using published literature, records, and expert opinions 
Baltussen et al. showed that DOTS as well as incremental programs like DOTS plus, Full 
combination of DS-TB and MDR-TB strategies all are cost-effective in terms of DALYs 
averted per cost unit in high burden TB countries in Africa and South-East Asia 
(Baltussen et al., 2005). 
A recent study shows that shortening of the DS-TB treatment from six-months to 
four-months remain cost-effective option for Brazil, South Africa, Bangladesh and 
Tanzania (Gomez et al., 2016). Another study results also support this finding in South 
Africa (Knight et al., 2015). 
Although several studies conducted economic evaluation between different types 
of treatment model or regimen, economic evaluation between CHW and CM models has 
not been performed. The two methods of delivering DS-TB care in Bangladesh based on 
the service area of particular NGOs provide us with the opportunity to evaluate the cost-
effectiveness of two methods of delivering DOTS to DS-TB patients. This study aims to 
conduct an economic evaluation between CHW and CM models of delivering DS-TB 
care with a societal perspective and Quality Adjusted Life Years (QALY) as the outcome. 
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Methods 
Study Design and Data Sources 
The study follows a stratified random sampling method. From the 64 districts of 
Bangladesh nine districts from the eight divisions (at least one from each division) were 
selected based on the high and low burden of TB cases. Then from each district two 
upazilas (sub-districts) will be selected randomly. From the registry of the DOTS center of 
the UHCs of these eighteen upazilas, lists of TB patients currently undergoing treatment or 
recently completed treatment will be collected. From each upazila 50 DS-TB patients were 
selected randomly for interview. The list of all districts and upazilas covered under the 
study is shown in Table 3.1. 
 
Institutional level data was also collected for assessing the provider level costs 
associated with TB treatment using a pre-set and pre-tested provider questionnaire. We 
interviewed the healthcare facility manager to get the annual human resources costs, costs 
for training, meeting, incentive payments, capital costs, and other costs.  Drug costs and 
diagnostic costs are assumed to be equal for both treatment model since both model 
follows the same guidelines published by NTP (National Tuberculosis Control Program 
(NTP), 2014). Capital costs were annuitized to get the annual costs. Facility quarterly 
reports from the year 2015 was used for estimating the total number of patients treated in 
each facility. Finally, average per patient costs were calculated for each type of treatment 
model.  
The DS-TB patients were interviewed using a pre-tested questionnaire adopted 
from the  Stop-TB questionnaire on patient’s cost (Stop TB Partnership DOTS Expansion 
Working Group (TB and Poverty subgroup), 2008).The variables of interest are the 
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duration of illness, time elapsed before diagnosis, present status of the illness, how many 
healthcare providers has been consulted, the direct costs incurred in each encounter, 
duration of DOTS treatment, transportation cost to DOTS center, any friend/relative 
accompanying with and the opportunity cost of their time, and the lost work days and 
income of the patients among others.  
Target Population and Study Sample 
This study covers pulmonary form of DS-TB patients aged 18 years or more from 
all administrative divisions of Bangladesh. Total 1,000 DS-TB patients’ data was 
collected for patient level cost and outcomes (QALY) estimation under this study. Out of 
these 1,000 patients, 402 were under CHW treatment model and 598 were under CM 
treatment model. Study locations are shown in the Appendix Figure 1A. 
Glick (H. A. Glick, 2011) proposed a sample size formula for cost-effectiveness 
evaluation of clinical trials. Although our study is not a typical clinical trial, given the 
nature of the intervention and the study design we can apply the formula for calculating 
the required sample size for our study.  The formula calculates the sample size for each of 
the two groups with similar standard deviation of costs and effect and same sample size: 
𝑛 =
2 (𝑍𝛼 + 𝑍𝛽)
2
[𝑠𝑑𝑐
2 +  (𝑊 ∗ 𝑠𝑑𝑞
2)
2
−  (2 𝑊𝜌 ∗ 𝑠𝑑𝑐 ∗ 𝑠𝑑𝑞)
(𝑊𝑄 − 𝐶)2
 
Where:  
Zα is the Z-statistic for the level of Type I error (set at 95%)  
Zβ is the Z-statistic for the level of Type II error (set at 80%) 
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sdq, sdc are the std deviations for each group for treatment effect and cost 
respectively  
W is the Maximum Willingness to Pay  
Q is the expected mean difference in treatment effectiveness  
C is the expected mean difference in treatment cost  
ρ is the expected correlation of the difference in cost (C) and effect (Q) 
This is a measure of the covariance of changes in effectiveness and changes in 
cost. Negative covariance, where cost decreases with increasing effectiveness result in a 
larger sample size. Positive covariance where cost increases with increasing effectiveness 
result in smaller sample sizes. 
With 95% confidence interval and 80% power of the test, we assumed that the 
standard deviation of costs (sdc) is 400 USD, standard deviation of effect (sdq) is 0.2 
QALY, ρ, correlation of difference in cost (C) and effect (Q) is 0.4. The expected mean 
difference in treatment effectiveness (Q) is 0.4 QALY and expected mean difference in 
treatment cost (C) is 500 USD. We set the willingness-to-pay threshold (W) at the three 
times of GDP of Bangladesh which is 3942 USD (BDT 315,360) (Macroeconomics, 
2001). We found the sample size for both treatment groups is 405 which is equal to our 
study sample size. 
Ethical Consideration 
The study has already got ethics approval from University of South Carolina in 
the USA where the PI is a PhD student. Institutional Board Review (IRB) approval was 
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also obtained from Jahangirnagar University in Bangladesh. A third and final approval 
was obtained from WHO Research Ethics Review Committee (WHO ERC). 
Settings and Locations 
DF implements their DS-TB program in 22 districts in the North-Western part of 
Bangladesh. The DS-TB patients detected in these areas are treated following same 
regimen but the delivery of the DOTS is done by the community members. Whereas, in 
rest of the 42 districts all over Bangladesh follows the treatment delivery method by 
community health workers. This study collected data from districts of all eight divisions 
of Bangladesh.   
Study Perspective 
The study will be conducted form the societal perspective, which will encompass 
all costs incurred by the health care providers, patients, and community. 
Comparators 
For the DS-TB patients standard 6 months regimen is followed by all participating 
NGOs. However, the mode of delivery is different for different NGOs. BRAC has 
employed Community Health Workers (CHWs) besides the DOTS centers to ensure 
patient compliance, while Damien Foundation (DF) trained and employed influential 
community members to help the patients to be adhered to the treatment protocol. Another 
NGO, Salvation Army Bangladesh, is using drug sellers at the pharmacies as the 
counselor and drug distributors for the TB patients. We treated drug sellers under the 
community model. This study will conduct economic evaluation between this two DS-TB 
treatment delivery models. 
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Time Horizon 
The study will take a life-time horizon to capture all costs and outcomes 
according to WHO guideline (Edejer, 2003). Since this study includes patients 18 years 
and older, we assume they will live through to their life expectancy (72 years in 2015). 
Mean age of the patient interviewed was 45 years. Therefore, we repeated the cycle for 
27 times to include their whole lifespan.  
Discount Rate 
The study will follow the WHO discount rate of 3% for both costs and outcomes 
(Edejer, 2003).  
Choice of Outcome 
Quality Adjusted Life Year (QALY) is the chosen outcome for this study.  
Measurement of Effectiveness 
QALY has been modeled using patient-level EuroQol-5 Dimensions-5 Levels 
(EQ-5D-5L) measure of health related quality of life (EuroQol Research Foundation, 
2017). We used Zimbabwe score sets for EQ-5D, since Zimbabwe is another developing 
country like Bangladesh and we assume the EQ-5D score sets would have been similar 
between populations of these two countries. Finally, the QALY measure was estimated 
after controlling for patient’s socio-economic factors. Lognormal (log value of QALY as 
dependent variable) has been found more suitable model. Recycled prediction has been 
used to find out the estimated QALY for each type of patient outcome (e.g., cure, failure, 
and default) for both regimens (Glick Book). For death state utility has been assumed 
zero. 
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Measurement of Costs 
Health systems costs were collected from different sources. Prevention and 
promotion costs, training costs, meeting costs, human resources costs, capital costs, and 
other costs were collected from DS-TB treatment facilities under the purview of the study 
using a pre-set provider questionnaire. Heath facility managers, personnel responsible for 
financial transactions were interviewed using the questionnaire and relevant costs were 
collected. Capital costs were annuitized using 5% interest rate and 10-year lifetime for 
Microscopes and Gene Xpert machines, and vehicles. Costs for drugs and diagnostic tests 
were assumed to be equal across two treatment modalities since both follows the same 
drug regimen and treatment protocol. Per patient cost of delivering DS-TB treatment for 
both types of regimen have been estimated dividing costs among the number of treated 
patients in one year in those facilities using total number of patients got treatment in 
2015.  Patient costs were collected through interviews of DS-TB patients using a pre-set 
and pre-tested questionnaire prepared on the basis of Stop-TB questionnaire on patient’s 
cost (Stop TB Partnership DOTS Expansion Working Group (TB and Poverty subgroup), 
2008). The questionnaire was translated in Bengali and the retranslated in English to 
validate the translation. Both patient and provider questionnaires were pre-tested and 
changes were incorporated before using those in the survey. Total costs of treating a 
patient under each regimen was calculated by summing up the patient and provider level 
costs. Then the cost was estimated using a Generalized Linear Model with Gamma 
variance and log link using data from 1,000 interviewed DS-TB patients who had 
complete information on disease outcomes. GLM diagnostics were used to validate the 
GLM variance and link. Recycled prediction was used to estimate the costs for each type 
 
81 
 
of patient outcome (e.g., cure, failure, default) for both regimens (H. Glick, Doshi, 
Sonnad, & Polsky, 2007). For death state costs were assumed to be zero.  
Models and Analysis 
A dynamic, stochastic, Markov simulation model was used to model the cost-
effectiveness of the two comparison regimens. Markov models have unique 
characteristics which fit the progression of TB well. For example, in a Markov model 
states are mutually exclusive, states are complete (i.e. no people are lost) and people 
remain in each state for a fixed period of time. Also, a Markov model is preferred over 
the decision trees when health event repeats over time, or have longer term health effects, 
effect of treatment either stops quickly after initial treatment or continue at an earlier 
level, and the risk of different health events does not depend on patient’s prior history. 
We can represent the Markov model for DS-TB as Figure 2.4. A more simplistic 
decision tree model can be shown as in Figure 5.1: 
From the Markov model and decision tree we can find that after starting of the 
treatment the DS-TB patient can move to either of the four states, e.g., cure/treatment 
complete, failure/relapse, default, and death. Cure state has been defined as those who 
had completed treatment protocol without any evidence of failure and had at least three 
consecutive negative cultures from samples collected at least 30 days apart in the final 12 
month of treatment, or “Treatment Completed”, those who completed treatment 
according to treatment protocol but did not meet the definition for cure because of lack of 
bacteriological results. 
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Cure/Treatment Completed
DOTS by CHW
Retreatment DOTS by CM
1
DOTS at Health Facility
DOTS by CHW
Fail
Transfer Out
DOTS by CHW
MDR-TB
1
Hospital Treatment
Smear Positive Pulmonary TB
1
Death
DOTS by CM
DOTS at Health Facility
Figure 5.1 Decision Tree of two comparison treatment strategies for DS-TB 
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Failure/relapse cases were defined as those who had been treated for DS-TB, were 
declared cure or treatment completed at the end of their most recent course of treatment, 
and later diagnosed with a recurrent episode of DS-TB. Lost to follow up/ default cases 
were defined as those DS-TB patients whose treatment was interrupted for two or more 
consecutive months for any reason  (National Tuberculosis Control Program (NTP), 
2013, 2014).  
Here death is the absorbing state, i.e., if a patient is dead he/she can move from 
that state to another. If any patient is cured he/she can remain cured, relapse/reinfection 
may occur, lost to follow-up (default) or can be dead. On the other hand, the 
failed/relapsed patients undergo another cycle of treatment and can culminate into cure, 
remain failed, can default, or can be dead as well. Similarly, from default state one can 
move over to other three states.  
Cost-effectiveness evaluation was performed using heemod package in R 
(Filipović-Pierucci, Zarca, & Durand-Zaleski, 2017). The BCEA package was also used 
to validate the results form analysis with heemod package (Filipović-Pierucci et al., 
2017). Cost and utility data was modeled using STATA 14.2 (StataCorp, 2015). 
Measurement of Transition Probabilities 
As mentioned earlier, cost-effectiveness analysis of these two regimens has not 
been undertaken yet. However, the programmatic outcome for the two treatment 
strategies has been derived from the quarterly reports on the health outcomes after 12-15 
months of completion of treatment, which were collected from the health facilities. Using 
the reports from 2015, total number of patients and their transition between different 
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states have been calculated. Transitional probabilities were estimated from these numbers 
of DS-TB patients in different states using Markov simulation as an evidence synthesis 
technique (Sutton, Welton, & Cooper, 2012). R has been used for the analysis along with 
r2jags package for estimating the transitional probabilities for two treatment regimens 
(Su & Yajima, 2012).  
From these two studies the transitional probabilities for first two cycles were 
estimated and furnished in Table 5.1.  
Table 5.1 Transitional Probabilities of DS--TB Treatment Regimens 
Input variable CM CHW 
Cure to Cure (tpC2C) 0.609 0.529 
Cure to Failure (tpC2F) 0.126 0.133 
Cure to Default (tpC2Def) 0.127 0.170 
Cure to Death (tpC2Death) 0.138 0.168 
Failure to Cure (tpF2C) 0.354 0.268 
Failure to Failure (tpF2F) 0.209 0.244 
Failure to Default (tpF2Def) 0.209 0.240 
Failure to Death (tpF2Death) 0.228 0.248 
Default to Cure (tpDef2C) 0.250 0.245 
Default to Failure (tpDef2F) 0.252 0.255 
Default to Default (tpDef2Def) 0.250 0.250 
Default to Death (tpDef2Death) 0.248 0.250 
 
Parameters 
Patient level cost for each regimen as well as the per patient provider costs are 
shown in Table 5.2.   
Table 5.3 shows parameters for the cost-effectiveness analysis along with their 
distributions. Parameters mainly consist of transitional probabilities for transition 
between different states, costs for treating each type of states, and the utility of each 
states. Apart from this initial age was determined as the mean age of the interviewed 
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population (45 years). Time horizon was therefore fixed at 27 years, accounting for the 
rest of the general life expectancy of Bangladeshi people (life expectancy at birth in 
Bangladesh is 72 years (The World Bank, 2017b)). Both age and cycle parameters were 
kept fixed for the model. 
Costs parameters follow gamma distribution as mentioned earlier and measured in 
2015 Bangladeshi Taka (BDT). Utility values are measured in QALY and their 
distributions were lognormal.  
Table 5.2 Patient, Provider and Total Costs for two regimens of DS-TB treatment in 
Bangladesh 
Costs CHW CM 
A. Patient Level Costs  Mean (BDT)  Mean (BDT) 
Direct Costs     
 Before Diagnosis Costs 10,894.24 14,895.78 
 TB Diagnosis Costs 777.37 1,328.08 
 Follow-up Costs 213.55 144.33 
 Drug Collection Costs 2.81 22.49 
 Hospital Costs  1,421.63 3,250.39 
 Additional Food Costs 1,926.06 2,457.74 
 Accompanying Person Costs 365.7 389.66 
 MDR-TB Relocation Costs    
 Drug Side-effects Costs 438.33 432.11 
Total Direct Costs 16,039.69 22,920.58 
Indirect Costs    
 Patient Opportunity Costs (Income Loss) 432.8 396.63 
Accompanying Person Opportunity Costs 508.28 784.68 
Total Indirect Costs 941.08 1,181.31 
Total Patient Level Costs 16,980.77 24,101.89 
B. Provider Level Costs   
 Prevention and Promotion Costs Not reported Not reported 
 Diagnostic Costs Same Same 
 Drug Costs Same Same 
 Training Costs 6.23 44.02 
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 Meeting Costs 0.70 5.67 
 Incentive Payment 100.99 13.21 
 Human Resources Costs 1,827.20 1,592.01 
 Capital Costs 36.56 94.41 
 Other Costs 2.29 11.26 
Total Provider Level Costs 19,73.97 1,760.56 
Total Costs 18,954.74 25,862.45 
 
Table 5.3 Input Parameters for Cost-Effectiveness Analysis of DS-TB Treatments 
Variable 
Category 
Distributiona Value Low High Reference 
Starting age of 
cohort (mean) 
Fixed 45 Years - - Study Data 
Time horizon Fixed 27 Years - - World 
Bank 
Cost of Cure 
(CM) 
Gamma BDT 
25,095 
BDT 
20,076 
BDT 
30,114 
Study Data 
Cost of Failure 
(CM) 
Gamma BDT 
31,849 
BDT 
25,479 
BDT 
38,219 
Study Data 
Cost of Default 
(CM) 
Gamma BDT 
34,132 
BDT 
27,306 
BDT 
40,958 
Study Data 
Cost of Cure 
(CHW) 
Gamma BDT 
17,719 
BDT 
14,175 
BDT 
21,263 
Study Data 
Cost of Failure 
(CHW) 
Gamma BDT 
22,488 
BDT 
17,990 
BDT 
26,985 
Study Data 
Cost of Default 
(CHW) 
Gamma BDT 
24,100 
BDT 
19,280 
BDT 
28,920 
Study Data 
Utility of Cure 
(CM) 
Lognormal 0.783 0.626 0.940 Study Data 
Utility of 
Failure (CM) 
Lognormal 0.738 0.590 0.886 Study Data 
Utility of 
Default (CM) 
Lognormal 0.742 0.594 0.890 Study Data 
Utility of Cure 
(CHW) 
Lognormal 0.776 0.621 0.931 Study Data 
Utility of 
Failure (CHW) 
Lognormal 0.732 0.586 0.878 Study Data 
Utility of 
Default (CHW) 
Lognormal 0.736 0.589 0.883 Study Data 
Discount Rate Fixed 3% 0% 6% Edejer, 
2003 
a In Probabilistic Sensitivity Analysis 
Results 
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Base Case Results 
Base case results show that over the 27 cycles each DS-TB patient under CM treatment 
model gains 3.61 QALYs with a cost of BDT 131,555. For the DS-TB patients under the 
CHW model the cost is 81,650 and the QALY gain is 3.12. The Incremental Cost-
Effectiveness Ratio (ICER) is 103,454, i.e., the CM model is cost-effective if per QALY 
gain one can afford more than BDT 131,454 (Table 5.4). 
Table 5.4 Base Case Results 
Treatment Model Cost Per Patient 
(BDT) 
QALY Gained ICER 
CM 131,555 3.61 103,454 
CHW 81,650 3.12 
 
Deterministic Sensitivity Analysis 
Parameters were varied on different scales for high and low values and univariate 
sensitivity analysis was performed to assess the robustness of the findings. A tornado plot 
has been prepared to illustrate the effect of change in each variable. Based on the findings 
in one-way sensitivity analysis, input parameters were varied accordingly to see their 
impact in probabilistic sensitivity analysis. 
In the tornado plot, shown in the Figure 5.2, we find that the most influential 
parameters were utility of cure state for CM model, followed by utility of cure state of 
CHW model, costs of cure state of CM model, utility of loss to follow-up state of CHW 
model, and utility of loss to follow-up state of CM model. according to the more effects 
on the results. 
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Figure 5.2 Tornado Plot of Deterministic Sensitivity Analysis 
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Probabilistic Sensitivity Analysis 
In probabilistic sensitivity analysis, the costs values and utility values for each 
state were varied by 20%.  Initially, the base case Markov model with all parameters with 
their values and distribution was run for 1000 iterations and the base case results were 
assessed using incremental cost effectiveness ratio (ICER), Cost-effectiveness 
Acceptability Curve (CEAC), and Expected Value of Perfect Information (EVPI).  
Incremental Cost-effectiveness Ratio (ICER) 
From the results reported in the Table 6 shows that over life-time the CM method 
costs BDT 197,680; while CHW model costs BDT 76,836. At the same time QALY 
gained by CM model is 6.13 whereas in CHW model QALY gain is 2.91. Therefore, the 
resultant ICER is BDT 37,487 per QALY gained. It shows that CM method is cost-
effective if willingness to pay is more than BDT 37,487 (Table 5.5). Results shown in the 
cost effectiveness plane also shows that the ICER is in the North-East Quadrant (Figure 
5.4).  
Table 5.5 ICER from Probabilistic Model 
Treatment 
Model 
Cost Per 
Patient (BDT) 
QALY Gained ICER EVPI 
CM 197,680 6.13 37,487 18,388 
CHW 76,836 2.91 
 
Cost-Effectiveness Acceptability Curve (CEAC) 
Since the ICER for each QALY gain is BDT 37,480, cost-effectiveness 
acceptability curve for CM and CHW crosses over at that point. After the value CM 
becomes more cost-effective and thereby acceptable (Figure 5.5). 
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Expected Value of Perfect Information (EVPI) 
EVPI is the absolute limit of the value of further research that would completely 
eliminate the uncertainty around the parameters in the model. EVPI value of BDT 18,388 
shows that with reducing uncertainty around the parameters would require only BDT 
18,388. It is also evident from the figure 6 that with EVPI peaks between BDT 300,00 
0.00
0.25
0.50
0.75
1.00
0 10000 20000 30000 40000 50000
Willingness to pay
P
ro
b
a
b
ili
ty
 o
f 
c
o
s
t-
e
ff
e
c
ti
v
e
n
e
s
s
Strategy
chw
cm
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and BDT 400,000. It signifies that with increasing willingness-to-pay EVPI also 
increases till certain value, then it declines. 
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Figure 5.6 Expected Value of Perfect Information (EVPI) Curve 
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Discussions 
The study results show that the CM method of DS-TB treatment is cost-effective 
in Bangladesh from a societal perspective. ICER form base case analysis is BDT 103,454 
(USD 1293) which is even lower than per capita GDP of Bangladesh in 2015, which is 
USD 1342. The deterministic sensitivity analysis shows that the utility garnered from the 
cure status of CM method is the principal factor behind the result. Even when we 
changed the utility value by 20% (within a range of 0 and 1), we found that the CM 
method remains cost-effective. 
Several studies have also been conducted to assess the cost-effectiveness of 
DOTS program itself. DOTS was found cost-effective in developing country settings, 
Thailand (Hunchangsith et al., 2012), Egypt and Syria (Vassall et al., 2002), Botswana 
(Moalosi et al., 2003), Haiti (Jacquet et al., 2006), Uganda (Okello et al., 2003), Brazil 
(Mohan et al., 2007). These studies invariably documented that the DOTS strategy or 
involving the communities in the care process is cost-effective over SAT. In Malawi it 
was shown that community based DOTS was cost-effective than the usual hospital-based 
model (Floyd, Skeva, Nyirenda, Gausi, & Salaniponi, 2003). 
         Very few studies compared between community member DOTS model and 
community health worker DOTS model. In a study conducted in Thailand, the results 
show that community member model is dominant, while ICER was USD 1,100 for each 
DALY gained in health worker model (Hunchangsith et al., 2012). In some countries, 
randomized controlled trials (RCT) were conducted to find the efficacy of DOTS model. 
In Nepal, both family based DOTS and Community based DOTS were found to be 
capable of attaining international targets for treatment success (Newell, Baral, Pande, 
 
94 
 
Bam, & Malla, 2006). In Senegal, it was found that the package based on improved 
patient counseling and communication, decentralization of treatment, patient choice of 
DOT supporter, and reinforcement of supervision led to improved patient outcomes 
(Thiam et al., 2007).    
Community members can be anyone in the community. Neighbors are mostly 
selected by DF to cater drugs daily to the DS-TB patients. Salvation Army in Dhaka city 
deployed drug sellers in the vicinity to provide anti-TB drugs to the DS-TB patients on 
regular basis. This idea of involving community is not novel; The Union prefers the 
integration of community members in the treatment procedure (Aït-Khaled et al., 2010). 
Most important objective of the DOTS model was to enhance the adherence to the TB 
drug regimen (World Health Organization & Stop TB Initiative, 2010). In Bangladesh, it 
has been found that community based models works better than the hospital-based model 
(Islam et al., 2002). But comparison between community member model and community 
health workers have not been done to move forward with the best and cost-effective 
model. 
From costs figures for the two methods, we see that patients incur more costs for 
DS-TB treatment in case of CM model. Patients’ costs were higher for before diagnosis 
costs, diagnosis costs, hospital costs, and additional food costs. On the other hand, 
providers with CM model spend more on training, while CHW model spend more on 
incentives to the CHWS. Each CHW gets a remuneration of BDT 500 for successful 
completion of the DS-TB regimen. Interestingly, no facility reported any costs for 
prevention activities. Also note that, present treatment guidelines for DS-TB does not 
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require any hospitalization. These show that CM model lacks in early diagnosis of the 
patients which leads to undue hospitalization and more costs.    
However, CM model is successful in reducing stigma related to TB disease. It has 
been documented in several studies that effective stigma reducing strategies are focused 
on individual and community levels (Heijnders & Van Der Meij, 2006). Stigma related to 
TB disease and its care is widespread in Bangladesh and women are the worst sufferer 
(Somma et al., 2008). Community member’s involvement reduce the chance of spread of 
the news of TB infection and thereof avoid gossiping, undue fear of transmitting the 
disease and potential discrimination. If community health workers do not divulge the 
news of TB disease, her daily presence in a particular house is a telltale sign for 
neighbors which leads to discrimination for the TB patient. Therefore, CHW models are 
not adequate to ensure the adherence and proper treatment which is evident in the utility 
value of CM method. 
This study has several limitations. Although for transitional probabilities we used 
quarterly reports from 18 facilities under the survey, the reported outcomes were not 
verified like controlled trial settings. This can make the results biased. Cost and 
effectiveness data from the patients may suffer from the recall bias, although we included 
only those patients who completed their treatment not more than six months.  
Despite these limitations, this study tried to collect the patient and provider level 
data comprehensively using pre-set questionnaires. To our best knowledge, it is also the 
first study to conduct economic evaluation between CHW and CM model of DS-TB 
treatment in developing country setting. 
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Community based DOTS is getting acceptance worldwide due to its proven 
efficacy. However, early diagnosis and treatment of TB cases is still a far cry due to lack 
of knowledge about TB in general population and absence of any proper prevention 
programs. This indicates the importance of deploying community members in 
disseminating the knowledge about TB signs and symptoms which may facilitate early 
diagnosis of the disease as well as reduce the stigma associated with TB disease.   
In conclusion, the evidence of cost-effectiveness of CM method encourages us to 
adopt this model all over Bangladesh. More involvement of the community members of 
all sort will help prevent the transmission of the disease, early diagnosis will lead to early 
cure at low costs, and treatment adherence will help us to attain the End TB strategy by 
2035. 
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CHAPTER 6 
STUDY III 
6.1 ECONOMIC EVALUATION OF MULTI DRUG-RESISTANT TUBERCULOSIS 
(MDR-TB) TREATMENT APPROACHES IN BANGLADESH3 
                                                          
3 Haider, M. R. To be submitted. 
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Introduction: Worldwide Tuberculosis (TB) control has been halted by the emergence 
of multi-drug resistant TB (MDR-TB). Bangladesh has also experienced surge in the 
number of MDR-TB cases with a 29% of MDR-TB cases were found among the re-
treatment of pulmonary TB cases in 2015. In Bangladesh, two MDR-TB treatment 
regimens (9-month and 20-24 month) are practiced and this study intends to conduct 
economic evaluation between those two.  
Methods: The incremental cost-effectiveness ratio (ICER) of treating MDR-TB patients, 
35 years old on average, by the 9-month regimen versus the 20-24-month regimen was 
compared using a Markov model with life-time horizon (37 years). The measure of 
effectiveness, Quality adjusted life year (QALY) and cost of treatment was collected 
from 145 MDR-TB patients (58 undergone the 9-month treatment and 87 from the 20-24-
month regimen) in Bangladesh. Transition probabilities between Markov states were 
estimated from two published studies and cost and QALY both were discounted at a rate 
of 3%. Deterministic and probabilistic sensitivity analyses were conducted in a Monte 
Carlo Simulation using R.  
Results: Based on the study data, each patient under the 9-month regimen gained 6.21 
QALY with a total cost of BDT 987,418. Whereas, each patient under CHW model 
gained 5.74 QALY by incurring costs of BDT 1,501,221. Therefore, the 9-month 
regimen is clearly dominating over the 20-24-month regimen because it costs less while it 
gains more QALY.  
Conclusions: Our study results suggest that the shorter 9-month regimen remains cost-
effective in Bangladesh setting with changing costs and utility parameters varied in the 
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probabilistic sensitivity analysis. MDR-TB treatment is itself cost-effective in developed 
countries and with cost-effective shorter regimen both treatment adherence and efficacy 
of the treatment will be improved.  
Keywords: Economic Evaluation, Multi Drug Resistant Tuberculosis, Cost-
effectiveness, Cost, QALY, Bangladesh Regimen, Bangladesh 
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Introduction 
Tuberculosis (TB) is a deadly tropical disease caused by Mycobacterium 
tuberculosis, a bacillus which typically affects lungs (pulmonary tuberculosis) in addition 
to other parts of the human body. Tuberculosis is prevalent in the temperate region of the 
world and this tropical disease is endemic in South-East Asian and African countries. 
India and China, the two largest countries in terms of population, had the highest number 
of cases (26% and 12% respectively) in 2012. Bangladesh, a South Asian country with 
hot tropical weather, also harbors the disease in huge numbers of afflicted people. 
Bangladesh is a high burden TB country and its number of Multi-Drug Resistant TB 
(MDR-TB) patients is on the rise (World Health Organization (WHO), 2016a).  
The world has experienced a slow gain in TB control in recent years and that 
progress has been halted by the emergence of MDR-TB and Extremely Drug Resistant 
TB (XDR-TB) strains. Bangladesh has also experienced a surge in the number of MDR-
TB cases with a 29% of MDR-TB cases found among the re-treatment of pulmonary TB 
cases in 2015 (World Health Organization (WHO), 2016a). 
Bangladesh follows a model involving community health workers or community 
members to provide drugs regularly to the patients undergoing drug sensitive TB 
(DSTB). Under the public private partnership models different Non-governmental 
organizations (NGOs) are responsible for directly observed treatment short-course 
(DOTs). Any lack of adherence may result in menacing drug resistant strains, MDR or 
XDR TB; treatment for both the conditions are costly and time consuming. The current 
WHO guidelines prescribed treatment regimen is of 20-24 months, while the shortest 
effective MDR-TB treatment regimen spans over nine months (Deun et al., 2010).  The 
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prolonged treatment schedule may result in more incidence of treatment discontinuation. 
WHO in cooperation with STOP TB Partnership came up with a response plan in 2007-
2008 and Bangladesh is one of the seven countries using shorter treatment regimens for 
MDR-TB in June 2013 (World Health Organization (WHO), 2013c).  
National Tuberculosis Control Program (NTP) in Bangladesh follows the 20-24-
month treatment regimen for MDR-TB patients. The NTP follows the Programmatic 
Management of Drug-resistant TB (PMDT) guideline (Falzon et al., 2011) and the 
treatment is supervised and administered by DOTS providers (National Tuberculosis 
Control Program (NTP), 2013) 
Damien Foundation (DF) runs their own protocol of treatment for MDR-TB 
patients, which span over 9 months and differs in drug composition as well. DF generally 
admits the MDR-TB patients in one of their three hospitals located in Jalchatra of 
Madhupur in Tangail district, Shomvuganj in Mymensingh district and at Anantapur in 
Netrakona district for four months of intensive phase; which is followed by the 
continuation phase of five months for which drugs are administered at patients’ home by 
DOTs providers (Damien Foundation Bangladesh, 2015).  DF has initiated a shorter 
regimen treatment of 9 months in 1997 (Van Deun et al., 2010), which eventually came 
to known as “Bangladesh” regimen (Aung et al., 2014). In a recent publication in 2014, 
DF researchers presented their findings from their observation study that 84.4% of the 
patients undergone the shorter regimen had bacteriologically favorable outcomes up to 
two years after treatment completion (Aung et al., 2014). This success of Bangladesh 
regimen inspired United Sates Agency for International Development (USAID), the 
International Union Against Tuberculosis and Lung Disease (the Union), and Janssen 
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Research & Development, LLC to commission a clinical trial to find out the effectiveness 
of the regimen in other countries like Ethiopia, Mongolia, South Africa, and Vietnam 
(International Union Against Tuberculosis and Lung Disease (The Union), 2017). 
Although several studies showed the cost-effectiveness of MDR-TB treatment as 
a whole in developed and developing country settings (Diel, Nienhaus, Lampenius, 
Rüsch-Gerdes, & Richter, 2014; Diel, Vandeputte, et al., 2014; Fitzpatrick & Floyd, 
2012), no study was conducted to perform economic evaluation of two regimens, the 9-
month regimen (shorter) and current WHO recommended the 20-24-month regimen 
(current). This study aims to fill the void in conducting the cost-effectiveness evaluation 
of these two treatment regimens from a societal perspective (including both patients and 
payer perspectives) using Quality Adjusted Life Years (QALYs) as the outcome for 
effectiveness, which qualifies this as a cost-utility study in health economics parlance 
(Drummond, Sculpher, Claxton, Stoddart, & Torrance, 2015). 
Methods 
Study Design and Data Sources 
The study follows a purposive sampling method for interviewing MDR-TB 
patients. According to the recent estimates in 2014 number of laboratory-confirmed 
MDR-TB patients was 954 in Bangladesh and the prevalence of MDR-TB is 5,100 in 
2015 (World Health Organization (WHO), 2016a). In our study area, it is understandable 
that the number will be significantly lower. Therefore, we collected the information of 
the MDR-TB patients from the TB control programs and reach those who were accessible 
(Brazier et al., 2002). 
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Institution-level data has been collected for assessing the provider level costs 
associated with TB treatment. Number of patients diagnosed and treated in 2015 has been 
collected from the secondary sources such as the World TB report published by WHO 
and the Annual TB report of NTP, Bangladesh. Drug costs have been collected from the 
STOP TB Global Drug Facility website. Costs for diagnostic tests have been estimated 
after consulting with local experts who are knowledgeable of the MDR-TB programs in 
Bangladesh and also know the market price of different tests. 
Cost Of Illness (COI) includes direct, indirect and tangibles costs incurred by the 
patients (Centers for Disease Control and Prevention (CDC), 2013) and in this study the 
TB patients will be traced and interviewed for the detail cost descriptions. The variables 
of interest are the duration of illness, time elapsed before diagnosis, present status of the 
illness, how many healthcare providers has been consulted, the direct costs incurred in 
each encounter, duration of DOTS treatment, transportation cost to DOTS center, any 
friend/relative accompanying with and the opportunity cost of their time, and the lost 
work days and income of the patients among others. The programmatic cost has been 
collected using a pre-set questionnaire and using annuitization for capital costs per patient 
costs were calculated for each regimen. 
The study will seek data on tuberculosis burden on the population of Bangladesh 
from different sources, e.g., published reports, program documentations and various 
surveys and the incidence of TB will be extracted from those sources. To find the QALYs 
gained through the program we interviewed patients using EuroQoL 5D-5L questionnaire 
and used the tariff provided by EuroQol. 
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Target Population and Study Sample 
This study covers the adult (more than 18 years old) MDR-TB patients all over 
Bangladesh. 145 MDR-TB patients’ data was used for patient level cost and outcomes 
(QALY) estimation for this study. Out of these 145 patients, 58 were under the 9-month 
regimen and 87 were under the 20-24-month regimen, who were under treatment in four 
MDR-TB treatment facilities (two for each regimens). Table 1 shows the number of 
patients interviewed under each regimen and the districts to which they belonged. In the 
Appendix Figure 1 the geographic location of the study districts is shown. 
Glick (H. A. Glick, 2011) proposed a sample size formula for cost-effectiveness 
evaluation of clinical trials. Although our study is not a typical clinical trial, given the 
nature of the intervention and the study design we can apply the formula for calculating 
the required sample size for our study.  The formula calculates the sample size for each of 
the two groups with similar standard deviation of costs and effect and same sample size: 
𝑛 =
2 (𝑍𝛼 + 𝑍𝛽)
2
[𝑠𝑑𝑐
2 +  (𝑊 ∗ 𝑠𝑑𝑞
2)
2
−  (2 𝑊𝜌 ∗ 𝑠𝑑𝑐 ∗ 𝑠𝑑𝑞)
(𝑊𝑄 − 𝐶)2
 
Where:  
Zα is the standard normal quantile for the level of Type I error (set at 95%)  
Zβ is the standard normal quantile for the level of Type II error (set at 80%) 
sdq, sdc are the std deviations for each group for treatment effect and cost 
respectively  
W is the Maximum Willingness to Pay  
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Q is the expected mean difference in treatment effectiveness  
C is the expected mean difference in treatment cost  
ρ is the expected correlation of the difference in cost (C) and effect (Q) 
This is a measure of the covariance of changes in effectiveness and changes in 
cost. Negative covariance, where cost decreases with increasing effectiveness result in a 
larger sample size. Positive covariance where cost increases with increasing effectiveness 
result in smaller sample sizes. 
With 95% confidence interval and 80% power of the test, we assumed that the 
standard deviation of costs (sdc) is 100 USD, standard deviation of effect (sdq) is 0.25 
QALY, ρ, correlation of difference in cost (C) and effect (Q) is 0.5. The expected mean 
difference in treatment effectiveness (Q) is 0.15 QALY and expected mean difference in 
treatment cost (C) is 1000 USD. We set the willingness-to-pay threshold (W) at the three 
times of GDP of Bangladesh which is 3942 USD (BDT 315,360) (Macroeconomics, 
2001). We found the sample size for one group is 70 and another is 104 with a 2:1 sample 
size ratio. 
Settings and Locations 
DF implements their MDR program in 22 districts in the North-west part of 
Bangladesh. The MDR-TB patients detected in these areas are treated following the 9-
month regimen. Whereas, in rest of the 42 districts all over Bangladesh follows the 20-
24-month regimen. Thus this study covers the whole country.   
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Ethical consideration 
The study has already got ethics approval from University of South Carolina in 
the USA where the PI is a PhD student. Institutional Board Review (IRB) approval will 
also be taken from Jahangirnagar University in Bangladesh. A third and final approval 
was obtained from WHO Research Ethics Review Committee (WHO ERC). 
Study Perspective 
The study will be conducted form the societal perspective, which will encompass 
all costs incurred by the health care providers, patients, and community. 
Comparators 
The two distinct programs carried out by NTP and DF will be the comparators in 
this study. DF runs a 9-month regimen which administers high-dose Gatifloxacin (GFX), 
Ethambutol (EMB), Pyrazinamide (PZA), and Clofazimine (CFZ) throughout, 
supplemented during the minimum 4-month intensive phase by Kanamycin (KM), 
Prothionamide (PTH), and Isoniazide (INH) (Aung et al., 2014). 
NTP follows the 20-24-month regimen which includes Kanamycin (KM), 
Ofloxacin (OFX), Pyrazinamide (PZA), Ethonamide (ETO), and Cycloserine (CS) in 6-
10 months (on average 8 month) long intensive phase and Ofloxacin (OFX), 
Pyrazinamide (PZA), Ethonamide (ETO), and Cycloserine (CS) in 13-18 months (on 
average 12 months) of continuation phase of treatment (National Tuberculosis Control 
Program (NTP), 2013). 
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Time Horizon 
The study will take a life-time horizon to capture all costs and outcomes 
according to WHO guideline (Edejer, 2003). Since this study includes patients 18 years 
and older, we assume they will live through to their life expectancy (72 years in 2015). 
Mean age of the patient interviewed was 35 years. Therefore, we repeated the cycle for 
37 times to include their whole lifespan.  
Discount Rate 
The study will follow the WHO discount rate of 3% for both costs and outcomes 
(Edejer, 2003).  
Choice of Outcome 
Quality Adjusted Life Year (QALY) is the chosen outcome for this study.  
Measurement of Effectiveness 
QALY has been modeled using patient-level EuroQol-5 Dimensions-5 Levels 
(EQ-5D-5L) measure of health related quality of life (EuroQol Research Foundation, 
2017). We used Zimbabwe score sets for EQ-5D, since Zimbabwe is another developing 
country like Bangladesh and we assume the EQ-5D score sets would have been similar 
between populations of these two countries. Finally, the QALY measure was estimated 
after controlling for patient’s socio-economic factors. Lognormal (log value of QALY as 
dependent variable) has been found more suitable model. Recycled prediction has been 
used to find out the estimated QALY for each type of patient outcome (e.g., cure, failure, 
and default) for both regimens (Glick Book). For death state utility has been assumed 
zero. 
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Measurement of Costs 
Health systems costs were collected from different sources. Prevention and 
promotion costs, training costs, meeting costs, human resources costs, capital costs, and 
other costs were collected from MDR-TB treatment facilities under the purview of the 
study using a pre-set provider questionnaire. Heath facility managers, personnel 
responsible for financial transactions were interviewed using the questionnaire and 
relevant costs were collected. Capital costs were annuitized using 5% interest rate and 10-
year lifetime for Microscopes and Gene Xpert machines, and vehicles. Costs for drugs 
were derived from the Stop TB Global Drug Repository (Stop TB Partnership, 2017) and 
per patient drug costs were calculated for each regimen (Appendix Table 1 and Table 2). 
Diagnostic tests costs were derived from expert knowledge from the officials working in 
MDR-TB program in Bangladesh (Appendix Table 3 and Table 4). Per patient cost of 
delivering MDR-TB treatment for both types of regimen have been estimated dividing 
costs among the number of treated patients in one year in those facilities using Annual 
Tuberculosis Report by NTP, Bangladesh (National Tuberculosis Control Program 
(NTP), 2015).  Patient costs were collected through interviews of MDR-TB patients using 
a pre-set questionnaire prepared on the basis of Stop-TB questionnaire on patient’s cost 
(Stop TB Partnership DOTS Expansion Working Group (TB and Poverty subgroup), 
2008). The questionnaire was translated English to Bengali and then retranslated back 
into English to validate the translation. Both patient and provider questionnaires were 
pre-tested and changes were incorporated before using those in the survey. Total costs of 
treating a patient under each regimen was calculated by summing up the patient and 
provider level costs. Then the cost was modeled using a Generalized Linear Model with 
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Gamma family and log link using data from 145 interviewed MDR-TB patients who had 
complete information on disease outcomes. GLM diagnostics were used to validate the 
GLM family and link. Recycled prediction was used to estimate the costs for each type of 
patient outcome (e.g., cure, failure, default) for both regimens (H. Glick et al., 2007). For 
death state costs were calculated as zero. 
Models and Analysis 
A dynamic, stochastic, Markov simulation model was used to estimate the cost-
effectiveness of the two comparison regimens. Markov model has some unique 
characteristics which fit the progression of TB well. For example, in Markov model states 
are mutually exclusive, states are complete (i.e. no people are lost) and people remain in 
that state for a fixed period of time. Also, Markov model is preferred over the decision 
trees when health event repeats over time, or have longer term health effects, effect of 
treatment either stops quickly after initial treatment or continue at an earlier level, and the 
risk of different health events does not depend on patient’s prior history. 
A simplistic decision tree model can be shown in Figure 6.1: 
From the Markov model and decision tree we find that after starting of the 
treatment the MDR-TB patient can move to either of the four states, e.g., cure/treatment 
complete, failure/relapse, default, and death. Cure state has been defined as those who 
had completed treatment protocol without any evidence of failure and had at least three 
consecutive negative cultures from samples collected at least 30 days apart in the final 12 
month of treatment, or “Treatment Completed”, those who completed treatment 
according to treatment protocol but did not meet the definition for cure because of lack of 
bacteriological results. 
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Figure 6.1 Decision Tree of two comparison treatment strategies for MDR-TB 
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Failure/relapse cases were defined as those whose treatment was needed to be terminated 
or at least change of two anti-TB drugs due to lack of conversion, bacteriological 
reversion in the continuation phase, evidence of additional acquired resistance, or adverse 
drug reaction. Lost to follow up/ default cases were defined as those MDR-TB patients 
whose treatment was interrupted for two or more consecutive months for any reason 
(National Tuberculosis Control Program (NTP), 2013).  
Here death is the absorbing state, i.e., if a patient is dead he/she can move from 
that state to another. If any patient is cured he/she can remain cured, relapse/reinfection 
may occur, lost to follow-up (default) or can be dead. On the other hand, the 
failed/relapsed patients undergo another cycle of treatment and can culminate into cure, 
remain failed, can default, or can be dead as well. Similarly, from default state one can 
move over to other three states.  
Cost-effectiveness evaluation was performed using heemod package in R 
(Filipović-Pierucci et al., 2017). BCEA package was also used to validate the results form 
analysis with heemod package (Filipović-Pierucci et al., 2017). Cost and utility data was 
modeled using STATA 14.2 (StataCorp, 2015). 
Measurement of Transition Probabilities 
As mentioned earlier, cost-effectiveness analysis of these two regimens has not 
been undertaken yet. However, the programmatic outcome for the two treatment 
strategies has been derived from two papers. One paper reported the results of the 
standardized treatment spanning 20-24 month (Van Deun et al., 2004). Another paper 
published recently reported the results of the alternative regimens of 9 month (Aung et 
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al., 2014). Both studies were conducted in Bangladesh. Transitional probabilities were 
estimated from these two studies using Markov simulation as an evidence synthesis 
technique (Sutton, Welton, & Cooper, 2012). R has been used for the analysis along with 
r2jags packages for estimating the transitional probabilities for two treatment regimens 
(Su & Yajima, 2012).  
From these two studies the transitional probabilities for first two cycles were 
estimated and furnished in Table 6.1.  
Table 6.1 Transition Probabilities of MDR-TB Treatment Regimens 
Input variable 20-24-Month Regimena 9-Month Regimenb 
Cure to Cure (tpC2C) 0.813 0.846 
Cure to Failure (tpC2F) 0.071 0.043 
Cure to Default (tpC2Def) 0.024 0.080 
Cure to Death (tpC2Death) 0.092 0.031 
Failure to Cure (tpF2C) 0.143 0.119 
Failure to Failure (tpF2F) 0.431 0.486 
Failure to Default (tpF2Def) 0.139 0.040 
Failure to Death (tpF2Death) 0.287 0.355 
Default to Cure (tpDef2C) 0.088 0.023 
Default to Failure (tpDef2F) 0.087 0.499 
Default to Default (tpDef2Def) 0.637 0.365 
Default to Death (tpDef2Death) 0.188 0.113 
a Source: (Aung et al., 2014)  
b Source: (Van Deun et al., 2004) 
Parameters 
Patient level cost for each regimen as well as the per patient provider costs are 
shown in Table 6.2.   
Table 6.3 shows parameters for the cost-effectiveness analysis along with their 
distributions. Parameters mainly consist of transitional probabilities for transition 
between different states, costs for treating each type of states, and the utility of each 
states. Apart from this initial age was determined as the mean age of the interviewed 
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population (35 years). Time horizon was therefore fixed at 37 years, accounting for the 
rest of the general life expectancy of Bangladeshi people (life expectancy at birth in 
Bangladesh is 72 years (The World Bank, 2017b)). Both age and cycle parameters were 
kept fixed for the model. Transmission of secondary infection was assumed to be .003 
annually based on the findings of a study that 0.03 new secondary cases may develop 
among the MDR-TB population (Sloot, Schim van der Loeff, Kouw, & Borgdorff, 2014). 
Costs parameters follow a gamma distribution as mentioned earlier and are 
measured in 2015 Bangladeshi Taka (BDT). Utility values are measured in QALY and 
their distributions were lognormal.  
Table 6.2 Patient, Provider and Total Costs for two regimens of MDR-TB treatment in 
Bangladesh 
Costs DS-TB Patients MDR-TB Patients 
A. Patient Level Costs  Mean  Mean  
Direct Costs     
 Before Diagnosis Costs 13287.16 14844.23 
 TB Diagnosis Costs 1106.69 684.63 
 Follow-up Costs 172.16 877.17 
 Drug Collection Costs 14.6 1.17 
 Hospital Costs  2515.23 7669.4 
 Additional Food Costs 2244.01 2678.39 
 Accompanying Person Costs 380.03 2114.7 
 MDR-TB Relocation Costs 0 341.24 
 Drug Side-effects Costs 434.58 1647.28 
Total Direct Costs 20154.46 30858.21 
Indirect Costs   
 Patient Opportunity Costs (Income Loss) 407.07 1522.86 
Accompanying Person Opportunity Costs 673.57 2593.91 
Total Indirect Costs 1080.64 4116.77 
Total Patient Level Costs 21235.10 34974.98 
B. Provider Level Costs   
 Prevention and Promotion Costs 652.17 202.02 
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 Diagnostic Costs 17825.00 38300.00 
 Drug Costs 42761.50 61833.27 
 Training Costs 2608.70 767.68 
 Meeting Costs 2608.70 808.08 
 Incentive Payment 3100.00 3100.00 
 Human Resources Costs 23728.70 28267.15 
 Capital Costs 22100.92 10101.01 
 Other Costs 345.73 101.01 
Total Provider Level Costs 115731.41 143480.23 
Total Costs 136966.51 178455.21 
 
 
Table 6.3 Input Parameters for Cost-Effectiveness Analysis 
Variable 
Category 
Distributiona Value Low High Reference 
Starting age of 
cohort (mean) 
Fixed 35 Years - - Study Data 
Time horizon Fixed 37 Years - - (LE Data) 
Cost of Cure (20-
24 Month) 
Gamma BDT 
194893 
BDT 
151740 
BDT 
238046 
Study Data 
Cost of Failure 
(20-24 Month) 
Gamma BDT 
204155 
BDT 
149920 
BDT 
258390 
Study Data 
Cost of Default 
(20-24 Month) 
Gamma BDT 
206983  
BDT 
162744 
BDT 
251222 
Study Data 
Cost of Cure (9 
Month) 
Gamma BDT 
125977 
BDT 
98084 
BDT 
153870 
Study Data 
Cost of Failure (9 
Month) 
Gamma BDT 
131964 
BDT 
96905 
BDT 
167023 
Study Data 
Cost of Default (9 
Month) 
Gamma BDT 
133972 
BDT 
105376 
BDT 
162568 
Study Data 
Utility of Cure 
(20-24 Month) 
Lognormal 0.777 0.524 1.00 Study Data 
Utility of Failure 
(20-24 Month) 
Lognormal 0.710 0.428 0.99 Study Data 
Utility of Default 
(20-24 Month) 
Lognormal 0.757 0.543 0.971 Study Data 
Utility of Cure (9 
Month) 
Lognormal 0.813 0.560 1.00 Study Data 
Utility of Failure 
(9 Month) 
Lognormal 0.746 0.464 1.00 Study Data 
Utility of Default 
(9 Month) 
Lognormal 0.793 0.579 1.00 Study Data 
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Discount Rate Fixed 3% 0% 6% Edejer, 
2003 
Probability of 
Secondary 
transmission (per 
year) 
Binomial 0.03 0 0.06 Germany 
Paper 
a In Probabilistic Sensitivity Analysis 
Results 
Base Case Results 
The base case results show that after 37 cycles (years) each patient under the 9-
month regimen gained 6.21 QALY with a total cost of BDT 987,418. Whereas, each 
patient under CHW model gained 5.74 QALY by incurring costs of BDT 1,501,221 
(Table 5). Therefore, the 9-month regimen is clearly dominating the 20-24-month 
regimen because it costs less while it gains more QALY.  
Table 6.5 Base Case Results 
Regimen Cost Per Patient 
(BDT) 
QALY Gained ICER 
9 Month (DF) 987,418 6.21 -1,086,095 
(Dominates) 20-24 Month (NTP) 1,501,221 5.74 
 
Deterministic Sensitivity Analysis 
Parameters were varied on different scales for high and low values and univariate 
sensitivity analysis was performed to see the robustness of the findings. A tornado plot 
has been prepared to see the effect of change in each variable. Based on the findings in 
one-way sensitivity analysis, input parameters were varied accordingly to see their impact 
in probabilistic sensitivity analysis. 
In tornado plot, shown in the Figure 6.2, we find that the most influential 
parameters were costs of cure state of the 20-24-month regimen, cost of cure state of the 
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9-month regimen, costs of failure state of 9 month regimen, cost of failure state of the 20-
24-month regimen according to the more effects on the results. Among the utility values 
utility of cure state of the 9-month regimen has more effect than utilities of other states.  
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Figure 6.2 Tornado Plot of Deterministic Sensitivity Analysis 
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Probabilistic Sensitivity Analysis 
In probabilistic sensitivity analysis, the costs values and utility values for each 
state were varied by 20%.  At first the base case Markov model with all parameters with 
their values and distribution was run for 1000 iterations and the base case results were 
assessed in the form of incremental cost effectiveness ratio (ICER), Cost-effectiveness 
Acceptability Curve (CEAC), and Expected Value of Perfect Information (EVPI).  
Incremental Cost-effectiveness Ratio (ICER) 
From the results reported in the Table 5 shows that over life-time the 9-month 
regimen costs about BDT 942,315 while the 20-24-month standard regimen costs BDT 
1,434,254. At the same time QALY gained by the 9-month regimen is 6.00 whereas in 
the 20-24-month regimen QALY is gained 5.51. Therefore, the resultant ICER is -BDT 
997,257 per QALY gained. It shows that 9 month regimen dominates the 20-24-month 
regimen (Table 5). Results shown in the cost effectiveness plane also shows that the 
ICER is in the North-West Quadrant which makes the 9-month regimen dominant over 
the 20-24-month regimen (Figure 6.4).  
Table 6.5 ICER from Probabilistic Model 
Regimen Cost Per 
Patient (BDT) 
QALY Gained ICER EVPI 
9 Month (DF) 942,315 6.00 -997,257 
(Dominates) 
13,719 
20-24 Month 
(NTP) 
1,434,254 5.51 
 
Cost-Effectiveness Acceptability Curve (CEAC) 
CEAC has been shown in Figure 6.3. Since the 9-month regimen dominates over 
the 20-24-month regimen, the CEAC for the 9-month regimen is over 0.75 form the 
beginning. With increasing willingness-to-pay CEAC value gets bigger. On the other 
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hand, it decreases for the 20-24-month regimen for higher values (Figure 6.4). 
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Expected Value of Perfect Information (EVPI) 
EVPI is the absolute limit of the value of further research that would completely 
eliminate the uncertainty around the parameters in the model. EVPI value of BDT 13, 
719 shows that with reducing uncertainty around the parameters would require only BDT 
13,719. It is also evident from the Figure 6 that with increasing willingness-to-pay the 
EVPI decreases and offsets the need of further research due to the small gains. 
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Discussions 
The study results show that the 9-month “Bangladesh” regimen is cost-effective 
from a societal perspective. Bangladesh regimen has more cure rate and it provides more 
utility to the patient than those who undergone the 20-24-month regimen which WHO 
currently endorse. However, in 2012 a clinical trial named the STREAM (Standardized 
Treatment Regimen of Anti-Tuberculosis Drugs for Patients with MDR TB) in Ethiopia, 
Mongolia, South Africa, and Vietnam had been initiated (International Union Against 
Tuberculosis and Lung Disease (The Union), 2017). The primary objective of the first 
stage of the trial is to evaluate the effectiveness of the shorter “Bangladesh” regimen in 
other settings (Moodley & Godec, 2016). Damien Foundation initiated the 
Fluoroquinolone based shorter regimen and tested over 12-year period (Van Deun et al., 
2010); but the study lacks in terms of it was only an observational study and more 
patients opted out from participation in the study; patients with HIV were not included; 
and cohorts were enrolled consecutively, i.e., various regimens were tested in various 
time periods, and cohort sizes were not predetermined (TBFACTS.ORG, 2017). Since in 
the published description of the trial does not mention any undertaking of cost-
effectiveness analysis alongside the clinical trial this study provides an important 
evidence of cost-effectiveness for the shorter regimen.   
Several studies have also been conducted to assess the cost-effectiveness of 
different MDR-TB treatment regimens. Fitzpatrick et al. (2012) conducted a systemic 
review of studies which used primary data and outcome which eventually includes only 
four studies conducted in Estonia, Peru, the Philippines, and Tomsk, Russia. Cost per 
DALY averted with second line drugs were $598, $163, $143, $745 respectively. The 
 
122 
 
cost per DALY averted was lower than GDP per capita in all 14 WHO sub-regions 
considered. In other studies, Diel and colleagues showed that the treatment of MDR-TB 
is cost-effective in Germany (Diel, Nienhaus, et al., 2014)and European Union (EU) 
countries combined (Diel, Vandeputte, et al., 2014).  
Our study results suggest that shorter regimen is cost-effective in Bangladesh 
setting. Since Bangladesh is developing country, the findings can be emulated in other 
developing countries. There is already evidence that MDR-TB treatment is itself cost-
effective in developed countries; with shorter regimen treatment adherence will increase 
in efficacy of the treatment. Although STREAM trial will evaluate the incidence of 
adverse drug reactions among the shorter and current regimens, in this study we found 
that the adverse drug events were less among the patients undergoing shorter regimen. 
Both shorter duration of treatment and lesser adverse drug reactions translated into more 
QALY for the shorter regimen and eventually made the shorter regimen cost-effective. 
This study has several limitations. For transitional probabilities we used one study 
for each treatment regimens due to lack of published study. This made the results biased. 
Results from the STREAM study will help to fill this void and the clinical trial results can 
be used for future studies. Cost and effectiveness data from the patients may suffer from 
the recall bias, especially for the patients under the 20-24-month regimen. Health care 
facility level cost data were also collected from four facilities (two for each regimen) may 
suffer from biased estimates. 
Despite these limitations, this study tried to collect the patient and provider level 
data comprehensively using pre-set questionnaires. To our best knowledge, it is also the 
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first study to conduct economic evaluation between shorter and current regimens of 
MDR-TB treatment. 
Growing evidence of efficacy compels the policy makers to adopt the shorter 
regimen as the approved regimen in near future. Results of this study makes the case for 
shorter regimen stronger with the evidence of cost-effectiveness which is often 
considered as the pivotal consideration for allocating scarce resources. 
We can conclude that the evidence of cost-effectiveness of shorter regimen of 
MDR-TB and the efficacy of the regimen from other studies reflect that it is high time to 
adopt the shorter regimen as the prescribed treatment for MDR-TB treatment. This will 
prevent the deadly disease to spread among the vulnerable population worldwide and 
help us to reach the End TB strategy goals.   
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APPENDIX A- STUDY III SUPPLEMENTAL INFORMATION 
Table A.1 MDR-TB Drug Costs 
Drug 
Short 
Form Dose (mg) Price 
Daily 
Dose (mg) Daily dose Price 
Kanamycin Km 1000 79.25 500 0.79 
Moxifloxacin Mfx 400 mg 39 400 0.39 
Prothionamide Pto 250 13.39 500 0.27 
Levofloxacin Lfx 750 10.00 750 0.10 
Cycloserine Cs 250 28.80 500 0.58 
Ethionamdie Eto 250 7.77 500 0.16 
Clofazimine Cfz 100 103.86 100 1.04 
Pyrazinamide Z 500 17.305 1000 0.05 
High dose Isoniazid (H) H 300 12.76 900 0.06 
Ethambutol Eto 400 20.29 400 0.03 
 
Table A.2 Drug Costs for MDR-TB Treatment Regimes 
Phase 20-24-month regimen 
Duration 
(month) 
Price (Each 
Day) 
Price 
(Period) BDT 
Intensive Z-KM-Eto-Cs-Ofx/Lvx 8 1.68 402.10  
Continu
ation Z-Eto-Cs-Ofx/Lvx 14 0.89 370.82  
    Total 772.916 61833 
Phase 9-month regimen 
Duration 
(month) 
Price (Each 
Day) 
Price 
(Period) BDT 
Intensive 
Km-Mfx-Pto-Cfz-Z-
Hhigh-dose-E 4 2.60 311.69  
Continu
ation Mfx-Cfz-Z-E 5 1.49 222.83  
    Total 534.5187 42762 
   
135 
 
Table A.3 Diagnostic Test Costs for 20-24-Month Regimen 
SL 
Laboratory 
Investigations 
At base line 
or before 
starting the 
treatment 
Rate 
(Tk) 
During 
Intensive Phase 
(Injectable 
Period- usually 
8 month*) 
Total Amount 
in 8* Month 
(Investigation 
Rate X 
Frequency) 
During 
Continuation Phase 
(Oral Medication 
only-Usually 12 
month***) 
Total Amount 
in 12* Month 
(Investigation 
Rate X 
Frequency) 
1 
Pure Tone 
Audiometry 
(PTA) 
Must 750 Monthly 
6000 
  
No clear decision 
regarding this! 
  
2 S. Creatinine Must 350 Monthly** 
2800 
  
Need based on 
symptoms / Clinical 
Decision** 
1400 
3 S. Electrolyte Must 900 Monthly** 
7200 
  
Need based on 
symptoms / Clinical 
Decision** 
3600 
4 
S. Bilirubin, 
SGPT, ALP 
Must 950 
Every 1-3 
Monthly 
2850 
  
Need based on 
symptoms / Clinical 
Decision** 
3800 
5 
Thyroid Function 
Test (TSH) 
Must 900 
Every 6 
Monthly 
900 
  
Every 6 Monthly 1800 
6 
Complete Blood 
Count (CBC) 
Must 450 
Need based on 
symptoms / 
Clinical 
Decision** 
900 
  
Need based on 
symptoms / Clinical 
Decision** 
1800 
7 S. Uric Acid Must 400 
Need based on 
symptoms / 
Clinical 
Decision** 
800 
  
Need based on 
symptoms / Clinical 
Decision** 
1600 
8 
Random Blood 
Sugar (RBS) 
Must 250 
Need based on 
symptoms / 
Clinical 
Decision* 
500 
  
Need based on 
symptoms / Clinical 
Decision** 
1000 
9 Chest X Ray Must 450 
Every 6 
Monthly 
450 
  
Every 6 Monthly 900 
10 
Pregnancy Test 
(Female at Child 
Bearing Age) 
Must 300 
Need based on 
symptoms / 
Clinical 
Decision** 
  
  
Need based on 
symptoms / Clinical 
Decision** 
  
 
Expenditure at 
Baseline/Patient 
5700 
Expenditure at 
Intensive 
Phase/Patient 
  
  
 22400 
  
Expenditure in 
Continuation 
Phase/Patient 
15900 
  
Table A.4 Diagnostic Test cost for 9-Month Regimen 
 4 Month  5 Month Total 
Intensive 
Phase (22400/8)*5 
Continuation 
Phase (15900/12)*5 
17825 
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APPENDIX B- PATIENT QUESTIONNAIRE (DS-TB) 
Face Sheet for DRUG SENSITIVE TB Patient Interview 
IDENTIFICATION 
 
DIVISION:     
 
DISTRICT:     
 
UPAZILA:     
 
NAME AND TYPE OF THE FACILITY: 
(Union Health Center =01, Upazila Health Complex =02, District 
Hospital =03) 
    
 
HEALTH FACILITY CODE:       
 
TYPE OF THE PROVIDER: 
(BRAC =01, Damien Foundation =02, Other (Please specify)=03)     
 
RESPONDENT: 
(Patient=01, Friend/Guardian=02, Other (Please specify)=03)     
 
SEX OF THE RESPONDENT: 
(Male=01, Female= 02)     
 
SEX OF THE PATIENT: 
(Male=01, Female= 02)     
 
NAME OF THE DOT PROVIDER:  
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INTERVIEWER VISITS 
 1 2 3 FINAL VISIT 
 
DATE 
    
INTERVIEWER’S 
NAME & CODE 
    
RESULT 
CODE   
 
 
RESULT CODE* 
    
RESULT 
CODE   
 
*RESULT CODES: 
01     COMPLETED     03 POSTPONED 05 PARTLY COMPLETED 
02 NOT AVAILABLE 04 REFUSED 96 OTHER, SPECIFY________________ 
 
SUPERVISOR FIELD EDITOR OFFICE EDITOR KEYED BY 
 
 
 
 
 
 
 
 
 Collect information from only those patients who have completed their treatment 
within last two months. 
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Section 1: Patient Information  
(TO BE FILLED BY INTERVIEWER TRANSFERING INFORMATION FROM THE TB CARD)                                                                                        
 Options   
Consent obtained from 
patient or caregiver? 
Yes……………………………….1 
No…………………………………2 
 
     
 
 
No. Questions and 
filters Coding categories Response 
Skip 
101 Patient age 
 
 
 
 
Years   
Months   
 
 
 
102 Patient Sex Male……………………………1 
Female..……………………….2 
 
     
 
 
103 BCG Vaccine No 
Scar……………………………1 
Scar Seen……………………….2 
 
     
 
 
104 Type of TB  Pulmonary smear positive..……1 
Pulmonary smear negative…….2 
Xpert MTB/RIF Positive………...3 
Extra-Pulmonary ………………...4                          
Please Specify_______________ 
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105 Type of Patient New…………………….…….1 
Failure………………...……..2 
Transfer in..…………………3 
Relapse……………………..4 
Treatment after loss to follow 
up/default.……………….….5                           
Other ………………..………6 
Specify________________ 
 
 
 
     
 
 
 
106 Referred by which 
type of provider? 
Private Practitioner (Graduate)…1 
Private Practitioner (Non-
Graduate)………………………..2 
Govt. field staff…………………..3 
Shasthya Sebika (SS)/Non-govt. 
field staff (NGFS)……………….4 
Village Doctor (VD)……………..5 
Community Volunteer………….6 
Govt. Hospital…………………..7 
Private Hospital………………...8 
Community Health Care Provider 
(CHCP)………………………….9 
TB Patient……………………… 
Other____________________10 
Please specify 
 
 
 
 
 
 
     
 
 
107 Results of sputum 
Examination  
Month Smear 1 Smear 2 Xpert Result Weight (kg) 
0     
2/3     
3/4     
5     
6/8     
 
108 Treatment Regimen Cat I……………………………1 
Cat II…………………………..2 
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109 Treatment outcome Cured…………………….…….1 
Treatment completed....……..2 
Died………....…………………3 
Treatment failure……………..4 
Lost to follow 
up/Default.…………………….5                           
Transfer Out…………..………6 
Not Evaluated…………………7 
 
 
 
     
 
 
 
110 HIV Status  Positive…………………….…….1 
Negative………………......……..2 
Not Tested…....…………………3 
Unknown………….……………..4 
Declined.…………………….….5                           
 
     
 
 
111 Type of Drug 
Reaction 
   
112 Date of starting 
treatment 
 Day   
Month   
Year   
 
 
113 Date of treatment 
completion 
 Day   
Month   
Year   
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Section 2.0: Previous treatment 
PATIENT INTERVIEW SECTION                               Start time: Hours  |__|__|  Minutes  |__|__| 
No. Questions and filters Coding categories Response Skip 
201 Have you ever had TB 
treatment before? 
CROSS-CHECK WITH 
INFORMATION FROM 
PATIENT CARD 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
301 
202 Have you completed your 
previous TB treatment? 
CROSS-CHECK WITH 
INFORMATION FROM 
PATENT CARD 
Yes……………………………1 
No…………………………….2 
 
     
 
 
If 1 
►  
301 
203 Why did not you complete 
your previous treatment? 
 
[For each option, record 1 
if the option is mentioned 
and record 2 if the option 
has not been mentioned.] 
A. Distance to the facility   
B. Lack of money for treatment 
costs 
 
C. Drug Side Effects  
D. Moved/Migrated  
E. Thought that no more 
treatment was necessary 
 
E. Other 
Please 
Specify________________ 
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Section 3: Delay, Prediagnostic & Diagnostic Costs 
No. Questions and filters Coding categories Response Skip 
301 What symptoms did you 
experience that led you to 
seek treatment for your 
most recent illness with 
TB?  
 
 
[For each option, record 1 
if the option is mentioned 
and record 2 if the option 
has not been mentioned.] 
a. Cough   
b. Evening rise of 
temperature/low grade fever 
 
c. Night sweats  
d. Coughing up blood  
e. Weight loss  
f. Other 
Specify_____________________ 
 
302 How long did you 
experience these symptoms 
before you went to seek 
treatment? 
 
[For each option, record 
number of weeks if 
mentioned yes in the 
previous question.] 
 
a. Cough Weeks   
 
 
b. Evening rise of 
temperature/low grade fever 
Weeks   
 
c. Night sweats Weeks   
 
d. Coughing up blood 
Weeks   
 
e. Weight loss Weeks   
 
f. Other 
Specify_____________________ 
Weeks   
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Section 3.1 First Visit 
303 After you experienced 
the symptoms, which 
provider did you go to 
first?  
Community Clinic…………….…….1 
Union Subcenter………….....……..2 
Upazila Health Complex…..………3 
District Hospital……..……………..4 
Pharmacy & Drug Store……….….5                           
Homoeopath………………..………6 
Private Hospital……..……………..7 
Village Doctor………………………8 
Traditional Healer………………….9                           
Other………………………..………10 
Specify______________________ 
 
 
        
   
 
 
304 What was the distance to 
the provider from your 
home? 
 Kilometer     
 
 
305 What was the travel time 
to reach this provider? 
 Hour   
Minute   
 
 
306 What was the waiting 
and consultation time 
with the provider? 
 Hour   
Minute   
 
 
307 What was the registration 
(ticket) cost paid by you? 
In TAKA 
IF not known put 99999 
IF no registration cost 000 
     
 
 
308 What was the 
consultation fee you have 
paid? In TAKA 
IF not known put 99999 
IF no consultation fee 000 
     
 
 
309 What was the cost you 
paid for diagnostic tests? 
In TAKA 
IF not known put 99999 
IF no cost for tests 000 
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310 What was the cost for x-
ray? In TAKA 
IF not known put 99999 
IF no cost for x-ray 000 
     
 
 
311 What was the costs of 
drugs? In TAKA 
IF not known put 99999 
IF no cost for drugs 000 
     
 
 
312 What was travel costs? 
(INCLUDE ALL 
TRAVEL RELATED 
COSTS: RETURN 
TRAVEL, TRAVEL 
FOR LABORATIRY 
TESTS, DTUGS, COST 
FOR 
ACCOMPANYING 
PERSONS) In TAKA 
IF not known put 99999 
IF no travel cost 000 
     
 
 
313 What was the food costs? 
In TAKA 
IF not known put 99999 
IF no food cost 000 
     
 
 
314 What was cost for 
accommodation? 
IF not known put 99999 
IF no accommodation cost 000 
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Section 3.2 Second Visit 
No. Questions and filters Coding categories Response Skip 
315 Once you experience 
the symptoms to which 
provider did you go 
after you have seen the 
provider type 
_________________? 
(MENTION THE 
FIRST VISIT’S 
PROVIDER TYPE) 
Community Clinic…………….…….1 
Union Subcenter………….....……..2 
Upazila Health Complex…..………3 
District Hospital……..……………..4 
Pharmacy & Drug Store……….….5                           
Homoeopath………………..………6 
Private Hospital……..……………..7 
Village Doctor………………………8 
Traditional Healer………………….9                           
Other………………………..………10 
Specify______________________ 
 
 
        
   
 
 
316 What was the distance 
to the provider from 
your home? 
 Kilometer     
 
 
317 What was the travel 
time to reach this 
provider? 
 Hour   
Minute   
 
 
318 What was the waiting 
and consultation time 
with the provider? 
 Hour   
Minute   
 
 
319 What was the 
registration (ticket) cost 
paid by you? In TAKA 
IF not known put 99999 
IF no registration cost 000 
     
 
 
320 What was the 
consultation fee you 
have paid? In TAKA 
IF not known put 99999 
IF no consultation fee 000 
     
 
 
321 What was the cost you 
paid for diagnostic 
tests? In TAKA 
IF not known put 99999 
IF no cost for tests 000 
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322 What was the cost for 
x-ray? In TAKA 
IF not known put 99999 
IF no cost for x-ray 000 
     
 
 
323 What was the costs of 
drugs? In TAKA 
IF not known put 99999 
IF no cost for drugs 000 
     
 
 
324 What was travel costs? 
(INCLUDE ALL 
TRAVEL RELATED 
COSTS: RETURN 
TRAVEL, TRAVEL 
FOR LABORATIRY 
TESTS, DTUGS, 
COST FOR 
ACCOMPANYING 
PERSONS) In TAKA 
IF not known put 99999 
IF no travel cost 000 
     
 
 
325 What was the food 
costs? In TAKA 
IF not known put 99999 
IF no food cost 000 
     
 
 
326 What was cost for 
accommodation? 
IF not known put 99999 
IF no accommodation cost 000 
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Section 3.3 Third Visit 
No. Questions and filters Coding categories Response Skip 
327 Once you experience the 
symptoms to which 
provider did you go after 
you have seen the 
provider type 
_________________? 
(Mention the second 
visit’s provider type) 
Community Clinic…………….…….1 
Union Subcenter………….....……..2 
Upazila Health Complex…..………3 
District Hospital……..……………..4 
Pharmacy & Drug Store……….….5                           
Homoeopath………………..………6 
Private Hospital……..……………..7 
Village Doctor………………………8 
Traditional Healer………………….9                           
Other………………………..………10 
Specify______________________ 
 
 
        
   
 
 
328 What was the distance to 
the provider from your 
home? 
 Kilometer     
 
 
329 What was the travel time 
to reach this provider? 
 Hour   
Minute   
 
 
330 What was the waiting 
and consultation time 
with the provider? 
 Hour   
Minute   
 
 
331 What was the 
registration (ticket) cost 
paid by you? In TAKA 
IF not known put 99999 
IF no registration cost 000 
     
 
 
332 What was the 
consultation fee you 
have paid? In TAKA 
IF not known put 99999 
IF no consultation fee 000 
     
 
 
333 What was the cost you 
paid for diagnostic tests? 
In TAKA 
IF not known put 99999 
IF no cost for tests 000 
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334 What was the cost for x-
ray? In TAKA 
IF not known put 99999 
IF no cost for x-ray 000 
     
 
 
335 What was the costs of 
drugs? In TAKA 
IF not known put 99999 
IF no cost for drugs 000 
     
 
 
336 What was travel costs? 
(INCLUDE ALL 
TRAVEL RELATED 
COSTS: RETURN 
TRAVEL, TRAVEL 
FOR LABORATIRY 
TESTS, DTUGS, COST 
FOR 
ACCOMPANYING 
PERSONS) In TAKA 
IF not known put 99999 
IF no travel cost 000 
     
 
 
337 What was the food 
costs? In TAKA 
IF not known put 99999 
IF no food cost 000 
     
 
 
338 What was cost for 
accommodation? 
IF not known put 99999 
IF no accommodation cost 000 
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Section 3.4 Fourth Visit 
No. Questions and filters Coding categories Response Skip 
339 Once you experience 
the symptoms to which 
provider did you go 
after you have seen the 
provider type 
_________________? 
(Mention the third 
visit’s provider type) 
Community Clinic…………….…….1 
Union Subcenter………….....……..2 
Upazila Health Complex…..………3 
District Hospital……..……………..4 
Pharmacy & Drug Store……….….5                           
Homoeopath………………..………6 
Private Hospital……..……………..7 
Village Doctor………………………8 
Traditional Healer………………….9                           
Other………………………..………10 
Specify______________________ 
 
 
        
   
 
 
340 What was the distance 
to the provider from 
your home? 
 Kilometer     
 
 
341 What was the travel 
time to reach this 
provider? 
 Hour   
Minute   
 
 
342 What was the waiting 
and consultation time 
with the provider? 
 Hour   
Minute   
 
 
343 What was the 
registration (ticket) cost 
paid by you? In TAKA 
IF not known put 99999 
IF no registration cost 000 
     
 
 
344 What was the 
consultation fee you 
have paid? In TAKA 
IF not known put 99999 
IF no consultation fee 000 
     
 
 
345 What was the cost you 
paid for diagnostic 
tests? In TAKA 
IF not known put 99999 
IF no cost for tests 000 
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346 What was the cost for 
x-ray? In TAKA 
IF not known put 99999 
IF no cost for x-ray 000 
     
 
 
347 What was the costs of 
drugs? In TAKA 
IF not known put 99999 
IF no cost for drugs 000 
     
 
 
348 What was travel costs? 
(INCLUDE ALL 
TRAVEL RELATED 
COSTS: RETURN 
TRAVEL, TRAVEL 
FOR LABORATIRY 
TESTS, DTUGS, 
COST FOR 
ACCOMPANYING 
PERSONS) In TAKA 
IF not known put 99999 
IF no travel cost 000 
     
 
 
349 What was the food 
costs? In TAKA 
IF not known put 99999 
IF no food cost 000 
     
 
 
350 What was cost for 
accommodation? 
IF not known put 99999 
IF no accommodation cost 000 
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Section 3.5 Fifth Visit 
No. Questions and filters Coding categories Response Skip 
351 Once you experience 
the symptoms to which 
provider did you go 
after you have seen the 
provider type 
_________________? 
(Mention the fourth 
visit’s provider type) 
Community Clinic…………….…….1 
Union Subcenter………….....……..2 
Upazila Health Complex…..………3 
District Hospital……..……………..4 
Pharmacy & Drug Store……….….5                           
Homoeopath………………..………6 
Private Hospital……..……………..7 
Village Doctor………………………8 
Traditional Healer………………….9                           
Other………………………..………10 
Specify______________________ 
 
 
        
   
 
 
352 What was the distance 
to the provider from 
your home? 
 Kilometer     
 
 
353 What was the travel 
time to reach this 
provider? 
 Hour   
Minute   
 
 
354 What was the waiting 
and consultation time 
with the provider? 
 Hour   
Minute   
 
 
355 What was the 
registration (ticket) cost 
paid by you? In TAKA 
IF not known put 99999 
IF no registration cost 000 
     
 
 
356 What was the 
consultation fee you 
have paid? In TAKA 
IF not known put 99999 
IF no consultation fee 000 
     
 
 
357 What was the cost you 
paid for diagnostic 
tests? In TAKA 
IF not known put 99999 
IF no cost for tests 000 
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358 What was the cost for 
x-ray? In TAKA 
IF not known put 99999 
IF no cost for x-ray 000 
     
 
 
359 What was the costs of 
drugs? In TAKA 
IF not known put 99999 
IF no cost for drugs 000 
     
 
 
360 What was travel costs? 
(INCLUDE ALL 
TRAVEL RELATED 
COSTS: RETURN 
TRAVEL, TRAVEL 
FOR LABORATIRY 
TESTS, DTUGS, 
COST FOR 
ACCOMPANYING 
PERSONS) In TAKA 
IF not known put 99999 
IF no travel cost 000 
     
 
 
361 What was the food 
costs? In TAKA 
IF not known put 99999 
IF no food cost 000 
     
 
 
362 What was cost for 
accommodation? 
IF not known put 99999 
IF no accommodation cost 000 
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Section 3.6 Sixth Visit 
No. Questions and filters Coding categories Response Skip 
363 Once you experience 
the symptoms to which 
provider did you go 
after you have seen the 
provider type 
_________________? 
(Mention the fifth 
visit’s provider type) 
Community Clinic…………….…….1 
Union Subcenter………….....……..2 
Upazila Health Complex…..………3 
District Hospital……..……………..4 
Pharmacy & Drug Store……….….5                           
Homoeopath………………..………6 
Private Hospital……..……………..7 
Village Doctor………………………8 
Traditional Healer………………….9                           
Other………………………..………10 
Specify______________________ 
 
 
        
   
 
 
364 What was the distance 
to the provider from 
your home? 
 Kilometer     
 
 
365 What was the travel 
time to reach this 
provider? 
 Hour   
Minute   
 
 
366 What was the waiting 
and consultation time 
with the provider? 
 Hour   
Minute   
 
 
367 What was the 
registration (ticket) cost 
paid by you? In TAKA 
IF not known put 99999 
IF no registration cost 000 
     
 
 
368 What was the 
consultation fee you 
have paid? In TAKA 
IF not known put 99999 
IF no consultation fee 000 
     
 
 
369 What was the cost you 
paid for diagnostic 
tests? In TAKA 
IF not known put 99999 
IF no cost for tests 000 
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370 What was the cost for 
x-ray? In TAKA 
IF not known put 99999 
IF no cost for x-ray 000 
     
 
 
371 What was the costs of 
drugs? In TAKA 
IF not known put 99999 
IF no cost for drugs 000 
     
 
 
372 What was travel costs? 
(INCLUDE ALL 
TRAVEL RELATED 
COSTS: RETURN 
TRAVEL, TRAVEL 
FOR LABORATIRY 
TESTS, DTUGS, 
COST FOR 
ACCOMPANYING 
PERSONS) In TAKA 
IF not known put 99999 
IF no travel cost 000 
     
 
 
373 What was the food 
costs? In TAKA 
IF not known put 99999 
IF no food cost 000 
     
 
 
374 What was cost for 
accommodation? 
IF not known put 99999 
IF no accommodation cost 000 
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Section 3.7 Seventh Visit 
No. Questions and filters Coding categories Response Skip 
375 Once you experience 
the symptoms to which 
provider did you go 
after you have seen the 
provider type 
_________________? 
(Mention the sixth 
visit’s provider type) 
Community Clinic…………….…….1 
Union Subcenter………….....……..2 
Upazila Health Complex…..………3 
District Hospital……..……………..4 
Pharmacy & Drug Store……….….5                           
Homoeopath………………..………6 
Private Hospital……..……………..7 
Village Doctor………………………8 
Traditional Healer………………….9                           
Other………………………..………10 
Specify______________________ 
 
 
        
   
 
 
376 What was the distance 
to the provider from 
your home? 
 Kilometer     
 
 
377 What was the travel 
time to reach this 
provider? 
 Hour   
Minute   
 
 
378 What was the waiting 
and consultation time 
with the provider? 
 Hour   
Minute   
 
 
379 What was the 
registration (ticket) cost 
paid by you? In TAKA 
IF not known put 99999 
IF no registration cost 000 
     
 
 
380 What was the 
consultation fee you 
have paid? In TAKA 
IF not known put 99999 
IF no consultation fee 000 
     
 
 
381 What was the cost you 
paid for diagnostic 
tests? In TAKA 
IF not known put 99999 
IF no cost for tests 000 
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382 What was the cost for 
x-ray? In TAKA 
IF not known put 99999 
IF no cost for x-ray 000 
     
 
 
383 What was the costs of 
drugs? In TAKA 
IF not known put 99999 
IF no cost for drugs 000 
     
 
 
384 What was travel costs? 
(INCLUDE ALL 
TRAVEL RELATED 
COSTS: RETURN 
TRAVEL, TRAVEL 
FOR LABORATIRY 
TESTS, DTUGS, 
COST FOR 
ACCOMPANYING 
PERSONS) In TAKA 
IF not known put 99999 
IF no travel cost 000 
     
 
 
385 What was the food 
costs? In TAKA 
IF not known put 99999 
IF no food cost 000 
     
 
 
386 What was cost for 
accommodation? 
IF not known put 99999 
IF no accommodation cost 000 
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Section 3.8 Eighth Visit 
No. Questions and filters Coding categories Response Skip 
387 Once you experience 
the symptoms to which 
provider did you go 
after you have seen the 
provider type 
_________________? 
(Mention the seventh 
visit’s provider type) 
Community Clinic…………….…….1 
Union Subcenter………….....……..2 
Upazila Health Complex…..………3 
District Hospital……..……………..4 
Pharmacy & Drug Store……….….5                           
Homoeopath………………..………6 
Private Hospital……..……………..7 
Village Doctor………………………8 
Traditional Healer………………….9                           
Other………………………..………10 
Specify______________________ 
 
 
        
   
 
 
388 What was the distance 
to the provider from 
your home? 
 Kilometer     
 
 
389 What was the travel 
time to reach this 
provider? 
 Hour   
Minute   
 
 
390 What was the waiting 
and consultation time 
with the provider? 
 Hour   
Minute   
 
 
391 What was the 
registration (ticket) cost 
paid by you? In TAKA 
IF not known put 99999 
IF no registration cost 000 
     
 
 
392 What was the 
consultation fee you 
have paid? In TAKA 
IF not known put 99999 
IF no consultation fee 000 
     
 
 
393 What was the cost you 
paid for diagnostic 
tests? In TAKA 
IF not known put 99999 
IF no cost for tests 000 
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394 What was the cost for 
x-ray? In TAKA 
IF not known put 99999 
IF no cost for x-ray 000 
     
 
 
395 What was the costs of 
drugs? In TAKA 
IF not known put 99999 
IF no cost for drugs 000 
     
 
 
396 What was travel costs? 
(INCLUDE ALL 
TRAVEL RELATED 
COSTS: RETURN 
TRAVEL, TRAVEL 
FOR LABORATIRY 
TESTS, DTUGS, 
COST FOR 
ACCOMPANYING 
PERSONS) In TAKA 
IF not known put 99999 
IF no travel cost 000 
     
 
 
397 What was the food 
costs? In TAKA 
IF not known put 99999 
IF no food cost 000 
     
 
 
398 What was cost for 
accommodation? 
IF not known put 99999 
IF no accommodation cost 000 
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Section 4.0: Treatment Costs 
Section 4.1 Cost Related to DOT 
No. Questions and filters Coding categories Response Skip 
401 From where did you get 
your TB drugs?  
Health facility………………….…….1 
Home……………………….....……..2 
Community…………………..………3 
Pharmacy……………..……………..4 
Workplace……………….……….….5                           
Other………………………..………9 
Specify______________________ 
 
 
     
 
 
402 How often do you 
travel to the health 
facility / hospital for 
picking up your TB 
drugs? 
 Times/month   
 
 
403 How long does it take 
to go to the place for 
picking up the drugs 
(ONE WAY)? 
A. On Foot 
Hour   
Minute   
 
 
B. By Transport 
Hour   
Minute   
 
 
404 How long does one of 
these visits take on 
average, including time 
on the road and waiting 
time (total turnaround 
time)? 
 Hour   
Minute   
 
 
405 From your home to the 
facility, how much does 
it cost if you take 
transport? (both ways) 
IF not known put 99999      
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406 
If you go to a facility to 
pick up your drugs, 
how much do you 
spend on food on that 
day? (on the road, 
while waiting, lunch 
etc.) 
IF not known put 99999      
 
 
407 Do you have to pay 
administration fees 
when picking up your 
TB drugs? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
409 
408 What was the 
administration cost? 
IF not known put 99999 
IF no administration cost 000 
     
 
 
409 Do you have to pay for 
accommodation when 
picking up your TB 
drugs? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
411 
410 What was the 
accommodation cost? 
IF not known put 99999 
IF no accommodation cost 000 
     
 
 
Section 4.2 Cost related to Follow Up Tests 
411 Did you ever have to 
go to the health facility 
in addition to your 
regular visits for 
follow up tests since 
the beginning of 
treatment? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
414 
412 If yes, how many 
times? 
 Times   
 
 
413 If yes, did you have to 
pay any additional 
costs any time during 
the entire period? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
421 
414 If so, what kind of costs 
and how much did you 
 
A. Fees 
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pay last time (In 
TAKA)? 
 
 
IF not known put 
99999 
IF no cost put 000 
 
B. Sputum Test 
     
 
 
C. X -ray 
     
 
 
D. TB Drugs 
     
 
 
E. Other Drugs 
     
 
 
F. Others 
     
 
415 How long does one of 
these follow-up visits 
take on average, 
including time on the 
road, waiting time and 
tests (total turnaround 
time)? 
 
Hour   
Minute   
 
 
 
Section 5.0: Cost related to accompanied persons (Friends/Guardian) 
No. Questions and filters Coding categories Response Skip 
501 Does any 
family/friend/DOT 
supporter accompany you 
on any visits before 
diagnosis and/or during 
diagnosis? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
507 
502 If YES, on how many visits 
has your family/friend/DOT 
supporter accompanied you 
or gone with you before 
diagnosis and/or during 
diagnosis? 
 Times    
 
 
503 What was the cost for pre-
diagnosis/diagnosis visits of 
A. Transport Cost      
 
 
   
162 
 
your accompanying person 
in Taka)? 
 
IF not known put 99999 
IF no cost put 000 
B. Food Cost      
 
 
C. Accommodation Cost 
     
 
 
504 Does your accompanying 
person earn? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
506 
505 If earn, how much the 
person earn per day (in 
TAKA)? 
IF not known put 99999 
 
     
 
 
506 Why did someone 
accompany you? 
 
[For each option, record 1 
if the option is mentioned 
and record 2 if the option 
has not been mentioned.] 
A. Distance    
B. Security  
C. Administrative barrier  
D. Too ill to travel alone  
E. Was required for treatment  
F. Other 
Please 
Specify________________ 
 
507 Does any 
family/friend/DOT 
supporter accompany you 
on any visits during 
treatment (taking drugs)? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
601 
508 If YES, on how many visits 
has your family/friend/DOT 
supporter accompanied you 
or gone with you during 
treatment? 
 
Times    
 
 
509 What was the cost for visits 
of your accompanying 
A. Transport Cost      
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person during your 
treatment in TAKA)? 
 
IF not known put 99999 
IF no cost put 000 
B. Food Cost      
 
 
C. Accommodation Cost 
     
 
 
510 Does your accompanying 
person earn? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
512 
511 If earn, how much the 
person earn per day (In 
TAKA)? 
 
     
 
 
512 Why did someone 
accompany you? 
 
[For each option, record 1 
if the option is mentioned 
and record 2 if the option 
has not been mentioned.] 
 
IF not known put 99999 
A. Distance    
B. Security concern  
C. Administrative barrier  
D. Too ill to travel alone  
E. Was required for treatment  
F. Other 
Please 
Specify________________ 
 
 
Section 6.0: Hospitalization Costs 
No. Questions and filters Coding categories Response Skip 
601 Have you been hospitalized 
before (but due to TB) or 
during your TB treatment? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
701 
602 If YES, how many times 
were you hospitalized for 
this illness? 
 
Times    
 
 
603 A. Hospital Administration Fees      
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How much did you pay 
during your last stay at the 
hospital (In TAKA)? 
 
IF not known put 99999 
IF no cost put 000 
 
B. Hospital stay charges      
 
 
C. Food (Not provided by the 
hospital) 
     
 
 
D. Transport (Both Ways)      
 
 
E. Drugs 
     
 
 
F. Diagnostic Tests       
 
 
G. Others      
 
 
604 Did any attendant/caregiver 
stay with you at the 
hospital? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
701 
605 If YES, how many days 
he/she stay with you (sleep 
there)? 
 Days   
 
 
606 Were there any extra costs 
for your relative/friend for 
staying at the hospital? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
506 
607 What was the cost for the 
accompanying person 
during your hospitalization 
(stayed at night)? In TAKA 
 
IF not known put 99999 
 
 
A. Transport Cost 
     
 
 
B. Food Cost      
 
 
C. Accommodation Cost      
 
 
D. Other Cost      
 
 
608 Does your accompanying 
person earn? 
Yes……………………………1 
No…………………………….2 
Don’t Know.………………….3 
 
     
 
If 2 
/3 
►  
610 
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609 If earn, how much the 
accompanying person earn 
per day? 
      
 
 
610 Did any other family/friend 
visit you while in hospital? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2  
►  
701 
611 If YES, How many people 
visited you? 
 Days   
 
 
612 On an average, how many 
times did each of these 
person visit you? 
 Times   
 
 
613 What was the cost for 
EACH VISIT of them (IN 
TAKA)? 
 
IF not known put 99999 
 
A. Transport Cost      
 
 
B. Food Cost      
 
 
C. Accommodation Cost 
     
 
 
D. Other Cost 
     
 
 
614 How long were the visits 
including traveling time? 
 Hour   
Minute   
 
 
 
Section 7.0: Other Costs, Other Illnesses and Coping Costs 
Section 7.1 Other Costs 
No. Questions and filters Coding categories Response Skip 
701 Did you buy any 
supplements for your diet 
because of the TB illness, 
for example vitamins, 
meat, energy drinks, soft 
drinks, fruits or 
medicines? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
703 
702 If YES, how much did you 
spend approximately on 
A. Meat 
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each of these items each 
month (in TAKA)? 
 
IF not known put 99999 
B. Fish      
 
C. Fruits 
      
 
D. Drinks 
     
 
E. Vegetables      
 
F. Vitamins/Herbs      
 
G. Others      
 
Section 7.2 Other illnesses 
703 Do you have any chronic 
illness for which you are 
receiving treatment? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
707 
704 If YES, which disease do 
you have? 
 
[For each option, record 1 
if the option is mentioned 
and record 2 if the option 
has not been mentioned.] 
A. Diabetes   
B. Heart Disease  
C. High Blood Pressure  
D. Cancer  
E. Arthritis  
F. Other 
Specify 
 
G. Other 
Specify 
 
705 Are there any additional 
costs for you because of 
this other illness besides 
the costs that you have 
already mentioned? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
707 
706 If YES, how much are 
these additional costs on 
average per month? In 
TAKA 
A. Drugs       
 
 
B. Diagnostic tests      
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IF not known put 99999 
C. Transport      
 
D. Fees 
     
 
E. Others 
     
 
707 How much did you spend 
on healthcare on average 
per month BEFORE the 
TB illness? In TAKA 
IF not known put 99999      
 
 
708 How much did you spend 
on healthcare on average 
per month AFTER the TB 
illness? In TAKA 
IF not known put 99999      
 
 
Section 7.3 Coping Costs 
709 Has your illness with TB 
resulted in a financial 
burden? 
Yes……………………………1 
No…………………………….2 
 
     
 
 
710 Did you borrow any 
money to cover costs due 
to the TB illness? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
715 
711 If YES, how much did you 
borrow? In TAKA 
IF not known put 99999 
     
 
 
712 From whom did you 
borrow? 
[For each option, record 1 
if the option is mentioned 
and record 2 if the option 
has not been mentioned.] 
A. Family   
B. Neighbor  
C. Friend  
D. Bank  
E. Cooperative  
F. NGO  
G. Money lender   
H. Others 
Specify______________________ 
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713 Have you already paid 
back the borrowed 
money? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
716 
714 How are you planning to 
pay back the money? 
In 
Full……………………………1 
In Installment..………………….2 
 
     
 
If 2 
►  
716 
715 If you are paying in 
installment, what is the 
monthly installment? In 
TAKA 
IF not known put 99999      
 
 
716 Have you sold any of your 
property to finance the 
cost of the TB illness? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
718 
717 How much money did you 
get from the sale of each 
of these properties? 
 
 
IF not known put 99999 
A. Land      
 
 
B. Livestock      
 
C. Transport/Vehicle      
 
D. Household item      
 
E. Farm produce 
     
 
 
F. Jewelry      
 
 
G. Savings (FDR)      
 
 
H. Other 
Specify 
     
 
 
718 Have you employed any 
household help for your 
illness? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
801 
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719 How much do you pay 
monthly to the household 
help? In TAKA 
IF not known put 99999      
 
 
Section 8.0 Patient Income and Patient’s Household Income 
Section 8.1 Personal Income 
No. Questions and filters Coding categories Response Skip 
801 Who is the primary 
income earner of the 
household? 
Patient…………………….…….1 
Patient’s Wife.…………...……..2 
Patient’s Husband..……………3 
Patient’s Mother………………..4 
Patient’s Father…………..…….5 
Patient’s Son….………………..6 
Patient’s Daughter..……..…….7                                                    
Other ………………..………….8 
Specify________________ 
 
 
 
     
 
 
 
802 What is the highest level 
of Education (In years) of 
these individuals? 
 
[For each option, record 
the number of years spent 
studying. if the person is 
illiterate/did not go to 
school record “0”] 
A. Patient  
 
 
B. Primary Income Earner (If Other 
than patient) 
 
 
C. Household Head (If Other than 
patient) 
 
 
B. Spouse of Household Head (If 
Other than patient) 
 
803 Are you involved in 
income earning activities? 
Yes, formal work…………………1 
Yes, agricultural and other 
household work………………….2 
Yes, informal work………………3 
No…………………………………4 
 
     
 
If 4 
►  
809 
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804 If No, why are you not 
involved in any income 
earning activities? 
Cannot work due to illness …….1 
Stopped working after contracting 
TB …….……...…………...……..2 
Retired…………………….…….3 
Student……...…………...……..4 
Other……………....……………5 
Specify----------------------------- 
 
     
 
 
805 Have you left your job 
due to your TB illness? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
If 2 
►  
809 
806 If YES, how many months 
ago did you leave your 
job? 
 
Months   
 
 
807 What was your monthly 
income when you were 
working? In TAKA 
IF not known put 99999      
 
 
808 How regularly did you 
work before you became 
ill with TB? 
Throughout the year…….…….1 
Seasonal/part of the year.……..2 
Day Labor………....……………3 
Other……………....……………4 
Specify----------------------------- 
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809 What was your main 
occupation before your 
illness with TB? 
Service…………………….…….1 
Agriculture…...…………...……..2 
Household work…....……………3 
Construction……………….…….4 
Garments worker………...……..5 
Transport…....…………..………6 
Student…………………….…….7 
Retired…...…………...………….8 
Other………….…....……………9 
Specify----------------------------- 
 
     
 
 
810 Did you have to change 
jobs when you became ill 
with TB? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
 
811 What is your main 
occupation after your 
illness with TB? 
Service…………………….…….1 
Agriculture…...…………...……..2 
Household work…....……………3 
Construction……………….…….4 
Garments worker………...……..5 
Transport…....…………..………6 
Student…………………….…….7 
Retired…...…………...………….8 
Other………….…....……………9 
Specify----------------------------- 
 
     
 
 
812 How many hours did you 
work on average per day 
BEFORE you became ill 
with TB? 
 Hours   
 
 
813 How many hours do you 
work on average NOW 
per day? 
 Hours   
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814 If answer to 812 differs 
from answer to 813:Is the 
change related to the TB 
illness?  
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
If 2 
►  
818 
815 What was your estimated 
personal income per 
month BEFORE the TB 
illness?  In TAKA 
IF not known put 99999      
 
 
816 What is your estimated 
personal income per 
month NOW?  In TAKA 
IF not known put 99999      
 
 
817 Is someone doing the 
work you used to do after 
your illness? 
Spouse…………………….…….1 
Son…………...…………...……..2 
Daughter……..…....……………3 
Friend…….……………….…….4 
Nobody…………………...……..5 
Other………….…....……………9 
Specify----------------------------- 
 
     
 
 
818 Do you have children of 
or below school age? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
If 2 
►  
822 
819 Are all of your children 
attending school 
regularly? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
If 1 
►  
822 
820 Did your children go to 
school regularly before 
your recent illness with 
TB? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
 
821 If your children do not go 
to school, indicate the 
reasons for not attending 
school regularly?  
 
A. Needs to help around the house   
B. No money for school fess  
C. Also sick  
D. Has to work to earn  
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[For each option, record 1 
if the option is mentioned 
and record 2 if the option 
has not been mentioned.] 
 
E. Take care of patient  
F. Other 
Specify___________________ 
 
822 Has the TB illness 
affected your social or 
private life in any way? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
If 2 
►  
823 
823 If YES, how was your 
social life affected?  
 
[For each option, record 1 
if the option is mentioned 
and record 2 if the option 
has not been mentioned.] 
 
 
 
A. Divorce   
B. Loss of job  
C. Dropped out of school  
D. Separated from spouse  
E. Disruption of sexual life  
F. Sick child  
G. Other 
Specify___________________ 
 
8824 What is your religion? Islam…………………….…….1 
Hindu………...…………...……..2 
Christian……..…....……………3 
Buddhism.……………….…….4 
Other………….…....……………5 
Specify----------------------------- 
 
     
 
 
Section 8.2 Household Income 
825 How much do you 
estimate was the average 
income of your household 
per month BEFORE the 
TB illness?  (for all 
persons in the house, 
including patient; includes 
welfare payments, 
government assistance or 
A. Patient’s income      
 
 
B. Income of rest of the household      
 
 
C. Govt. assistance      
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other social support)? In 
TAKA 
 
IF not known put 99999 
D. Other      
 
 
826 How much do you 
estimate was the average 
income of your household 
per month NOW?  (for all 
persons in the house, 
including patient; includes 
welfare payments, 
government assistance or 
other social support)? In 
TAKA 
 
IF not known put 99999 
A. Patient’s income      
 
 
B. Income of rest of the household 
     
 
 
D. Govt. assistance 
     
 
 
E. Other      
 
 
827 How many people 
regularly sleep in your 
house?  (including patient) 
  
    
 
 
828 How many members of 
the household are 
employed for 
wage/salary? (including 
patient) 
  
    
 
 
829 Besides yourself, does 
anyone else of your 
household receive 
treatment for TB? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
If 2 
►  
823 
830 If YES, how many 
household members are 
suffering from TB? 
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Section 9.0 Socioeconomic Indicators 
Section 9.0 Questions about the household RESPONSES Skip 
901 What is the main 
source of lighting 
for the 
household?  
 
 
Electrical mains .................................... 01 
Solar electricity .................................... 02 
Generator .............................................. 03 
Gas…………………………………………..….04 
Kerosine/Oil lamp ................................ 05 
Candles / Torch .................................... 06 
Coleman (Kerosene/Pressure lanterns)…….07 
Improvised lamp ................................... 08 
Others ................................................... 96 
Specify ____________________________ 
 
No source of lighting ............................ 98 
  
902 What is the main 
source of water 
for drinking and 
food preparation 
for the 
household?  
 
 
 
Piped into household ............................ 01 
Piped to yard/plot ................................. 02 
Piped into neighborhood ....................... 03 
Protected well ....................................... 04 
Unprotected well .................................. 05 
Protected Spring  .................................. 06 
Unprotected Spring  .............................. 07 
River/stream ......................................... 08 
Pond/lake/dam ...................................... 10 
Communal tank .................................... 11 
Rainwater.............................................. 12 
Tank truck / Water cart ......................... 13 
Bottled water  ....................................... 14 
Other____________________ ............. 96 
                    (Specify) 
Not reported .......................................... 99 
  
903 What type of fuel 
is mainly used in 
your household 
for cooking?  
 
 
Gas ........................................................ 01 
Stove with kerosene .............................. 02 
Firewood ............................................... 03 
Charcoal ............................................... 04  
Dung ..................................................... 05 
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Electricity  ............................................ 06 
Biogas ................................................... 07 
Straw/shrubs/grass ................................ 08 
Saw dust ............................................... 09 
Others ................................................... 96 
Specify _____________________________ 
 
904 What kind of 
toilet facility do 
people in your 
house mainly 
use?  
 
 
Own flush toilet ...................................... 01 
Shared flush toilet ................................... 02 
Ventilated improved pit latrine ............... 03 
Pit latrine with slab ................................. 04 
Pit latrine without slab / open pit ............ 05 
Bowl/Bucket system ............................... 06 
Closet oversea/river ................................ 07 
No facility/bush/seashore ....................... 08 
Other____________________ ..............  96 
                    (Specify) 
Not reported ..................................... ….  99 
  
905 Main 
material of the 
floor for the 
principal 
residence 
structure 
 
Natural Floor: 
Earth ....................................................... 11 
Sand ........................................................ 12 
Rudimentary: 
  Wood planks ......................................... 21 
  Palm/bamboo ........................................ 22 
Finished:  
  Polished wood ...................................... 31 
  Vinyl/asphalt strips ............................... 32 
  Marble/Ceramic tiles ............................ 33 
  Floor tile ............................................... 34 
  Cement / Concrete/ ............................... 35 
  Brick ..................................................... 36  
  Carpet ................................................... 37 
  Unpolished............................................ 38 
  Other____________________ ............  96 
                    (Specify) 
 
  Not reported ................................... ….  99 
  
906 Main 
material of the 
roof of the 
principal 
residence 
 
Natural roofing 
  No roof ................................................. 11 
  Thatch/palm leaf ................................... 12 
Rudimentary roofing 
   Bamboo ............................................... 21 
   Wood planks ........................................ 22 
   Cardboard ............................................ 23 
Finished roofing 
   Tin / Metal ........................................... 31 
   Wood ................................................... 32 
   Ceramic Tiles ...................................... 33 
  
  
  
  
   
177 
 
   Cement / Concrete ............................... 34 
   Other____________________ ............ 96 
                    (Specify) 
 
907 Main 
material of the 
exterior walls of 
principal 
residence 
 
Natural Walls 
  No walls ................................................ 11 
  Cane/Palm/Trunks ................................ 12 
  Dirt ....................................................... 13 
Rudimentary walls 
  Bamboo with mud / matting ................. 21 
  Stone with mud ..................................... 22 
  Mud ...................................................... 23 
  Fibro ..................................................... 24 
 Plywood ................................................. 25 
  Cardboard ............................................. 26 
Finished walls 
  Tin / Metal sheets ................................. 31 
  Cement / Concrete ................................ 32 
  Brick ..................................................... 31 
  Stone with lime/cement ........................ 33 
  Bricks ................................................... 34 
  Wood planks/shingles ........................... 35 
Other____________________ ............... 96 
                    (Specify) 
  
908 What type of fuel 
does your 
household mainly 
use for cooking? 
ELECTRICITY . . . . . . . . .  . . . . . . . . . . . . . 01 
LPG . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . 02 
NATURAL GAS . . . . . . . . . . . . . . . . . . . . . . 03 
BIOGAS . . . . . . . . . . .  . . . . . . . . . . . . . . . . . 04 
KEROSENE . . . . . . . . . . . . . . . . . . . . . . . . . 05 
COAL, LIGNITE . . . . .. . . . . . . . . . . . . . . . . . 06 
CHARCOAL . . . . . . . . . . . . . . . . . . . . . . . . . 07 
WOOD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 08 
STRAW/SHRUBS/GRASS . . . . . . . . . . . . . . 09 
AGRICULTURAL CROP . . . . . . . . . . . . . . . . 10 
ANIMAL DUNG . . . . . . . . . .  . . . . . . . . . . . . 11 
NO FOOD COOKED 
IN HOUSEHOLD . . . . . . . . . . . . . . . . . . . . . 95  
OTHER 96 
(SPECIFY) 
 If 95 
►  
911 
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912 Does your household or any member of the household own the items? Yes No Responses 
Electricity connection? A. Electricity ..................................... 1 2  
Solar Electricity? B. Solar electricity……………. 1 2  
A radio? C. Radio............................................. 1 2  
A television? D. Television ..................................... 1 2  
A mobile phone? E. Mobile phone ................................ 1 2  
A non-mobile phone? F. Non-mobile phone ......................... 1 2  
A refrigerator? G. Refrigerator .................................. 1 2  
A DVD/VCD player? H. DVD/VCD player ......................... 1 2  
An electric fan? I. Fan ................................................. 1 2  
An Almirah/wardrobe? J.   Almirah ........................................ 1 2  
A water pump K.  Water Pump ................................. 1 2  
An IPS?Generator L.  Generator/IPS............................... 1 2  
An air conditioner M.  AC ............................................... 1 2  
A computer/laptop? N. Computer/Laptop .......................... 1 2  
913 In your opinion, is your 
household a high income 
household, a middle income 
household or a poor household? 
High income……………………………………1 
Middle income………………………………….2 
Low 
income……………………………………..3 
 
914 How many people live in your 
household? 
Total household size 
 
 
915 How many adult members (15 
years or older) 
Number of adults in the household 
 
 
916 How many children (less than 
15 years) 
Number of children in the household 
 
 
909 Is the cooking 
usually done in 
the house, in a 
separate building, 
or outdoors? 
IN THE HOUSE . . . . . . . . . . . . . . . . . . . . . . . . 1 
IN A SEPARATE BUILDING . . . . . . . . . . . . 2 
OUTDOORS . . . . . . . . . . . . . . . . . . . . . . . . . . 3 
OTHER 6 
(SPECIFY) 
 
   
 
 
910 Do you have a 
separate room 
which is used as a 
kitchen? 
Yes…………………….…….1 
No……...…………...……..2 
 
   
 
 
911 Does your 
household own 
any homestead? 
Yes…………………….…….1 
No……...…………...……..2 
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917 How many separate sleeping 
rooms are there for the use of 
your household members in 
your residence? 
Number of rooms 
 
918 What is your current place of 
residence? 
Urban……………………………………1 
Urban slum…………………….……….2 
Rural……………………………………..3 
Other……………………………………..4 
Specify__________________________ 
 
 
919 If the government could provide 
you with some service to ease 
the burden of TB on you and 
your household, what would you 
prefer to have? 
DO NOT READ. INDICATE 
THE ITEMS MENTIONED. IF 
NOT IN THE LIST, ADD ANY 
NEW GOVT. SERVICE 
MENTIONED. 
Transport vouchers..………………………1 
Food vouchers…………………….……….2 
More efficient service……………………..3 
Other……………………………………..4 
Specify____________________________ 
 
 
920 How much would you be willing 
to pay  for not becoming ill with 
TB in the first place? In TAKA 
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Section 10.0 Performance of the Facility 
The next part of the survey is about the quality of TB care that you received during your visits to 
this facility. Please answer the questions in this part of the survey about this facility only.  Do not 
include any other facilities in your answer. 
No. Questions and 
filters Coding categories Response 
Skip 
Section 10.1 Availability of TB Services 
1001 Are the waiting 
time(s) before being 
served by health 
providers of this 
facility acceptable 
to you?   
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1002 How often are you 
attended to by the 
same health 
providers in this 
facility? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1003 How often are the 
service hours of this 
facility 
inconvenient for 
you to get your TB 
treatment? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1004 How often are 
drugs not available 
when you require 
them? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1005 How often do you 
experience 
difficulties in 
obtaining TB 
services in this 
facility because of 
language barriers? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
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1006 How often do you 
have to go to 
another health unit 
for TB services or 
treatment? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1007 Is this health 
facility easy to 
reach (distance)? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1008 How often are TB 
services available 
during the working 
hours of this 
facility? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1009 How often are the 
relevant health 
providers you come 
to see in this facility 
available? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
Section 10.2 Communication and Information 
1010 Do the health 
providers in this 
facility tell you 
when you stop 
spreading TB to 
others?  
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
 
1011 Do the health 
providers in this 
facility tell you that 
TB can be cured? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
 
1012 Do the health 
providers in this 
facility tell you 
about the 
importance of 
observed treatment? 
Yes…………………….…….1 
No……...…………...……..2 
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1013 Do the health 
providers in this 
facility tell you 
about the side 
effects of TB 
drugs? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
 
1014 Do the health 
providers in this 
facility tell you 
about the need for 
sputum tests at 
given points during 
your treatment 
schedule? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
 
1015 Do the health 
providers in this 
facility tell you 
about the duration 
of the TB 
treatment? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
 
1016 During your visits 
to this facility, do 
health providers tell 
you about how to 
store your drugs 
obtained for your 
treatment? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
 
1017 Does the health 
provider in this 
facility tell you 
when next to come 
back for TB 
services? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
 
Section 10.3 Patient – Provider interaction and counselling 
1018 During your visits 
to this facility, how 
often does the 
health provider treat 
you with respect?  
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
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1019 During your visits 
to this facility, how 
often does the 
health provider 
listen carefully to 
you? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1020 During your visits 
to this facility, how 
often do health 
providers explain 
things in a way you 
can understand? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1021 During your visits 
to this facility, how 
often do you have 
sufficient time to 
discuss your 
problems? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1022 During your visits 
to this facility, how 
often do health 
providers discuss 
with you how to 
deal with your 
problems? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1023 During your visits 
to this facility, how 
often do you 
experience 
discrimination 
because you have 
TB? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1024 During your visits 
to this facility, how 
often is your 
privacy respected 
during 
examination? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
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1025 Do health providers 
at this facility tell 
you how TB can 
affect your every 
day life? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
Section 10.4 Infrastructure 
1026 How often is this 
facility clean?  
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1027 How often is there 
safe drinking water 
in this facility? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1028 How often are the 
toilets in this 
facility usable? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1029 How often do you 
find enough 
comfortable places 
to sit on in this 
facility?  
 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
     
 
 
Section 10.5 Professional Competence 
1030 Does this facility 
offer services to 
examine your 
sputum? 
Yes…………………….…….1 
No……...…………...……..2 
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1031 Does this facility 
offer home based 
TB treatment? 
 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
 
1032 Were you 
physically 
examined during 
your first visit to 
this health facility? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
 
1033 Was your sputum 
examined when you 
were diagnosed 
with TB? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
 
1034 How many working 
days were there 
between your first 
sputum submission 
and the time you 
got your results? 
 
0-2 Working days……….…….1 
3-4 Working days ……...……..2 
More than 5 Working days...…3 
 
 
 
     
 
 
1035 In case of germs in 
your sputum that 
cause TB, were 
your close contacts 
examined by the TB 
facility?  
 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
 
1036 How often is there a 
treatment observer 
checking on your 
daily intake of TB 
drugs? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
Section 10.6 Affordability 
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1037 How often do you 
have to pay for your 
regular TB services 
(e.g. sputum tests, 
TB-drugs, X-rays, 
etc.)? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1038 How often do you 
have to pay a tip in 
order to receive TB 
services? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1039 How often do costs 
(e.g. transport) 
prevent you from 
getting to the health 
facility? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
Section 10.7 Support 
1040 How often do you 
receive transport 
support from the 
health facility? 
 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1041 How often do you 
receive food 
support from the 
health facility? 
 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1042 How often do you 
receive financial 
assistance from the 
health facility? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
Section 10.8 Stigma 
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1043 Does the health 
provider talk to you 
the same way you 
are spoken to when 
you receive services 
other than TB? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1044 Does the health 
provider welcome 
you into the health 
facility when you 
visit for TB 
services? 
 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1045 Does the health 
provider turn 
his/her face away 
when speaking with 
you? 
 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1046 Do you feel that 
you are treated with 
dignity when you 
visit the health 
facility? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
 
Section 11.0 Quality of Life 
Section 11.1 Health Related Quality of Life (FACIT-TB Questionnaire) 
How would you describe your 
level of feeling for the following 
statements: (record the number 
in the right column) 
 
No
t 
At 
All 
Slight
ly 
Moderately Quite 
A Bit 
Extrem
ely 
Response 
A. Physical well-being       
1101 I feel ill 1 2 3 4 5  
1102 I get tired easily 1 2 3 4 5  
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1103 I have a lack of energy 1 2 3 4 5  
1104 I have pain 1 2 3 4 5  
1105 I feel weak all over 1 2 3 4 5  
1106 I feel fatigued 1 2 3 4 5  
1107 I have been short of 
breath 
1 2 3 4 5  
1108 I have nausea-“a sense 
of vomiting outbreak” 
1 2 3 4 5  
1109 Because of my physical 
condition, I have 
trouble meeting the 
needs of my family 
1 2 3 4 5  
1110 I am bothered by fever 
(episode of high body 
temperature) 
1 2 3 4 5  
1111 I am forced to spend 
time in bed 
1 2 3 4 5  
1112 I have discomfort or 
pain in my stomach area 
1 2 3 4 5  
1113 I have had itching 1 2 3 4 5  
1114 I have a loss of appetite 1 2 3 4 5  
1115 I have been coughing 1 2 3 4 5  
1116 I am bothered by side 
effects of treatment 
1 2 3 4 5  
1117 Dusts Worsen my 
symptoms 
1 2 3 4 5  
B. Social and economic 
well-being 
      
1118 I feel close to my 
friends 
1 2 3 4 5  
1119 I get emotional support 
from my family 
1 2 3 4 5  
1120 I am satisfied with my 
family communication 
about my illness 
1 2 3 4 5  
1121 My family has accepted 
my illness 
1 2 3 4 5  
1122 I feel close to my 
partner (or the person 
1 2 3 4 5  
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who is my main 
support) 
1123 I get support from my 
friends 
1 2 3 4 5  
1124 My physical condition 
and/or medical 
treatment cause me 
financial difficulties 
1 2 3 4 5  
C. Emotional well-
being/Stigma of having 
TB 
      
1125 I worry that my 
condition will get worse 
1 2 3 4 5  
1126 I worry about dying 1 2 3 4 5  
1127 I am concerned about 
what the future holds 
for me 
1 2 3 4 5  
1128 I am embarrassed by 
my illness 
1 2 3 4 5  
1129 It is hard to tell other 
people about my 
infection 
1 2 3 4 5  
1130 I am losing hope in the 
fight against my illness 
1 2 3 4 5  
1131 I am bothered by the 
change in weight 
1 2 3 4 5  
1132 I worry about spreading 
my infection 
1 2 3 4 5  
1133 I feel nervous 1 2 3 4 5  
1134 I feel sad 1 2 3 4 5  
1135 I am satisfied with how 
I am coping with my 
illness 
1 2 3 4 5  
D. Functional well-being       
1136 I am content with the 
quality of my life right 
now 
1 2 3 4 5  
1137 My work (include work 
at home) is fulfilling 
1 2 3 4 5  
1138 I am able to work 
(include work at home) 
1 2 3 4 5  
1139 I am able to enjoy life 1 2 3 4 5  
1140 I am enjoying the things 
I usually do for fun 
1 2 3 4 5  
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1141 I have accepted my 
illness 
1 2 3 4 5  
1142 I am sleeping well 1 2 3 4 5  
E. Spiritual well-being       
1143 I find strength in my 
faith or spiritual belief 
1 2 3 4 5  
1144 My illness has 
strengthened my faith 
or spiritual belief 
1 2 3 4 5  
1145 My life is still 
productive 
1 2 3 4 5  
Section 11.2 EQ-5D-5L Questionnaire 
Under each heading, please tick the ONE box that best describes your health TODAY. 
Sl Category Options Response 
1146 Mobility I have no problems in walking 
about.................................1 
I have slight problems in walking 
about.............................2 
I have moderate problems in walking 
about......................3 
I have severe problems in walking 
about...........................4 
I am unable to walk 
about..................................................5 
 
1147 Self-Care I have no problems washing or dressing 
myself...............1 
I have slight problems washing or 
dressing myself...........2 
I have moderate problems washing or 
dressing myself....3 
I have severe problems washing or 
dressing myself........4 
I am unable to wash or dress 
myself.................................5 
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1148 Usual Activities 
(e.g., work, 
study, 
housework, 
family or 
leisure 
activities) 
I have no problems doing my usual 
activities....................1 
I have slight problems doing my usual 
activities................2 
I have moderate problems doing my 
usual activities.........3 
I have severe problems doing my usual 
activities.............4 
I am unable to do my usual 
activities.................................5 
 
1149 Pain/Discomfor
t 
I have no pain or 
discomfort...............................................
1 
I have slight pain or 
discomfort...........................................2 
I have moderate pain or 
discomfort....................................3 
I have severe pain or 
discomfort........................................4 
I have extreme pain or 
discomfort......................................5 
 
1150 Anxiety/Depres
sion 
I am not 
anxious/depressed....................................
...........1 
I am slightly 
anxious/depressed....................................
.....2 
I am moderately 
anxious/depressed..................................3 
I am severely 
anxious/depressed....................................
..4 
I am extremely 
anxious/depressed....................................
5 
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Section 11.3 SF-6D Questionnaire 
Under each heading, please tick the ONE box that best describes your health TODAY. 
Sl Category Options Respon
se 
115
1 
Physical 
Functioning 
My health does not limit me in vigorous 
activities..................................1 
My health limits me a little in vigorous 
activities.....................................2 
My health limits me a little in moderate 
activities...................................3 
My health limits me a lot in moderate 
activities......................................4 
My health limits me a little in bathing and 
dressing...............................5 
My health limits me a lot in bathing and 
dressing..................................6 
 
115
2 
Role 
Limitation 
I have no problems with your work or other regular daily 
activities as a result of your physical health or any emotional 
problems......................1 
I am limited in the kind of work or other activities as a result 
of your physical 
health..............................................................................................2 
I accomplish less than you would like as a result of emotional 
problems..............................................................................................
..........3 
You are limited in the kind of work or other activities as a 
result of your physical health and accomplish less than you 
would like as a result of emotional 
problems.....................................................................................4 
 
115
3 
Social 
Functioning 
My health limits my social activities none of the 
time..................................1 
My health limits my social activities a little of the 
time.................................2 
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My health limits my social activities some of the 
time..................................3 
My health limits my social activities most of the 
time...................................4 
My health limits my social activities all of the 
time.......................................5 
115
4 
Pain I have no 
pain................................................................................................1 
I have pain, but it does not interfere with my normal work (both 
outside the home and 
housework)...................................................................................2 
I have pain that interferes with your normal work (both outside the 
home and housework) a little 
bit.............................................................................3 
I have pain that interferes with your normal work (both outside the 
home and housework) 
moderately.........................................................................4 
I have pain that interferes with your normal work (both outside the 
home and housework) quite a 
bit...........................................................................5 
I have pain that interferes with your normal work (both outside the 
home and housework) 
extremely..........................................................................6 
 
115
5 
Mental Health I feel tense or downhearted and low none of the 
time.................................1 
I feel tense or downhearted and low a little of the 
time................................2 
I feel tense or downhearted and low some of the 
time................................3 
I feel tense or downhearted and low most of the 
time.................................4 
I feel tense or downhearted and all of the 
time............................................5 
 
115
6 
Vitality I have a lot of energy all of the 
time..............................................................1 
I have a lot of energy most of the 
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time.........................................................2 
I have a lot of energy some of the 
time........................................................3 
I have a lot of energy a little of the 
time........................................................4 
I have a lot of energy none of the 
time..........................................................5 
 
Section 11.4 Visual Analog Scale 
1157 Visual Analog Scale Score  
1158 Comments by interviewer on the interview 
 
 
 
 
 
1159 INTERVIEWERS:  CHECK YOUR FILLED IN QUESTIONNAIRE CAREFULLY 
BEFORE LEAVING THE RESPONDENTS AND END YOUR INTERVIEW BY 
GIVING THANKS TO THE RESPONDENT. 
          RECORD THE END TIME OF THE 
INTERVIEW: 
Hour                           
Minutes 
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APPENDIX C – PATIENT QUESTIONNAIRE (MDR-TB) 
Face Sheet for MULTI-DRUG RESISTANT TB(MDR-TB) Patient 
Interview 
IDENTIFICATION 
 
DIVISION:     
 
DISTRICT:     
 
UPAZILA:     
 
NAME AND TYPE OF THE FACILITY: 
(NIDCH =01, District Chest Hospital =02, Damien Foundation Hospital 
=03, Other=04, Please Specify) 
    
 
HEALTH FACILITY CODE:       
 
DRUG REGIMEN FOLLOWED: 
(21 MONTH REGIMEN =01, 9 MONTH REGIMEN =02)     
 
RESPONDENT: 
(Patient=01, Friend/Guardian=02, Other (Please specify)=03)     
 
SEX OF THE RESPONDENT: 
(Male=01, Female= 02)     
 
SEX OF THE PATIENT: 
(Male=01, Female= 02)     
 
NAME OF THE DOT PROVIDER:  
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INTERVIEWER VISITS 
 1 2 3 FINAL VISIT 
 
DATE 
       
 
  
INTERVIEWER’S NAME 
& CODE 
    
RESULT 
CODE   
 
 
RESULT CODE* 
    
RESULT 
CODE   
 
*RESULT CODES: 
01     COMPLETED     03 POSTPONED 05 PARTLY COMPLETED 
02 NOT AVAILABLE 04 REFUSED 96 OTHER, SPECIFY____________________ 
 
SUPERVISOR FIELD EDITOR 
OFFICE 
EDITOR 
KEYED BY 
 
 
 
 
 
 
 
 
 Take information for only those patients (>18 years of age) who are undergoing the 
treatment or have completed their treatment within last two months. 
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Section 1: Patient Information  
(TO BE FILLED IN BY THE INTERVIEWER WITH HELP OF PATIENT TB CARD; FILL IN ALSO IF 
INTERVIEW IS REFUSED FRO NON-RESPONSE ANALYSIS)                                                                                             
 Options  
Consent obtained from patient 
or caregiver? 
Yes……………………………….1 
No…………………………………2 
 
     
 
No
. 
Questions and filters 
Coding categories Response 
10
1 
Patient age 
 
 
Years   
 
10
2 
Patient Sex Male ………………....……1 
Female….. ……………….2    
  
 
10
3 
Site Pulmonary ………………....……1 
Extra-Pulmonary ……………….2                           
Please Specify_______________ 
 
     
 
10
4 
History of contact with 
TB/ DR TB Patient 
Yes………………………………1 
No………………………………..2 
 
     
 
10
5 
IF YES, Relation and 
duration  
WRITE DOWN FROM PATIENT CARD  
10
6 
Medical Diagnosis other 
than TB 
WRITE DOWN FROM PATIENT CARD  
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10
7 
Registration Status CAT I Non converter……….…….1 
CAT I Failure.………………..…..2 
Treatment After loss to follow-up- CAT 
I…………………………..…3 
CAT I Relapse…………………..4 
CAT I Non converter……….…….5 
CAT II Failure……………………6 
Treatment After loss to follow-up- CAT 
Ii…………………………..…7 
CAT I Relapse…………………..8 
Close contact of DR TB with 
S/S………………………………..9 
Transfer In……………………10 
HIV Infected Patient………….11 
Pulmonary-clinically diagnosed, 
new/previously treated……….12 
Extra pulmonary, new/previously 
treated………………………….13 
Unknown TB treatment history..14 
New (Pulmonary), bacteriologically 
confirmed…..15 
 
 
 
     
 
 
10
8 
Type of Resistance MDR TB/XDR 
TB/Polyresistance………………1 
Monoresistance…………………2 
 
     
 
10
9 
Previous TB Treatment 
Episode including DR TB 
 
No. Start Date Regimen Outcome 
    
    
    
    
Drugs: 
First Line Drugs: 
H=Isoniazid 
R=Rifampicin 
E=Ethambutol 
Z=Pyrizinamide 
S=Streptomycin 
 
Second Line Drugs: 
Km=Kanamycin 
Ofx=Ofloxacin 
Lfx=Levofloxacin 
Eto=Ethionamide 
Cs=Cycloserine 
PAS=Para-aminosalicyclic Acid 
Cm=Capreomycin 
Clf=Clofazimine 
Lzd=Linezoli 
Trd=Terizidone 
Amx/Clv=Amxicillin+Clavulanate 
Acid 
Mfx=Moxifloxacin 
Other………………………………… 
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11
0 
Regimen and Drug Doses 
*Date: Date treatment 
started and doses, Change 
of doses (if any) 
Date
* 
Z 
(mg
) 
Km 
(gm) 
Ofx/Lf
x (mg) 
Eto 
(mg
) 
Cs 
(mg
) 
Cm 
(gm) 
PAS 
(gm) 
        
        
Date
* 
Clf 
(mg
) 
Amx/Cl
v (gm) 
Trd 
(mg) 
Lzd 
(mg
) 
Mfx 
(mg
) 
Othe
r 
Comment
s 
        
        
 
11
1 
Results of sputum 
Examination  
 
[Notation method: 
No AFB =0 
1-9 AFB per 100 HPF= 
Scanty (report number of 
AFB) 
10-99 AFB per 100 HPF= 
+ 
1-10 AFB per HPF= ++ 
>10 AFB=+++] 
Month Week Date of sample collection Result 
0    
1 1   
2   
3   
4   
2 1   
2   
3   
4   
3 1   
2   
3   
4   
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
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11
2 
Adverse Drug Reaction Date Adverse Drug 
Reaction 
Suspected 
Drug 
Measure Taken 
    
    
    
    
    
    
    
    
    
    
    
 
11
3 
Results of Culture 
 
[Notation Method: 
No growth reported=0 
Fewer than 10 
colonies=report number 
of colonies (1-9) 
10-100 Colonies=+ 
More than 100 
colonies=++ 
Innumerable or confluent 
growth=+++ 
Non-tuberculous 
mycobacteria= NTM 
Contaminated=contaminat
ed] 
Month Date of 
sample 
collection 
Result 
0   
1   
2   
3   
4   
5   
6   
7   
8   
9   
10   
11   
12   
13   
14   
15   
16   
17   
18   
19   
20   
21   
22   
23   
24   
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11
4 
Drug Susceptibility 
Testing (DST) Results 
 
[Notation: 
R=Resistant 
S=Susceptible 
C=Contaminated 
Unk=Unknown] 
 
Method: 
Xpert MTB/RIF……..1 
Line Probe Assay (LPA2 
Liquid Culture………...3 
Solid Culture (L-J)……4 
Method Date S H R E Km 
       
       
       
       
       
Method Date Ofx/Lfx Eto Other Other Other 
       
       
       
       
       
 
11
5 
In which phase of the 
treatment are you 
currently on? 
Injectable phase of 21 months regimen…1 
Continuation phase of 21 months 
regimen…2 
Injectable phase of 9 months regimen…3 
Continuation phase of 9 months regimen…4 
 
     
 
11
6 
How long are you on this 
phase of treatments? 
  
Months     
 
11
7 
HIV Status  Positive…………….…….1 
Negative………......……..2 
Not Tested…....…………3 
Unknown…….……………..4 
Declined.…………………….….5                           
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11
8 
Final outcome (If 
treatment is completed) 
Cured…………………….…….1 
Treatment completed....……..2 
Died………....…………………3 
Treatment failure……………..4 
Default.…………………….….5                           
Transfer Out…………..………6 
 
 
 
     
 
 
11
9 
Date of starting treatment  Day   
Month   
Year   
 
12
0 
Date of completion of 
treatment 
 Day   
Month   
Year   
 
 
 
  
  
203 
 
Section 2.0: Previous treatment 
PATIENT INTERVIEW SECTION                                                              Start time: Hours  |__|__|  
Minutes  |__|__| 
No. Questions and filters Coding categories Response Skip 
201 Have you ever had TB 
treatment before? 
CROSS-CHECK WITH 
INFORMATION FROM 
PATENT CARD 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
301 
202 What is your TB treatment 
history 
CROSS-CHECK WITH 
INFORMATION FROM 
PATENT CARD 
Cat I Treatment 
failure……………1 
Cat II Treatment 
failure..………….2 
Transfer to Cat-IV during non-
MDR  treatment……………3 
Treatment after default..………….4 
TB relapse……………………….5 
Other……………………………...6 
Specify ____________________ 
 
     
 
 
If 
1,2,5 
► 
301 
If 3 
►  
204 
203 Your treatment card 
indicated that you had 
default treatment. Why 
was previous treatment not 
completed? 
 
[For each option, record 1 
if the option is mentioned 
and record 2 if the option 
has not been mentioned.] 
A. Distance to the facility   
B. Lack of money for treatment 
costs 
 
C. Drug Side Effects  
D. Moved/Migrated  
E. Other 
Please Specify________________ 
 
204 If on Cat IV treatment, 
how long have you been 
on TB treatment before 
you were diagnosed with 
MDR-TB? 
  
Months     
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Section 3: Delay, Prediagnostic & Diagnostic Costs 
No. Questions and filters Coding categories Response Skip 
301 What symptoms did you 
experience that led you to 
seek treatment for your most 
recent illness with TB?  
 
 
[For each option, record 1 if 
the option is mentioned and 
record 2 if the option has not 
been mentioned.] 
a. Cough   
b. Evening rise of temperature/low 
grade fever 
 
c. Coughing up blood  
d. Weight loss  
e. Other 
Specify_____________________ 
 
302 How long did you experience 
these symptoms before you 
went to seek treatment? 
 
[For each option, record 
number of weeks if mentioned 
yes in the previous question.] 
 
a. Cough Weeks   
 
 
b. Evening rise of temperature/low 
grade fever 
Weeks   
 
c. Coughing up blood Weeks   
 
d. Weight loss Weeks   
 
e. Other 
Specify_____________________ 
Weeks   
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Section 3.1 First Visit 
303 After you experienced the 
symptoms, which provider 
did you go to first?  
Community 
Clinic…………….…….1 
Union Subcenter………….....……..2 
Upazila Health Complex…..………3 
District Hospital……..……………..4 
Pharmacy & Drug Store……….….5                           
Homoeopath………………..………6 
Private Hospital……..……………..7 
Traditional Healer………………….8                           
Other………………………..………9 
Specify______________________ 
 
 
     
 
 
     
304 What was the distance to the 
provider from your home? 
 
Kilometer     
 
 
305 What was the travel time to 
reach this provider? 
 Hour   
Minute   
 
 
306 What was the waiting and 
consultation time with the 
provider? 
 Hour   
Minute   
 
 
307 What was the registration 
(ticket) cost paid by you? In 
TAKA 
IF not known put 99999 
IF no registration cost 000 
     
 
 
308 What was the consultation 
fee you have paid? In 
TAKA 
IF not known put 99999 
IF no consultation fee 000 
     
 
 
309 What was the cost you paid 
for diagnostic tests? In 
TAKA 
IF not known put 99999 
IF no cost for tests 000 
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310 What was the cost for x-ray? 
In TAKA 
IF not known put 99999 
IF no cost for x-ray 000 
     
 
 
311 What was the costs of 
drugs? In TAKA 
IF not known put 99999 
IF no cost for drugs 000 
     
 
 
312 What was travel costs? 
(INCLUDE ALL TRAVEL 
RELATED COSTS: 
RETURN TRAVEL, 
TRAVEL FOR 
LABORATIRY TESTS, 
DTUGS, COST FOR 
ACCOMPANYING 
PERSONS) In TAKA 
IF not known put 99999 
IF no travel cost 000 
     
 
 
313 What was the food costs? In 
TAKA 
IF not known put 99999 
IF no food cost 000 
     
 
 
314 What was cost for 
accommodation? 
IF not known put 99999 
IF no accommodation cost 000 
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Section 3.2 Second Visit 
No. Questions and filters Coding categories Response Skip 
315 Once you experience the 
symptoms to which 
provider did you go after 
you have seen the 
provider type 
_________________? 
(MENTION THE FIRST 
VISIT’S PROVIDER 
TYPE) 
Community 
Clinic…………….…….1 
Union Subcenter………….....……..2 
Upazila Health Complex…..………3 
District Hospital……..……………..4 
Pharmacy & Drug Store……….….5                           
Homoeopath………………..………6 
Private Hospital……..……………..7 
Traditional Healer………………….8                           
Other………………………..………9 
Specify______________________ 
 
 
     
 
 
316 What was the distance to 
the provider from your 
home? 
 
Kilometer     
 
 
317 What was the travel time 
to reach this provider? 
 
Hour   
Minute   
 
 
318 What was the waiting 
and consultation time 
with the provider? 
 
Hour   
Minute   
 
 
319 What was the registration 
(ticket) cost paid by you? 
In TAKA 
IF not known put 99999 
IF no registration cost 000 
     
 
 
320 What was the 
consultation fee you have 
paid? In TAKA 
IF not known put 99999 
IF no consultation fee 000 
     
 
 
321 What was the cost you 
paid for diagnostic tests? 
In TAKA 
IF not known put 99999 
IF no cost for tests 000 
     
 
 
  
208 
 
3322 What was the cost for x-
ray? In TAKA 
IF not known put 99999 
IF no cost for x-ray 000 
     
 
 
323 What was the costs of 
drugs? In TAKA 
IF not known put 99999 
IF no cost for drugs 000 
     
 
 
324 What was travel costs? 
(INCLUDE ALL 
TRAVEL RELATED 
COSTS: RETURN 
TRAVEL, TRAVEL 
FOR LABORATIRY 
TESTS, DTUGS, COST 
FOR 
ACCOMPANYING 
PERSONS) In TAKA 
IF not known put 99999 
IF no travel cost 000 
     
 
 
325 What was the food costs? 
In TAKA 
IF not known put 99999 
IF no food cost 000 
     
 
 
326 What was cost for 
accommodation? 
IF not known put 99999 
IF no accommodation cost 000 
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Section 3.4 Fourth Visit 
No. Questions and filters Coding categories Response Skip 
339 Once you experience the 
symptoms to which 
provider did you go 
after you have seen the 
provider type 
_________________? 
(MENTION THE 
THIRD VISIT’S 
PROVIDER TYPE) 
Community 
Clinic…………….…….1 
Union Subcenter………….....……..2 
Upazila Health Complex…..………3 
District Hospital……..……………..4 
Pharmacy & Drug Store……….….5                           
Homoeopath………………..………6 
Private Hospital……..……………..7 
Traditional Healer………………….8                           
Other………………………..………9 
Specify______________________ 
 
 
     
 
 
340 What was the distance 
to the provider from 
your home? 
 
Kilometer     
 
 
341 What was the travel 
time to reach this 
provider? 
 
Hour   
Minute   
 
 
342 What was the waiting 
and consultation time 
with the provider? 
 
Hour   
Minute   
 
 
343 What was the 
registration (ticket) cost 
paid by you? In TAKA 
IF not known put 99999 
IF no registration cost 000 
     
 
 
344 What was the 
consultation fee you 
have paid? In TAKA 
IF not known put 99999 
IF no consultation fee 000 
     
 
 
345 What was the cost you 
paid for diagnostic tests? 
In TAKA 
IF not known put 99999 
IF no cost for tests 000 
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346 What was the cost for x-
ray? In TAKA 
IF not known put 99999 
IF no cost for x-ray 000 
     
 
 
347 What was the costs of 
drugs? In TAKA 
IF not known put 99999 
IF no cost for drugs 000 
     
 
 
348 What was travel costs? 
(INCLUDE ALL 
TRAVEL RELATED 
COSTS: RETURN 
TRAVEL, TRAVEL 
FOR LABORATIRY 
TESTS, DTUGS, COST 
FOR 
ACCOMPANYING 
PERSONS) In TAKA 
IF not known put 99999 
IF no travel cost 000 
     
 
 
349 What was the food 
costs? In TAKA 
IF not known put 99999 
IF no food cost 000 
     
 
 
350 What was cost for 
accommodation? 
IF not known put 99999 
IF no accommodation cost 000 
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Section 3.5 Fifth Visit 
No. Questions and filters Coding categories Response Skip 
351 Once you experience the 
symptoms to which 
provider did you go 
after you have seen the 
provider type 
_________________? 
(MENTION THE 
FOURTH VISIT’S 
PROVIDER TYPE) 
Community 
Clinic…………….…….1 
Union Subcenter………….....……..2 
Upazila Health Complex…..………3 
District Hospital……..……………..4 
Pharmacy & Drug Store……….….5                           
Homoeopath………………..………6 
Private Hospital……..……………..7 
Traditional Healer………………….8                           
Other………………………..………9 
Specify______________________ 
 
 
     
 
 
352 What was the distance 
to the provider from 
your home? 
 
Kilometer     
 
 
353 What was the travel 
time to reach this 
provider? 
 
Hour   
Minute   
 
 
354 What was the waiting 
and consultation time 
with the provider? 
 
Hour   
Minute   
 
 
355 What was the 
registration (ticket) cost 
paid by you? In TAKA 
IF not known put 99999 
IF no registration cost 000 
     
 
 
356 What was the 
consultation fee you 
have paid? In TAKA 
IF not known put 99999 
IF no consultation fee 000 
     
 
 
357 What was the cost you 
paid for diagnostic tests? 
In TAKA 
IF not known put 99999 
IF no cost for tests 000 
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358 What was the cost for x-
ray? In TAKA 
IF not known put 99999 
IF no cost for x-ray 000 
     
 
 
359 What was the costs of 
drugs? In TAKA 
IF not known put 99999 
IF no cost for drugs 000 
     
 
 
360 What was travel costs? 
(INCLUDE ALL 
TRAVEL RELATED 
COSTS: RETURN 
TRAVEL, TRAVEL 
FOR LABORATIRY 
TESTS, DTUGS, COST 
FOR 
ACCOMPANYING 
PERSONS) In TAKA 
IF not known put 99999 
IF no travel cost 000 
     
 
 
361 What was the food 
costs? In TAKA 
IF not known put 99999 
IF no food cost 000 
     
 
 
362 What was cost for 
accommodation? 
IF not known put 99999 
IF no accommodation cost 000 
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Section 3.6 Sixth Visit 
No. Questions and filters Coding categories Response Skip 
363 Once you experience the 
symptoms to which 
provider did you go after 
you have seen the 
provider type 
_________________? 
(MENTION THE FIFTH 
VISIT’S PROVIDER 
TYPE) 
Community 
Clinic…………….…….1 
Union Subcenter………….....……..2 
Upazila Health Complex…..………3 
District Hospital……..……………..4 
Pharmacy & Drug Store……….….5                           
Homoeopath………………..………6 
Private Hospital……..……………..7 
Traditional Healer………………….8                           
Other………………………..………9 
Specify______________________ 
 
 
     
 
 
364 What was the distance to 
the provider from your 
home? 
 
Kilometer     
 
 
365 What was the travel time 
to reach this provider? 
 
Hour   
Minute   
 
 
366 What was the waiting 
and consultation time 
with the provider? 
 
Hour   
Minute   
 
 
367 What was the registration 
(ticket) cost paid by you? 
In TAKA 
IF not known put 99999 
IF no registration cost 000 
     
 
 
3368 What was the 
consultation fee you have 
paid? In TAKA 
IF not known put 99999 
IF no consultation fee 000 
     
 
 
369 What was the cost you 
paid for diagnostic tests? 
In TAKA 
IF not known put 99999 
IF no cost for tests 000 
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370 What was the cost for x-
ray? In TAKA 
IF not known put 99999 
IF no cost for x-ray 000 
     
 
 
371 What was the costs of 
drugs? In TAKA 
IF not known put 99999 
IF no cost for drugs 000 
     
 
 
372 What was travel costs? 
(INCLUDE ALL 
TRAVEL RELATED 
COSTS: RETURN 
TRAVEL, TRAVEL 
FOR LABORATIRY 
TESTS, DTUGS, COST 
FOR 
ACCOMPANYING 
PERSONS) In TAKA 
IF not known put 99999 
IF no travel cost 000 
     
 
 
373 What was the food costs? 
In TAKA 
IF not known put 99999 
IF no food cost 000 
     
 
 
374 What was cost for 
accommodation? 
IF not known put 99999 
IF no accommodation cost 000 
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Section 3.7 Seventh Visit 
No. Questions and filters Coding categories Response Skip 
375 Once you experience the 
symptoms to which 
provider did you go 
after you have seen the 
provider type 
_________________? 
(MENTION THE SIXTH 
VISIT’S PROVIDER 
TYPE) 
Community 
Clinic…………….…….1 
Union Subcenter………….....……..2 
Upazila Health Complex…..………3 
District Hospital……..……………..4 
Pharmacy & Drug Store……….….5                           
Homoeopath………………..………6 
Private Hospital……..……………..7 
Traditional Healer………………….8                           
Other………………………..………9 
Specify______________________ 
 
 
     
 
 
376 What was the distance 
to the provider from 
your home? 
 
Kilometer     
 
 
377 What was the travel 
time to reach this 
provider? 
 
Hour   
Minute   
 
 
378 What was the waiting 
and consultation time 
with the provider? 
 
Hour   
Minute   
 
 
379 What was the 
registration (ticket) cost 
paid by you? In TAKA 
IF not known put 99999 
IF no registration cost 000 
     
 
 
380 What was the 
consultation fee you 
have paid? In TAKA 
IF not known put 99999 
IF no consultation fee 000 
     
 
 
381 What was the cost you 
paid for diagnostic tests? 
In TAKA 
IF not known put 99999 
IF no cost for tests 000 
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382 What was the cost for x-
ray? In TAKA 
IF not known put 99999 
IF no cost for x-ray 000 
     
 
 
383 What was the costs of 
drugs? In TAKA 
IF not known put 99999 
IF no cost for drugs 000 
     
 
 
384 What was travel costs? 
(INCLUDE ALL 
TRAVEL RELATED 
COSTS: RETURN 
TRAVEL, TRAVEL 
FOR LABORATIRY 
TESTS, DTUGS, COST 
FOR 
ACCOMPANYING 
PERSONS) In TAKA 
IF not known put 99999 
IF no travel cost 000 
     
 
 
385 What was the food 
costs? In TAKA 
IF not known put 99999 
IF no food cost 000 
     
 
 
386 What was cost for 
accommodation? 
IF not known put 99999 
IF no accommodation cost 000 
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Section 3.8 Eighth Visit 
No. Questions and filters Coding categories Response Skip 
387 Once you experience the 
symptoms to which 
provider did you go 
after you have seen the 
provider type 
_________________? 
(MENTION THE 
SEVENH VISIT’S 
PROVIDER TYPE) 
Community 
Clinic…………….…….1 
Union Subcenter………….....……..2 
Upazila Health Complex…..………3 
District Hospital……..……………..4 
Pharmacy & Drug Store……….….5                           
Homoeopath………………..………6 
Private Hospital……..……………..7 
Traditional Healer………………….8                           
Other………………………..………9 
Specify______________________ 
 
 
     
 
 
388 What was the distance 
to the provider from 
your home? 
 
Kilometer     
 
 
389 What was the travel 
time to reach this 
provider? 
 
Hour   
Minute   
 
 
390 What was the waiting 
and consultation time 
with the provider? 
 
Hour   
Minute   
 
 
391 What was the 
registration (ticket) cost 
paid by you? In TAKA 
IF not known put 99999 
IF no registration cost 000 
     
 
 
392 What was the 
consultation fee you 
have paid? In TAKA 
IF not known put 99999 
IF no consultation fee 000 
     
 
 
393 What was the cost you 
paid for diagnostic tests? 
In TAKA 
IF not known put 99999 
IF no cost for tests 000 
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394 What was the cost for x-
ray? In TAKA 
IF not known put 99999 
IF no cost for x-ray 000 
     
 
 
395 What was the costs of 
drugs? In TAKA 
IF not known put 99999 
IF no cost for drugs 000 
     
 
 
396 What was travel costs? 
(INCLUDE ALL 
TRAVEL RELATED 
COSTS: RETURN 
TRAVEL, TRAVEL 
FOR LABORATIRY 
TESTS, DTUGS, COST 
FOR 
ACCOMPANYING 
PERSONS) In TAKA 
IF not known put 99999 
IF no travel cost 000 
     
 
 
397 What was the food 
costs? In TAKA 
IF not known put 99999 
IF no food cost 000 
     
 
 
398 What was cost for 
accommodation? 
IF not known put 99999 
IF no accommodation cost 000 
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Section 4.0: Treatment Costs 
Section 4.1 Cost Related to DOT 
No. Questions and filters Coding categories Response Skip 
401 From where did you get 
your TB drugs?  
Health facility………………….…….1 
Home……………………….....……..2 
Community…………………..………3 
Pharmacy……………..……………..4 
Workplace……………….……….….5                           
Other………………………..………9 
Specify______________________ 
 
 
     
 
 
402 How often do you 
travel to the health 
facility / hospital for 
picking up your TB 
drugs? 
 Times/ 
month  
  
 
 
403 How long does it take 
to go to the place for 
picking up the drugs 
(ONE WAY)? 
A. On Foot 
Hour   
Minute   
 
 
B. By Transport 
Hour   
Minute   
 
 
404 How long does one of 
these visits take on 
average, including time 
on the road and waiting 
time (total turnaround 
time)? 
 Hour   
Minute   
 
 
405 From your home to the 
facility, how much does 
it cost if you take 
transport? (BOTH 
WAYS) 
IF not known put 99999      
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406 If you go to a facility to 
pick up your drugs, 
how much do you 
spend on food on that 
day? (on the road, 
while waiting, lunch 
etc.) 
IF not known put 99999      
 
 
407 Do you have to pay 
administration fees 
when picking up your 
TB drugs? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
409 
408 What was the 
administration cost? 
IF not known put 99999 
IF no administration cost 000 
     
 
 
409 Do you have to pay for 
accommodation when 
picking up your TB 
drugs? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
411 
410 What was the 
accommodation cost? 
IF not known put 99999 
IF no accommodation cost 000 
     
 
 
Section 4.2 Cost related to Follow Up Tests 
411 Did you ever have to 
go to the health facility 
in addition to your 
regular visits for 
follow up tests since 
the beginning of 
treatment? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
414 
412 If yes, how many 
times? 
 Times   
 
 
413 If yes, did you have to 
pay any additional 
costs any time during 
the entire period? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
421 
414 If so, what kind of costs 
and how much did you 
 
A. Fees 
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pay last time (In 
TAKA)? 
 
IF not known put 
99999 
IF no cost put 000 
 
B. Sputum Test 
     
 
 
C. X -ray 
     
 
 
D. TB Drugs 
     
 
 
E. Other Drugs 
     
 
 
F. Others 
     
 
415 How long does one of 
these follow-up visits 
take on average, 
including time on the 
road, waiting time and 
tests (total turnaround 
time)? 
 
Hour   
Minute   
 
 
 
Section 5.0: Cost related to accompanied persons (Friends/Guardian) 
No. Questions and filters Coding categories Response Skip 
501 Does any 
family/friend/DOT 
supporter accompany you 
on any visits before 
diagnosis and/or during 
diagnosis? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
507 
502 If YES, on how many visits 
has your family/friend/DOT 
supporter accompanied you 
or gone with you before 
diagnosis and/or during 
diagnosis? 
 Times    
 
 
503 What was the cost for pre-
diagnosis/diagnosis visits of 
A. Transport Cost      
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your accompanying person 
in Taka)? 
 
IF not known put 99999 
IF no cost put 000 
B. Food Cost      
 
 
C. Accommodation Cost 
     
 
 
504 Does your accompanying 
person earn? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
506 
505 If earn, how much the 
person earn per day (in 
TAKA)? 
IF not known put 99999 
     
 
 
506 Why did someone 
accompany you? 
 
[For each option, record 1 
if the option is mentioned 
and record 2 if the option 
has not been mentioned.] 
A. Distance    
B. Security  
C. Administrative barrier  
D. Too ill to travel alone  
E. Was required for treatment  
F. Other 
Please 
Specify________________ 
 
507 Does any 
family/friend/DOT 
supporter accompany you 
on any visits during 
treatment (taking drugs)? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
601 
508 If YES, on how many visits 
has your family/friend/DOT 
supporter accompanied you 
or gone with you during 
treatment? 
 Times    
 
 
509 What was the cost for visits 
of your accompanying 
person during your 
treatment in TAKA)? 
A. Transport Cost 
     
 
 
B. Food Cost      
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IF not known put 99999 
IF no cost put 000 
C. Accommodation Cost      
 
 
510 Does your accompanying 
person earn? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
512 
511 If earn, how much the 
person earn per day (In 
TAKA)? 
      
 
 
512 Why did someone 
accompany you? 
 
[For each option, record 1 
if the option is mentioned 
and record 2 if the option 
has not been mentioned.] 
A. Distance    
B. Security  
C. Administrative barrier  
D. Too ill to travel alone  
E. Was required for treatment  
F. Other 
Please 
Specify________________ 
 
 
Section 6.0: Hospitalization Costs 
No. Questions and filters Coding categories Response Skip 
601 Have you been hospitalized 
before (but due to TB) or 
during your TB treatment? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
701 
602 If YES, how many times 
were you hospitalized for 
this illness? 
 Times    
 
 
603 How much did you pay 
during your last stay at the 
hospital (In TAKA)? 
A. Hospital Administration Fees      
 
 
B. Hospital stay charges      
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IF not known put 99999 
IF no cost put 000 
C. Food (Not provided by the 
hospital) 
     
 
 
D. Transport (Both Ways)      
 
 
E. Drugs      
 
 
F. Diagnostic Tests 
      
 
 
G. Others      
 
 
604 Did any attendant/caregiver 
stay with you at the 
hospital? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
701 
605 If YES, how many days 
he/she stay with you (sleep 
there)? 
 
Days   
 
 
606 Were there any extra costs 
for your relative/friend for 
staying at the hospital? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
506 
607 What was the cost for the 
accompanying person 
during your hospitalization 
(stayed at night)? In TAKA 
IF not known put 99999 
IF no cost put 000 
 
A. Transport Cost 
     
 
 
B. Food Cost 
     
 
 
C. Accommodation Cost      
 
 
D. Other Cost      
 
 
608 Does your accompanying 
person earn? 
Yes……………………………1 
No…………………………….2 
Don’t Know.………………….3 
 
     
 
If 2 
/3 
►  
610 
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609 If earn, how much the 
accompanying person earn 
per day? 
IF not known put 99999 
      
 
 
610 Did any other family/friend 
visit you while in hospital? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2  
►  
701 
611 If YES, How many people 
visited you? 
 Days   
 
 
612 On an average, how many 
times did each of these 
person visit you? 
 
Times   
 
 
613 What was the cost for 
EACH VISIT of them (IN 
TAKA)? 
 
IF not known put 99999 
IF no cost put 000 
 
A. Transport Cost      
 
 
B. Food Cost      
 
 
C. Accommodation Cost      
 
 
D. Other Cost      
 
 
614 How long were the visits 
including traveling time? 
 Hour   
Minute   
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Section 7.0: Other Costs, Other Illnesses and Coping Costs 
Section 7.1 Other Costs 
No. Questions and filters Coding categories Response Skip 
701 Did you buy any 
supplements for your diet 
because of the TB illness, 
for example vitamins, 
meat, energy drinks, soft 
drinks, fruits or 
medicines? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
703 
702 If YES, how much did you 
spend approximately on 
each of these items each 
month (in TAKA)? 
 
IF not known put 99999 
 
 
A. Meat      
 
 
B. Fish      
 
C. Fruits 
      
 
D. Drinks      
 
E. Vegetables      
 
F. Vitamins/Herbs      
 
G. Others      
 
703 Did you have to move to 
be able to receive (MDR) 
TB treatment? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
705 
704 If YES: how much did 
you pay for relocation? (In 
TAKA) 
 
IF not known put 99999 
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705 Did you experience any 
adverse events during the 
treatment of (MDR-) TB? 
(Adverse events are any 
additional health problems 
that occur during(MDR-) 
TB treatment and that may 
be related to the treatment) 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
708 
706 If YES: Was treatment 
required of these events? 
This includes changes in 
TB drug regimen! 
Yes……………………………1 
No…………………………….2 
 
     
 
 
707 IF YES, How much did 
you spend on treatment of 
adverse events and/or 
changes in the TB drug 
regimen approximately? 
A. Drugs      
 
 
B. Fees      
 
C. Transport       
 
D. Accommodation      
 
E. Costs borne by guardian/friends      
 
 
F. Others 
     
 
 
Section 7.2 Other illnesses 
708 Do you have any chronic 
illness for which you are 
receiving treatment? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
712 
709 If YES, which disease do 
you have? 
 
[For each option, record 1 
if the option is mentioned 
and record 2 if the option 
has not been mentioned.] 
A. Diabetes   
B. Heart Disease  
C. High Blood Pressure  
D. Cancer  
E. Arthritis  
F. Other 
Specify 
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G. Other 
Specify 
 
710 Are there any additional 
costs for you because of 
this other illness besides 
the costs that you have 
already mentioned? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
712 
711 If YES, how much are 
these additional costs on 
average per month? In 
TAKA 
 
IF not known put 99999 
A. Drugs       
 
 
B. Diagnostic tests      
 
C. Transport      
 
D. Fees 
     
 
E. Others 
     
 
712 How much did you spend 
on healthcare on average 
per month BEFORE the 
TB illness? In TAKA 
      
 
 
713 How much did you spend 
on healthcare on average 
per month AFTER the TB 
illness? In TAKA 
      
 
 
Section 7.3 Coping Costs 
714 Has your illness with TB 
resulted in a financial 
burden? 
Yes……………………………1 
No…………………………….2 
 
     
 
 
715 Did you borrow any 
money to cover costs due 
to the TB illness? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
720 
716 If YES, how much did you 
borrow? In TAKA 
IF not known put 99999 
     
 
 
 A. Family   
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717 From whom did you 
borrow? 
[For each option, record 1 
if the option is mentioned 
and record 2 if the option 
has not been mentioned.] 
B. Neighbor  
C. Friend  
D. Bank  
E. Cooperative  
F. NGO  
G. Money lender   
H. Others 
Specify______________________ 
  
718 Have you already paid 
back the borrowed 
money? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
721 
719 How are you planning to 
pay back the money? 
In 
Full……………………………1 
In Installment..………………….2 
 
     
 
If 2 
►  
721 
720 If you are paying in 
installment, what is the 
monthly installment? In 
TAKA 
IF not known put 99999      
 
 
721 Have you sold any of your 
property to finance the 
cost of the TB illness? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
723 
722 How much money did you 
get from the sale of each 
of these properties? 
 
 
IF not known put 99999 
A. Land      
 
 
B. Livestock 
     
 
C. Transport/Vehicle 
     
 
D. Household item      
 
E. Farm produce      
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F. Jewelry      
 
 
G. Savings (FDR) 
     
 
 
H. Other 
Specify 
     
 
 
723 Have you employed any 
household help for your 
illness? 
Yes……………………………1 
No…………………………….2 
 
     
 
If 2 
►  
801 
724 How much do you pay 
monthly to the household 
help? In TAKA 
IF not known put 99999 
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Section 8.0 Patient Income and Patient’s Household Income 
Section 8.1 Personal Income 
No. Questions and filters Coding categories Response Skip 
801 Who is the primary income 
earner of the household? 
Patient…………………….…….1 
Patient’s Wife.…………...……..2 
Patient’s Husband..……………3 
Patient’s Mother………………..4 
Patient’s Father…………..…….5 
Patient’s Son….………………..6 
Patient’s Daughter..……..…….7                                                    
Other ………………..………….8 
Specify________________ 
 
 
 
     
 
 
 
802 What is the highest level of 
Education (In years) of 
these individuals? 
 
[For each option, record 
the number of years spent 
studying. if the person is 
illiterate/did not go to 
school record “0”] 
A. Patient  
 
 
B. Primary Income Earner (If Other 
than patient) 
 
 
C. Household Head (If Other than 
patient) 
 
 
B. Spouse of Household Head (If 
Other than patient) 
 
803 Are you involved in 
income earning activities? 
Yes, formal work…………………1 
Yes, agricultural and other 
household work………………….2 
Yes, informal work………………3 
No…………………………………4 
 
     
 
If 4 
►  
809 
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804 If No, why are you not 
involved in any income 
earning activities? 
Cannot work due to illness …….1 
Stopped working after contracting 
TB …….……...…………...……..2 
Retired…………………….…….3 
Student……...…………...……..4 
Other……………....……………5 
Specify----------------------------- 
 
     
 
 
805 Have you left your job due 
to your TB illness? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
If 2 
►  
809 
806 If YES, how many months 
ago did you leave your 
job? 
 
Months   
 
 
807 What was your monthly 
income when you were 
working? In TAKA 
IF not known put 99999      
 
 
808 How regularly did you 
work before you became 
ill with TB? 
Throughout the year…….…….1 
Seasonal/part of the year.……..2 
Day Labor………....……………3 
Other……………....……………4 
Specify----------------------------- 
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809 What was your main 
occupation before your 
illness with TB? 
Service…………………….…….1 
Agriculture…...…………...……..2 
Household work…....……………3 
Construction……………….…….4 
Garments worker………...……..5 
Transport…....…………..………6 
Student…………………….…….7 
Retired…...…………...………….8 
Other………….…....……………9 
Specify----------------------------- 
 
     
 
 
810 Did you have to change 
jobs when you became ill 
with TB? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
 
811 What is your main 
occupation after your 
illness with TB? 
Service…………………….…….1 
Agriculture…...…………...……..2 
Household work…....……………3 
Construction……………….…….4 
Garments worker………...……..5 
Transport…....…………..………6 
Student…………………….…….7 
Retired…...…………...………….8 
Other………….…....……………9 
Specify----------------------------- 
 
     
 
 
812 How many hours did you 
work on average per day 
BEFORE you became ill 
with TB? 
 Hours   
 
 
813 How many hours do you 
work on average NOW per 
day? 
 Hours   
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814 If answer to 812 differs 
from answer to 813:Is the 
change related to the TB 
illness?  
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
If 2 
►  
818 
815 What was your estimated 
personal income per month 
BEFORE the TB illness?  
In TAKA 
IF not known put 99999      
 
 
816 What is your estimated 
personal income per month 
NOW?  In TAKA 
IF not known put 99999      
 
 
817 Is someone doing the work 
you used to do after your 
ilnness? 
Spouse…………………….…….1 
Son…………...…………...……..2 
Daughter……..…....……………3 
Friend…….……………….…….4 
Nobody…………………...……..5 
Other………….…....……………9 
Specify----------------------------- 
 
     
 
 
818 Do you have children of or 
below school age? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
If 2 
►  
822 
819 Are all of your children 
attending school regularly? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
If 1 
►  
822 
820 Did your children go to 
school regularly before 
your recent illness with 
TB? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
 
821 If your children do not go 
to schoo1, indicate the 
reasons for not attending 
school regularly?  
 
A. Needs to help around the house   
B. No money for school fess  
C. Also sick  
D. Has to work to earn  
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[For each option, record 1 
if the option is mentioned 
and record 2 if the option 
has not been mentioned.] 
 
E. Take care of patient  
E. Other 
Specify___________________ 
 
822 Has the TB illness affected 
your social or private life 
in any way? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
If 2 
►  
823 
823 If YES, how was your 
social life affected?  
 
[For each option, record 1 
if the option is mentioned 
and record 2 if the option 
has not been mentioned.] 
 
 
 
A. Divorce   
B. Loss of job  
C. Dropped out of school  
D. Separated from spouse  
E. Disruption of sexual life  
F. Sick child  
G. Other 
Specify___________________ 
 
824 What is your religion? Islam…………………….…….1 
Hindu………...…………...……..2 
Christian……..…....……………3 
Buddhism.……………….…….4 
Other………….…....……………5 
Specify----------------------------- 
 
     
 
 
Section 8.2 Household Income 
825 How much do you 
estimate was the average 
income of your household 
per month BEFORE the 
TB illness?  (for all 
persons in the house, 
including patient; includes 
A. Patient’s income      
 
 
B. Income of rest of the household      
 
 
C. Govt. assistance 
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welfare payments, 
government assistance or 
other social support)? In 
TAKA 
 
IF not known put 99999 
D. Other      
 
 
826 How much do you 
estimate was the average 
income of your household 
per month NOW?  (for all 
persons in the house, 
including patient; includes 
welfare payments, 
government assistance or 
other social support)? In 
TAKA 
 
IF not known put 99999 
A. Patient’s income      
 
 
B. Income of rest of the household      
 
 
c. Govt. assistance      
 
 
D. Other      
 
 
827 How many people 
regularly sleep in your 
house?  (including patient) 
  
    
 
 
828 How many members of the 
household are employed 
for wage/salary? 
(including patient) 
  
    
 
 
829 Besides yourself, does 
anyone else of your 
household receive 
treatment for TB? 
Yes…………………….…….1 
No……...…………...……..2 
 
     
 
If 2 
►  
823 
830 If YES, how many 
household members are 
suffering from TB? 
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Section 9.0 Socioeconomic Indicators 
Section 9.0 Questions about the household RESPONSES Skip 
901 What is the main 
source of lighting 
for the 
household?  
 
 
Electrical mains .................................... 01 
Solar electricity .................................... 02 
Generator .............................................. 03 
Gas…………………………………………..….04 
Kerosine/Oil lamp ................................ 05 
Candles / Torch .................................... 06 
Coleman (Kerosene/Pressure lanterns)…….07 
Improvised lamp ................................... 08 
Others ................................................... 96 
Specify ____________________________ 
 
No source of lighting ............................ 98 
  
902 What is the main 
source of water 
for drinking and 
food preparation 
for the 
household?  
 
 
 
Piped into household ............................ 01 
Piped to yard/plot ................................. 02 
Piped into neighborhood ....................... 03 
Protected well ....................................... 04 
Unprotected well .................................. 05 
Protected Spring  .................................. 06 
Unprotected Spring  .............................. 07 
River/stream ......................................... 08 
Pond/lake/dam ...................................... 10 
Communal tank .................................... 11 
Rainwater.............................................. 12 
Tank truck / Water cart ......................... 13 
Bottled water  ....................................... 14 
Other____________________ ............. 96 
                    (Specify) 
Not reported .......................................... 99 
  
903 What type of fuel 
is mainly used in 
your household 
for cooking?  
 
 
Gas ........................................................ 01 
Stove with kerosene .............................. 02 
Firewood ............................................... 03 
Charcoal ............................................... 04  
Dung ..................................................... 05 
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Electricity  ............................................ 06 
Biogas ................................................... 07 
Straw/shrubs/grass ................................ 08 
Saw dust ............................................... 09 
Others ................................................... 96 
Specify _____________________________ 
 
904 What kind of 
toilet facility do 
people in your 
house mainly 
use?  
 
 
Own flush toilet ...................................... 01 
Shared flush toilet ................................... 02 
Ventilated improved pit latrine ............... 03 
Pit latrine with slab ................................. 04 
Pit latrine without slab / open pit ............ 05 
Bowl/Bucket system ............................... 06 
Closet oversea/river ................................ 07 
No facility/bush/seashore ....................... 08 
Other____________________ ..............  96 
                    (Specify) 
Not reported ..................................... ….  99 
  
905 Main 
material of the 
floor for the 
principal 
residence 
structure 
 
Natural Floor: 
Earth ....................................................... 11 
Sand ........................................................ 12 
Rudimentary: 
  Wood planks ......................................... 21 
  Palm/bamboo ........................................ 22 
Finished:  
  Polished wood ...................................... 31 
  Vinyl/asphalt strips ............................... 32 
  Marble/Ceramic tiles ............................ 33 
  Floor tile ............................................... 34 
  Cement / Concrete/ ............................... 35 
  Brick ..................................................... 36  
  Carpet ................................................... 37 
  Unpolished............................................ 38 
  Other____________________ ............  96 
                    (Specify) 
 
  Not reported ................................... ….  99 
  
906 Main 
material of the 
roof of the 
principal 
residence 
 
Natural roofing 
  No roof ................................................. 11 
  Thatch/palm leaf ................................... 12 
Rudimentary roofing 
   Bamboo ............................................... 21 
   Wood planks ........................................ 22 
   Cardboard ............................................ 23 
Finished roofing 
   Tin / Metal ........................................... 31 
   Wood ................................................... 32 
   Ceramic Tiles ...................................... 33 
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   Cement / Concrete ............................... 34 
   Other____________________ ............ 96 
                    (Specify) 
 
907 Main 
material of the 
exterior walls of 
principal 
residence 
 
Natural Walls 
  No walls ................................................ 11 
  Cane/Palm/Trunks ................................ 12 
  Dirt ....................................................... 13 
Rudimentary walls 
  Bamboo with mud / matting ................. 21 
  Stone with mud ..................................... 22 
  Mud ...................................................... 23 
  Fibro ..................................................... 24 
 Plywood ................................................. 25 
  Cardboard ............................................. 26 
Finished walls 
  Tin / Metal sheets ................................. 31 
  Cement / Concrete ................................ 32 
  Brick ..................................................... 31 
  Stone with lime/cement ........................ 33 
  Bricks ................................................... 34 
  Wood planks/shingles ........................... 35 
Other____________________ ............... 96 
                    (Specify) 
  
908 What type of fuel 
does your 
household mainly 
use for cooking? 
ELECTRICITY . . . . . . . . .  . . . . . . . . . . . . . 01 
LPG . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . 02 
NATURAL GAS . . . . . . . . . . . . . . . . . . . . . . 03 
BIOGAS . . . . . . . . . . .  . . . . . . . . . . . . . . . . . 04 
KEROSENE . . . . . . . . . . . . . . . . . . . . . . . . . 05 
COAL, LIGNITE . . . . .. . . . . . . . . . . . . . . . . . 06 
CHARCOAL . . . . . . . . . . . . . . . . . . . . . . . . . 07 
WOOD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 08 
STRAW/SHRUBS/GRASS . . . . . . . . . . . . . . 09 
AGRICULTURAL CROP . . . . . . . . . . . . . . . . 10 
ANIMAL DUNG . . . . . . . . . .  . . . . . . . . . . . . 11 
NO FOOD COOKED 
IN HOUSEHOLD . . . . . . . . . . . . . . . . . . . . . 95  
OTHER 96 
(SPECIFY) 
 If 95 
►  
911 
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912 Does your household or any member of the household own the items? Yes No Respon
ses 
Electricity connection? A. Electricity ..................................... 1 2  
Solar Electricity? B. Solar electricity……………. 1 2  
A radio? C. Radio ............................................. 1 2  
A television? D. Television ..................................... 1 2  
A mobile phone? E. Mobile phone ................................ 1 2  
A non-mobile phone? F. Non-mobile phone ......................... 1 2  
A refrigerator? G. Refrigerator .................................. 1 2  
A DVD/VCD player? H. DVD/VCD player ......................... 1 2  
An electric fan? I. Fan ................................................. 1 2  
An Almirah/wardrobe? J.   Almirah ........................................ 1 2  
A water pump K.  Water Pump ................................. 1 2  
An IPS?Generator L.  Generator/IPS ............................... 1 2  
An air conditioner M.  AC ............................................... 1 2  
A computer/laptop? N. Computer/Laptop .......................... 1 2  
913 In your opinion, is your 
household a high income 
household, a middle income 
household or a poor household? 
High income……………………………………1 
Middle income………………………………….2 
Low 
income……………………………………..3 
 
914 How many people live in your 
household? 
Total household size 
 
 
915 How many adult members (15 
years or older) 
Number of adults in the household 
 
 
916 How many children (less than 
15 years) 
Number of children in the household 
 
 
909 Is the cooking 
usually done in 
the house, in a 
separate building, 
or outdoors? 
IN THE HOUSE . . . . . . . . . . . . . . . . . . . . . . . . 1 
IN A SEPARATE BUILDING . . . . . . . . . . . . 2 
OUTDOORS . . . . . . . . . . . . . . . . . . . . . . . . . . 3 
OTHER 6 
(SPECIFY) 
 
   
 
 
910 Do you have a 
separate room 
which is used as a 
kitchen? 
Yes…………………….…….1 
No……...…………...……..2 
 
   
 
 
911 Does your 
household own 
any homestead? 
Yes…………………….…….1 
No……...…………...……..2 
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917 How many separate sleeping 
rooms are there for the use of 
your household members in 
your residence? 
Number of rooms 
 
918 What is your current place of 
residence? 
Urban……………………………………1 
Urban slum…………………….……….2 
Rural……………………………………..3 
Other……………………………………..4 
Specify__________________________ 
 
 
919 If the government could provide 
you with some service to ease 
the burden of TB on you and 
your household, what would you 
prefer to have? 
DO NOT READ. INDICATE 
THE ITEMS MENTIONED. IF 
NOT IN THE LIST, ADD ANY 
NEW GOVT. SERVICE 
MENTIONED. 
Transport vouchers..………………………1 
Food vouchers…………………….……….2 
More efficient service……………………..3 
Other……………………………………..4 
Specify____________________________ 
 
 
920 How much would you be willing 
to pay  for not becoming ill with 
TB in the first place? In TAKA 
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Section 10.0 Performance of the Facility 
The next part of the survey is about the quality of TB care that you received during your visits to 
this facility. Please answer the questions in this part of the survey about this facility only.  Do not 
include any other facilities in your answer. 
No. Questions and filters Coding categories Response Skip 
Section 10.1 Availability of TB Services 
1001 Are the waiting time(s) 
before being served by 
health providers of this 
facility acceptable to you?  
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1002 How often are you attended 
to by the same health 
providers in this facility? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1003 How often are the service 
hours of this facility 
inconvenient for you to get 
your TB treatment? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1004 How often are drugs not 
available when you require 
them? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1005 How often do you 
experience difficulties in 
obtaining TB services in 
this facility because of 
language barriers? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
  
243 
 
1006 How often do you have to 
go to another health unit for 
TB services or treatment? 
Never…………………….…….1 
Sometimes……………...……..2 
Usually……...…………………3 
Always….……………………..4 
 
 
     
 
 
1007 Is this health facility easy to 
reach (distance)? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1008 How often are TB services 
available during the 
working hours of this 
facility? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1009 How often are the relevant 
health providers you come 
to see in this facility 
available? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
Section 10.2 Communication and Information 
1010 Do the health providers in 
this facility tell you when 
you stop spreading TB to 
others?  
Yes………………….1 
No……...…………...2 
 
     
 
 
1011 Do the health providers in 
this facility tell you that TB 
can be cured? 
Yes………………….1 
No……...…………...2 
 
     
 
 
1012 Do the health providers in 
this facility tell you about 
the importance of observed 
treatment? 
Yes………………….1 
No……...…………...2 
 
     
 
 
1013 Do the health providers in 
this facility tell you about 
the side effects of TB 
drugs? 
Yes………………….1 
No……...…………...2 
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1014 Do the health providers in 
this facility tell you about 
the need for sputum tests at 
given points during your 
treatment schedule? 
Yes………………….1 
No……...…………...2 
 
     
 
 
1015 Do the health providers in 
this facility tell you about 
the duration of the TB 
treatment? 
Yes………………….1 
No……...…………...2 
 
     
 
 
1016 During your visits to this 
facility, do health providers 
tell you about how to store 
your drugs obtained for 
your treatment? 
Yes………………….1 
No……...…………...2 
 
     
 
 
1017 Does the health provider in 
this facility tell you when 
next to come back for TB 
services? 
Yes………………….1 
No……...…………...2 
 
     
 
 
Section 10.3 Patient – Provider interaction and counselling 
1018 During your visits to this 
facility, how often does the 
health provider treat you 
with respect?  
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1019 During your visits to this 
facility, how often does the 
health provider listen 
carefully to you? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1020 During your visits to this 
facility, how often do health 
providers explain things in a 
way you can understand? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
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1021 During your visits to this 
facility, how often do you 
have sufficient time to 
discuss your problems? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1022 During your visits to this 
facility, how often do health 
providers discuss with you 
how to deal with your 
problems? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1023 During your visits to this 
facility, how often do you 
experience discrimination 
because you have TB? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1024 During your visits to this 
facility, how often is your 
privacy respected during 
examination? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1025 Do health providers at this 
facility tell you how TB can 
affect your every day life? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
Section 10.4 Infrastructure 
1026 How often is this facility 
clean?  
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
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1027 Is there safe drinking water 
in this facility? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1028 How often are the toilets in 
this facility usable? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1029 How often do you find 
enough comfortable places 
to sit on in this facility?  
 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
     
 
 
Section 10.5 Professional Competence 
1030 Does this facility offer 
services to examine your 
sputum? 
Yes………………….1 
No……...…………...2 
 
     
 
 
1031 Does this facility offer 
home based TB treatment? 
 
Yes………………….1 
No……...…………...2 
 
     
 
 
1032 Were you physically 
examined during your first 
visit to this health facility? 
Yes………………….1 
No……...…………...2 
 
     
 
 
1033 Was your sputum examined 
when you were diagnosed 
with TB? 
Yes………………….1 
No……...…………...2 
 
     
 
 
1034 How many working days 
were there between your 
first sputum submission and 
the time you got your 
results? 
 
0-2 Working days……….…….1 
3-4 Working days ……...……..2 
More than 5 Working days...…3 
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1035 In case of germs in your 
sputum that cause TB, were 
your close contacts 
examined by the TB 
facility?  
 
Yes………………….1 
No……...…………...2 
 
     
 
 
1036 How often is there a 
treatment observer checking 
on your daily intake of TB 
drugs? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
Section 10.6 Affordability 
1037 How often do you have to 
pay for your regular TB 
services (e.g. sputum tests, 
TB-drugs, X-rays, etc.)? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1038 How often do you have to 
pay a tip in order to receive 
TB services? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1039 How often do costs (e.g. 
transport) prevent you from 
getting to the health 
facility? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
Section 10.7 Support 
1040 How often do you receive 
transport support from the 
health facility? 
 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
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1041 How often do you receive 
food support from the health 
facility? 
 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1042 How often do you receive 
financial assistance from the 
health facility? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
Section 10.8 Stigma 
1043 Does the health provider 
talk to you the same way 
you are spoken to when you 
receive services other than 
TB? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1044 Does the health provider 
welcome you into the health 
facility when you visit for 
TB services? 
 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1045 Does the health provider 
turn his/her face away when 
speaking with you? 
 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
 
 
     
 
 
1046 Do you feel that you are 
treated with dignity when 
you visit the health facility? 
Never……………………1 
Sometimes……………...2 
Usually……...………….3 
Always….……………….4 
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Section 11.0 Quality of Life  
Section 11.1 Health Related Quality of Life (FACIT-TB Questionnaire) 
How would you describe your level of 
feeling for the following statements: 
(record the number in the right column) 
 Not 
At All 
Slight
ly 
Moderat
ely 
Quite 
A Bit 
Extrem
ely 
Respo
nse 
A. Physical well-being       
110
1 
I feel ill 
1 2 3 4 5  
110
2 
I get tired easily 
1 2 3 4 5  
110
3 
I have a lack of energy 
1 2 3 4 5  
110
4 
I have pain 
1 2 3 4 5  
110
5 
I feel weak all over 
1 2 3 4 5  
110
6 
I feel fatigued 
1 2 3 4 5  
110
7 
I have been short of breath 
1 2 3 4 5  
110
8 
I have nausea-“a sense of vomiting 
outbreak” 
1 2 3 4 5  
110
9 
Because of my physical condition, I 
have trouble meeting the needs of 
my family 
1 2 3 4 5  
111
0 
I am bothered by fever (episode of 
high body temperature) 
1 2 3 4 5  
111
1 
I am forced to spend time in bed 
1 2 3 4 5  
111
2 
I have discomfort or pain in my 
stomach area 
1 2 3 4 5  
111
3 
I have had itching 
1 2 3 4 5  
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111
4 
I have a loss of appetite 
1 2 3 4 5  
111
5 
I have been coughing 
1 2 3 4 5  
111
6 
I am bothered by side effects of 
treatment 
1 2 3 4 5  
111
7 
Dusts Worsen my symptoms 
1 2 3 4 5  
B. Social and economic well-being       
111
8 
I feel close to my friends 
1 2 3 4 5  
111
9 
I get emotional support from my 
family 
1 2 3 4 5  
112
0 
I am satisfied with my family 
communication about my illness 
1 2 3 4 5  
112
1 
My family has accepted my illness 
1 2 3 4 5  
112
2 
I feel close to my partner (or the 
person who is my main support) 
1 2 3 4 5  
112
3 
I get support from my friends 
1 2 3 4 5  
112
4 
My physical condition and/or 
medical treatment cause me 
financial difficulties 
1 2 3 4 5  
C. Emotional well-being/Stigma of 
having TB 
      
112
5 
I worry that my condition will get 
worse 
1 2 3 4 5  
112
6 
I worry about dying 
1 2 3 4 5  
112
7 
I am concerned about what the 
future holds for me 
1 2 3 4 5  
112
8 
I am embarrassed by my illness 
1 2 3 4 5  
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112
9 
It is hard to tell other people about 
my infection 
1 2 3 4 5  
113
0 
I am losing hope in the fight against 
my illness 
1 2 3 4 5  
113
1 
I am bothered by the change in 
weight 
1 2 3 4 5  
113
2 
I worry about spreading my 
infection 
1 2 3 4 5  
113
3 
I feel nervous 
1 2 3 4 5  
113
4 
I feel sad 
1 2 3 4 5  
113
5 
I am satisfied with how I am coping 
with my illness 
1 2 3 4 5  
D. Functional well-being       
113
6 
I am content with the quality of my 
life right now 
1 2 3 4 5  
113
7 
My work (include work at home) is 
fulfilling 
1 2 3 4 5  
113
8 
I am able to work (include work at 
home) 
1 2 3 4 5  
113
9 
I am able to enjoy life 
1 2 3 4 5  
114
0 
I am enjoying the things I usually 
do for fun 
1 2 3 4 5  
114
1 
I have accepted my illness 
1 2 3 4 5  
114
2 
I am sleeping well 
1 2 3 4 5  
E. Spiritual well-being       
114
3 
I find strength in my faith or 
spiritual belief 
1 2 3 4 5  
114
4 
My illness has strengthened my 
faith or spiritual belief 
1 2 3 4 5  
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114
5 
My life is still productive 
1 2 3 4 5  
Section 11.2 EQ-5D-5L Questionnaire 
Under each heading, please tick the ONE box that best describes your health TODAY. 
Sl Category Options Response 
114
6 
Mobility I have no problems in walking 
about.................................1 
I have slight problems in walking 
about.............................2 
I have moderate problems in walking 
about......................3 
I have severe problems in walking 
about...........................4 
I am unable to walk 
about..................................................5 
 
114
7 
Self-Care I have no problems washing or dressing 
myself...............1 
I have slight problems washing or dressing 
myself...........2 
I have moderate problems washing or dressing 
myself....3 
I have severe problems washing or dressing 
myself........4 
I am unable to wash or dress 
myself.................................5 
 
114
8 
Usual 
Activities 
(e.g., work, 
study, 
housework, 
family or 
leisure 
activities) 
I have no problems doing my usual 
activities....................1 
I have slight problems doing my usual 
activities................2 
I have moderate problems doing my usual 
activities.........3 
I have severe problems doing my usual 
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activities.............4 
I am unable to do my usual 
activities.................................5 
114
9 
Pain/Discomfo
rt 
I have no pain or 
discomfort...............................................1 
I have slight pain or 
discomfort...........................................2 
I have moderate pain or 
discomfort....................................3 
I have severe pain or 
discomfort........................................4 
I have extreme pain or 
discomfort......................................5 
 
115
0 
Anxiety/Depre
ssion 
I am not 
anxious/depressed...............................................1 
I am slightly 
anxious/depressed.........................................2 
I am moderately 
anxious/depressed..................................3 
I am severely 
anxious/depressed......................................4 
I am extremely 
anxious/depressed....................................5 
 
Section 11.3 SF-6D Questionnaire 
Under each heading, please tick the ONE box that best describes your health TODAY. 
Sl Category Options Response 
115
1 
Physical 
Functioning 
My health does not limit me in vigorous 
activities..................................1 
My health limits me a little in vigorous 
activities.....................................2 
My health limits me a little in moderate 
activities...................................3 
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My health limits me a lot in moderate 
activities......................................4 
My health limits me a little in bathing and 
dressing...............................5 
My health limits me a lot in bathing and 
dressing..................................6 
115
2 
Role 
Limitation 
I have no problems with your work or other 
regular daily activities as a result of your 
physical health or any emotional 
problems......................1 
I am limited in the kind of work or other 
activities as a result of your physical 
health........................................................................2 
I accomplish less than you would like as a result 
of emotional 
problems...................................................................3 
You are limited in the kind of work or other 
activities as a result of your physical health and 
accomplish less than you would like as a result 
of emotional 
problems..................................................................4 
 
115
3 
Social 
Functioning 
My health limits my social activities none of the 
time..................................1 
My health limits my social activities a little of the 
time.................................2 
My health limits my social activities some of the 
time..................................3 
My health limits my social activities most of the 
time...................................4 
My health limits my social activities all of the 
time.......................................5 
 
115
4 
Pain I have no 
pain...............................................................................
.................1 
I have pain, but it does not interfere with my normal 
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work (both outside the home and 
housework)..................................................................
..2 
I have pain that interferes with your normal work 
(both outside the home and housework) a little 
bit............................................................................3 
I have pain that interferes with your normal work 
(both outside the home and housework) 
moderately...................................................................
..4 
I have pain that interferes with your normal work 
(both outside the home and housework) quite a 
bit...........................................................................5 
I have pain that interferes with your normal work 
(both outside the home and housework) 
extremely.....................................................................
.6 
115
5 
Mental Health I feel tense or downhearted and low none of the 
time.................................1 
I feel tense or downhearted and low a little of the 
time................................2 
I feel tense or downhearted and low some of the 
time................................3 
I feel tense or downhearted and low most of the 
time.................................4 
I feel tense or downhearted and all of the 
time............................................5 
 
115
6 
Vitality I have a lot of energy all of the time........................1 
I have a lot of energy most of the time....................2 
I have a lot of energy some of the time....................3 
I have a lot of energy a little of the time……...........4 
I have a lot of energy none of the time………........5 
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Section 11.4 Visual Analog Scale 
1157 Visual Analog Scale Score  
1158 Comments by interviewer on the interview 
 
 
 
 
 
 
 
1159 INTERVIEWERS:  CHECK YOUR FILLED IN QUESTIONNAIRE CAREFULLY 
BEFORE LEAVING THE RESPONDENTS AND END YOUR INTERVIEW BY 
GIVING THANKS TO THE RESPONDENT. 
          RECORD THE END TIME OF THE 
INTERVIEW: 
Hour                           
Minutes 
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APPENDIX D – PROVIDER QUESTIONNAIRE (DS-TB)  
 
IDENTIFICATION 
 
DIVISION_____________________________________________________ 
 
DISTRICT________________________________________________________________ 
 
UPAZILA  _________________________________________________ 
 
NAME OF THE FACILITY_________________________________________ 
 
TYPE OF THE FACILITY___________________________________________ 
(Union Health Center =01, Upazila Health Complex =02, District Hospital =03) 
 
TYPE OF THE PROVIDER___________________________________________ 
(BRAC =01, Damien Foundation =02, Other =03, Please specify) 
 
NAME OF THE MANAGER____________________________________ 
 
LOCATION OF FACILITY: RURAL=1, URBAN=2 
 
 
 
 
 
 
 
 
 
 
  
 
 
2
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INTERVIEWER VISITS 
 1 2 3 FINAL VISIT 
 
DATE            
INTERVIEWER’S NAME & 
CODE 
   CODE 
 
 
RESULT CODE*    RESULT CODE 
NEXT VISIT:         DATE     
TOTAL NO. OF VISITS                              TIME    
*RESULT CODES: 
 01 COMPLETED     
 02 NOT AVAILABLE 
 03 POSTPONED 
 04 REFUSED  
  
 05 PARTLY COMPLETED 
96 OTHER_________________ 
                          (SPECIFY)  
SUPERVISOR FIELD EDITOR OFFICE EDITOR KEYED BY 
 
NAME____________________  
 
DATE _________________ 
 
 
NAME___________________  
 
DATE _________________ 
 
NAME____________ 
 
DATE ______________ 
 
NAME_________  
 
DATE __________ 
 Section 1: Number of Personnel, their salary, and contribution to the TB Control Program 
Collect data based on each staff working on the day of data collection during day-shift (9:00am- 5:00pm). This table is for collecting information on TB clinics 
open on day of the interview.  
USE DECIMAL POINTS TO INDICATE PART-TIME WORK. FOR EXAMPLE, IF AN INDIVIDUAL WORKS IN TWO CLINICS, RECORD 0.5 FOR 
THIS PERSON IN BOTH 
 A  B C D E F G H 
SL# 
DESIGNATION 
Number 
Employed Monthly 
Salary 
Monthly 
Benefits 
TA/DA Overtime 
Incentive 
Payment 
Total 
% 
involvement 
with TB 
program 
101 Civil Surgeon    
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
102 
Junior 
Consultant 
(Chest Clinic) 
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103 
Upazila Health 
and Family 
Planning Officer 
(UHFPO) 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
104 
Medical Officer 
(TB/Leprosy) 
Designated 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
105 
Medical Officer 
Chest Disease 
Clinic 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
106 
Medical Officer 
Disease Control 
(MODC) 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
107 
Medical Officer, 
NGOs 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
108 
Program 
Organizer 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
109 
Medical 
Technologist 
(Laboratory) 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
110 Health Inspector    
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
111 
Assistant Health 
Inspector 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
112 
Family Planning 
Inspector 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
113 
Health Assistant 
(HA) 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
114 
Medical 
Assistant (MA) 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
115 
NGO 
Community 
Health Workers 
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116 
Leprosy and TB 
Control 
Assistant 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
117 
Statistical 
Assistant 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
118 
Gene Xpert 
Technician 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
119 
Community 
Health Worker 
(CHW)  
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
120 
 
 
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
121 
 
 
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
122 
 
 
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
123 
 
 
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
124 
 
 
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
125 
 
 
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
126 
 
 
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
127 
 
 
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
128 
 
 
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
129  
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130  
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
 
Section 2.0 Caseload (Number of New Patients Diagnosed, Number of Patients treated)  
Please collect these information from Quarterly TB case finding reporting form (TB-10) 
SL. Indicator Number 
  Quarter1 
(Oct 2015-Dec 2015) 
Quarter 2 
(Jan 2016-March 2016) 
Quarter 3 
(April 2016-June 2016) 
Quarter 4 
(July 2016-September 
2016) 
  Male  Female Total Male  Female Total Male  Female Total Male  Female Total 
 TB Case Detection 
Rate 
A B C D E F G H I J K L 
201 Total new pulmonary 
smear-positive cases 
notified 
            
202 Total new (relapses) 
smear positive cases 
notified 
            
203 Total new (failures) 
smear positive cases 
notified 
            
204 Total new (loss to follow 
up/after default) smear 
positive cases notified 
            
205 Xpert MTB/RIF positive 
RIF sensitive new cases 
            
206 Xpert MTB/RIF positive 
RIF sensitive previously 
treated cases 
            
207 Total new pulmonary 
smear-negative cases 
notified 
            
208 Total new 
extrapulmonary cases 
notified 
            
209 Total others previously 
treated* cases notified 
            
210 Total cases registered             
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 Laboratory Activity 
(Sputum Smear 
Microscopy) 
            
211 Number of presumptive 
TB cases/suspects 
examined for diagnosis 
by sputum smear 
microscopy 
            
212 Number of presumptive 
TB cases/suspects with 
positive sputum smear 
microscopy 
            
 Laboratory Activity 
(GeneXpert Test) 
            
213 Number of presumptive 
TB cases/suspects 
examined for diagnosis 
by Xpert MTB/RIF 
            
214 Number of presumptive 
TB cases/suspects with 
positive Xpert MTB/RIF 
result 
            
 HIV Activities             
214 Number of People living 
with HIV/AIDS 
(PLHWA) tested for 
Acid Fast Bacilli (AFB) 
            
215 Number of AFB positive 
result among tested 
PLWHA 
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Section 3.0 TB Patient Referral  
Please enumerate the number of TB patients referred by different providers using TB Form-10 
Sl. TB Patient Referral Number 
  Quarter 1 Quarter 2 Quarter 3 Quarter 4 
  A B C D 
301  Private Practitioner (Graduate)     
302  Private Practitioner (Non-Graduate)     
303  Govt. field staff     
304  Shasthya Sebika (SS)/ Non-govt. field staff (NGFS)     
305 Village Doctor (VD)     
306 Community Volunteer (CV)     
307 Govt. Hospital     
308 Private Hospital     
309 Community Health Care Provider (CHCP)     
310 TB Patient     
311 Others (Please specify)     
312 Total     
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Section 4.0 Treatment outcomes (TB Patients Registered 3-6 Months Earlier) 
Quarter  |__|__|  Year  |__|__| 
PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 3-6 MONTHS EARLIER (USING TB-12 
FORM) 
Sl. Type of Patients Smear 
Negative 
Smear 
Positive 
Died Failure Lost to 
Follow-up 
Transferred 
Out 
Not 
Evaluated 
Grand Total 
 M= Male 
F=Female 
M F M F M F M F M F M F M F M F Total 
 New Cases A B C D E F G H I J K L M N O P Q 
401 Smear Positive                  
402 Xpert MTB/RIF 
Positive 
                 
403 Smear Negative                  
 
PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 3-6 MONTHS EARLIER (USING TB-12 
FORM) 
Sl. Type of Patients Smear 
Negative 
Smear 
Positive 
Died Failure Lost to 
Follow-up 
Transferred 
Out 
Not 
Evaluated 
Grand Total 
 M= Male 
F=Female 
M F M F M F M F M F M F M F M F Total 
 Retreatment A B C D E F G H I J K L M N O P Q 
404 Relapses                  
405 Treatment after 
failure 
                 
406 Treatment after 
loss to follow 
up/Default 
                 
407 Others                   
408 Total                  
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Quarter |__|__|  Year  |__|__| 
PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 3-6 MONTHS EARLIER (USING TB-12 
FORM) 
Sl. Type of Patients Smear 
Negative 
Smear 
Positive 
Died Failure Lost to 
Follow-up 
Transferred 
Out 
Not 
Evaluated 
Grand Total 
 M= Male 
F=Female 
M F M F M F M F M F M F M F M F Total 
 New Cases A B C D E F G H I J K L M N O P Q 
409 Smear Positive                  
410 Xpert MTB/RIF 
Positive 
                 
411 Smear Negative                  
 
PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 3-6 MONTHS EARLIER (USING TB-12 
FORM) 
Sl. Type of Patients Smear 
Negative 
Smear 
Positive 
Died Failure Lost to 
Follow-up 
Transferred 
Out 
Not 
Evaluated 
Grand Total 
 M= Male 
F=Female 
M F M F M F M F M F M F M F M F Total 
 Retreatment A B C D E F G H I J K L M N O P Q 
412 Relapses                  
413 Treatment after 
failure 
                 
414 Treatment after 
loss to follow 
up/Default 
                 
415 Others                   
416 Total                  
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Quarter  |__|__|  Year  |__|__| 
PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 3-6 MONTHS EARLIER (USING TB-12 
FORM) 
Sl. Type of Patients Smear 
Negative 
Smear 
Positive 
Died Failure Lost to 
Follow-up 
Transferred 
Out 
Not 
Evaluated 
Grand Total 
 M= Male 
F=Female 
M F M F M F M F M F M F M F M F Total 
 New Cases A B C D E F G H I J K L M N O P Q 
417 Smear Positive                  
418 Xpert MTB/RIF 
Positive 
                 
419 Smear Negative                  
 
PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 3-6 MONTHS EARLIER (USING TB-12 
FORM) 
Sl. Type of Patients Smear 
Negative 
Smear 
Positive 
Died Failure Lost to 
Follow-up 
Transferred 
Out 
Not 
Evaluated 
Grand Total 
 M= Male 
F=Female 
M F M F M F M F M F M F M F M F Total 
 Retreatment A B C D E F G H I J K L M N O P Q 
420 Relapses                  
421 Treatment after 
failure 
                 
422 Treatment after 
loss to follow 
up/Default 
                 
423 Others                   
424 Total                  
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Quarter  |__|__|  Year  |__|__| 
PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 3-6 MONTHS EARLIER (USING TB-12 
FORM) 
Sl. Type of Patients Smear 
Negative 
Smear 
Positive 
Died Failure Lost to 
Follow-up 
Transferred 
Out 
Not 
Evaluated 
Grand Total 
 M= Male 
F=Female 
M F M F M F M F M F M F M F M F Total 
 New Cases A B C D E F G H I J K L M N O P Q 
425 Smear Positive                  
426 Xpert MTB/RIF 
Positive 
                 
427 Smear Negative                  
 
PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 3-6 MONTHS EARLIER (USING TB-12 
FORM) 
Sl. Type of Patients Smear 
Negative 
Smear 
Positive 
Died Failure Lost to 
Follow-up 
Transferred 
Out 
Not 
Evaluated 
Grand Total 
 M= Male 
F=Female 
M F M F M F M F M F M F M F M F Total 
 Retreatment A B C D E F G H I J K L M N O P Q 
428 Relapses                  
429 Treatment after 
failure 
                 
430 Treatment after 
loss to follow 
up/Default 
                 
431 Others                   
432 Total                  
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Section 5.0 Treatment outcomes (TB Patients Registered 12-15 Months Earlier) 
Quarter  |__|__|  Year  |__|__| 
PLEASE COMPLETE THIS TABLE FOR PULMONRY TB PATIENTS REGISTERED 12-15 MONTHS EARLIER (USING TB-11 
FORM) 
Sl. Type of Patients Cured Treatment 
Completed 
Died Failure Lost to 
Follow-
up/Defaulted 
Transferred 
Out 
Not 
Evaluated 
Grand Total 
 M= Male 
F=Female 
M F M F M F M F M F M F M F M F Total 
 New Cases A B C D E F G H I J K L M N O P Q 
501 Smear Positive                  
502 Xpert MTB/RIF 
Positive 
                 
503 Smear Negative                  
504 EP                  
506 Total                  
 
PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 12-15 MONTHS EARLIER (USING TB-11 
FORM) 
Sl. Type of Patients Smear 
Negative 
Smear 
Positive 
Died Failure Lost to 
Follow-up 
Transferred 
Out 
Not 
Evaluated 
Grand Total 
 M= Male 
F=Female 
M F M F M F M F M F M F M F M F Total 
 Retreatment A B C D E F G H I J K L M N O P Q 
507 Relapses                  
508 Failures                  
509 Treatment after 
loss to follow 
up/default 
                 
510 Others                   
511 Total                  
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Quarter  |__|__|  Year  |__|__| 
PLEASE COMPLETE THIS TABLE FOR PULMONRY TB PATIENTS REGISTERED 12-15 MONTHS EARLIER (USING TB-11 
FORM) 
Sl. Type of Patients Cured Treatment 
Completed 
Died Failure Lost to 
Follow-
up/Defaulted 
Transferred 
Out 
Not 
Evaluated 
Grand Total 
 M= Male 
F=Female 
M F M F M F M F M F M F M F M F Total 
 New Cases A B C D E F G H I J K L M N O P Q 
501 Smear Positive                  
502 Xpert MTB/RIF 
Positive 
                 
503 Smear Negative                  
504 EP                  
506 Total                  
 
PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 12-15 MONTHS EARLIER (USING TB-11 
FORM) 
Sl. Type of Patients Smear 
Negative 
Smear 
Positive 
Died Failure Lost to 
Follow-up 
Transferred 
Out 
Not 
Evaluated 
Grand Total 
 M= Male 
F=Female 
M F M F M F M F M F M F M F M F Total 
 Retreatment A B C D E F G H I J K L M N O P Q 
507 Relapses                  
508 Failures                  
509 Treatment after 
loss to follow 
up/default 
                 
510 Others                   
511 Total                  
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Quarter  |__|__|  Year  |__|__| 
PLEASE COMPLETE THIS TABLE FOR PULMONRY TB PATIENTS REGISTERED 12-15 MONTHS EARLIER (USING TB-11 
FORM) 
Sl. Type of Patients Cured Treatment 
Completed 
Died Failure Lost to 
Follow-
up/Defaulted 
Transferred 
Out 
Not 
Evaluated 
Grand Total 
 M= Male 
F=Female 
M F M F M F M F M F M F M F M F Total 
 New Cases A B C D E F G H I J K L M N O P Q 
501 Smear Positive                  
502 Xpert MTB/RIF 
Positive 
                 
503 Smear Negative                  
504 EP                  
506 Total                  
 
PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 12-15 MONTHS EARLIER (USING TB-11 
FORM) 
Sl. Type of Patients Smear 
Negative 
Smear 
Positive 
Died Failure Lost to 
Follow-up 
Transferred 
Out 
Not 
Evaluated 
Grand Total 
 M= Male 
F=Female 
M F M F M F M F M F M F M F M F Total 
 Retreatment A B C D E F G H I J K L M N O P Q 
507 Relapses                  
508 Failures                  
509 Treatment after 
loss to follow 
up/default 
                 
510 Others                   
511 Total                  
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Quarter  |__|__|  Year  |__|__| 
PLEASE COMPLETE THIS TABLE FOR PULMONRY TB PATIENTS REGISTERED 12-15 MONTHS EARLIER (USING TB-11 
FORM) 
Sl. Type of Patients Cured Treatment 
Completed 
Died Failure Lost to 
Follow-
up/Defaulted 
Transferred 
Out 
Not 
Evaluated 
Grand Total 
 M= Male 
F=Female 
M F M F M F M F M F M F M F M F Total 
 New Cases A B C D E F G H I J K L M N O P Q 
501 Smear Positive                  
502 Xpert MTB/RIF 
Positive 
                 
503 Smear Negative                  
504 EP                  
506 Total                  
 
PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 12-15 MONTHS EARLIER (USING TB-11 
FORM) 
Sl. Type of Patients Smear 
Negative 
Smear 
Positive 
Died Failure Lost to 
Follow-up 
Transferred 
Out 
Not 
Evaluated 
Grand Total 
 M= Male 
F=Female 
M F M F M F M F M F M F M F M F Total 
 Retreatment A B C D E F G H I J K L M N O P Q 
507 Relapses                  
508 Failures                  
509 Treatment after 
loss to follow 
up/default 
                 
510 Others                   
511 Total                  
 
 
  
 
 
2
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Section 6.0 Quantity and Cost of Drugs  
Number of TB Drugs received by the facility last year (January 2016- December 2016-PLEASE CONSULT LAST TWO REQUISITION 
FORM TB-08) 
Quarter  |__|__|  Year  |__|__| 
SL# Drug name 
Quantity 
measures  
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
CAT I Patients 
 
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
CAT II Patients 
 
Total received in 
this quarter  
Market price of drugs per 
unit 
  A B C D E 
601 
4FDC 
 
      
 
     
 
     
 
   .  
 
602 
3FDC 
(R150/H75/E275) 
      
 
     
 
     
 
   .  
 
603 
2 FDC 
(R150/H75) 
      
 
     
 
     
 
   .  
 
604 
3 FDC (R60/H30/Z150) 
(Dispersible) 
      
 
     
 
     
 
   .  
 
605 
2FDC (R60/H60)  
(Dispersible) 
      
 
     
 
     
 
   .  
 
606 
2FDC (R60/H30)  
(Dispersible) 
      
 
     
 
     
 
   .  
 
607 Z 400 mg (Dispersible)       
 
     
 
     
 
   .  
 
608 
H 100 mg 
(Dispersible)/For IPT 
      
 
     
 
     
 
   .  
 
609 R 150 mg       
 
     
 
     
 
   .  
 
610 H 300 mg       
 
     
 
     
 
   .  
 
611 R 450 mg       
 
     
 
     
 
   .  
 
612 Z 500 mg       
 
     
 
     
 
   .  
 
613 E 400 mg       
 
     
 
     
 
   .  
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614 E 100 mg       
 
     
 
     
 
   .  
 
615 S 1g       
 
     
 
     
 
   .  
 
616 Inj. Water, 5 ml       
 
     
 
     
 
   .  
 
617 D/ Syringe 5 cc       
 
     
 
     
 
   .  
 
618 DST Liquid culture       
 
     
 
     
 
   .  
 
619 DST Solid Culture       
 
     
 
     
 
   .  
 
620        
 
     
 
     
 
   .  
 
621        
 
     
 
     
 
   .  
 
622        
 
     
 
     
 
   .  
 
623        
 
     
 
     
 
   .  
 
624        
 
     
 
     
 
   .  
 
625        
 
     
 
     
 
   .  
 
 
Quarter  |__|__|  Year  |__|__| 
SL# Drug name 
Quantity received 
from National TB 
Control Program 
(NTP) (units) for 
CAT I Patients 
 
Quantity received from 
National TB Control 
Program (NTP) (units) 
for 
CAT II Patients 
 
Total received in 
this quarter  
  E F G 
601 
4FDC 
 
     
 
     
 
     
 
602 3FDC (R150/H75/E275)      
 
     
 
     
 
603 
2 FDC 
(R150/H75) 
     
 
     
 
     
 
604 
3 FDC (R60/H30/Z150) 
(Dispersible) 
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605 
2FDC (R60/H60)  
(Dispersible) 
     
 
     
 
     
 
606 
2FDC (R60/H30)  
(Dispersible) 
     
 
     
 
     
 
607 Z 400 mg (Dispersible)      
 
     
 
     
 
608 
H 100 mg 
(Dispersible)/For IPT 
     
 
     
 
     
 
609 R 150 mg      
 
     
 
     
 
610 H 300 mg      
 
     
 
     
 
611 R 450 mg      
 
     
 
     
 
612 Z 500 mg      
 
     
 
     
 
613 E 400 mg      
 
     
 
     
 
614 E 100 mg      
 
     
 
     
 
615 S 1g      
 
     
 
     
 
616 Inj. Water, 5 ml      
 
     
 
     
 
617 D/ Syringe 5 cc      
 
     
 
     
 
618 DST Liquid culture      
 
     
 
     
 
619 DST Solid Culture      
 
     
 
     
 
620       
 
     
 
     
 
621       
 
     
 
     
 
622       
 
     
 
     
 
623       
 
     
 
     
 
624       
 
     
 
     
 
625       
 
     
 
     
 
 
 
  
 
 
2
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Quarter  |__|__|  Year  |__|__| 
SL# Drug name 
Quantity received 
from National TB 
Control Program 
(NTP) (units) for 
CAT I Patients 
 
Quantity received from 
National TB Control 
Program (NTP) (units) 
for 
CAT II Patients 
 
Total received in 
this quarter  
  H I J 
601 
4FDC 
 
     
 
     
 
     
 
602 3FDC (R150/H75/E275)      
 
     
 
     
 
603 
2 FDC 
(R150/H75) 
     
 
     
 
     
 
604 
3 FDC (R60/H30/Z150) 
(Dispersible) 
     
 
     
 
     
 
605 
2FDC (R60/H60)  
(Dispersible) 
     
 
     
 
     
 
606 
2FDC (R60/H30)  
(Dispersible) 
     
 
     
 
     
 
607 Z 400 mg (Dispersible)      
 
     
 
     
 
608 
H 100 mg 
(Dispersible)/For IPT 
     
 
     
 
     
 
609 R 150 mg      
 
     
 
     
 
610 H 300 mg      
 
     
 
     
 
611 R 450 mg      
 
     
 
     
 
612 Z 500 mg      
 
     
 
     
 
613 E 400 mg      
 
     
 
     
 
614 E 100 mg      
 
     
 
     
 
615 S 1g      
 
     
 
     
 
616 Inj. Water, 5 ml      
 
     
 
     
 
  
 
 
2
7
6
 
617 D/ Syringe 5 cc      
 
     
 
     
 
618 DST Liquid culture      
 
     
 
     
 
619 DST Solid Culture      
 
     
 
     
 
620       
 
     
 
     
 
621       
 
     
 
     
 
622       
 
     
 
     
 
623       
 
     
 
     
 
624       
 
     
 
     
 
625       
 
     
 
     
 
 
Quarter  |__|__|  Year  |__|__| 
SL# Drug name 
Quantity received 
from National TB 
Control Program 
(NTP) (units) for 
CAT I Patients 
 
Quantity received from 
National TB Control 
Program (NTP) (units) 
for 
CAT II Patients 
 
Total received in 
this quarter  
  K L M 
601 
4FDC 
 
     
 
     
 
     
 
602 3FDC (R150/H75/E275)      
 
     
 
     
 
603 
2 FDC 
(R150/H75) 
     
 
     
 
     
 
604 
3 FDC (R60/H30/Z150) 
(Dispersible) 
     
 
     
 
     
 
605 
2FDC (R60/H60)  
(Dispersible) 
     
 
     
 
     
 
606 
2FDC (R60/H30)  
(Dispersible) 
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607 Z 400 mg (Dispersible)      
 
     
 
     
 
608 
H 100 mg 
(Dispersible)/For IPT 
     
 
     
 
     
 
609 R 150 mg      
 
     
 
     
 
610 H 300 mg      
 
     
 
     
 
611 R 450 mg      
 
     
 
     
 
612 Z 500 mg      
 
     
 
     
 
613 E 400 mg      
 
     
 
     
 
614 E 100 mg      
 
     
 
     
 
615 S 1g      
 
     
 
     
 
616 Inj. Water, 5 ml      
 
     
 
     
 
617 D/ Syringe 5 cc      
 
     
 
     
 
618 DST Liquid culture      
 
     
 
     
 
619 DST Solid Culture      
 
     
 
     
 
620       
 
     
 
     
 
621       
 
     
 
     
 
622       
 
     
 
     
 
623       
 
     
 
     
 
624       
 
     
 
     
 
625       
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Section 7.0 Quantity and Cost of Laboratory Reagents/Supplies/Equipment 
Number of Laboratory reagents/ supplies received by the facility last year (October 2015-September 2016- Laboratory Request Form) 
Quarter 4 (July 2016- September 2016) 
SL# 
Reagent/Lab supplies’ 
name 
Quantity 
measures 
per 
patient  
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
Quantity purchased 
from market  (units) 
Total received in 
this quarter 
Market price of reagents 
per unit 
  A B C D E 
701 
Carbol fuchsin (1%) 
Solution 
3.0 ml 
/sm+ 
     
 
     
 
     
 
   .  
 
702 Methylene Blue (0.1%) 
3.0 
ml/sm+ 
     
 
     
 
     
 
   .  
 
703 Sulphuric Acid (25%) 
6.0 
ml/sm+ 
     
 
     
 
     
 
   .  
 
704 Burning Spirit 
1.5 
ml/sm+ 
     
 
     
 
     
 
   .  
 
705 Slides 1 pc/sm+      
 
     
 
     
 
   .  
 
706 Sputum Containers 1 pc/sm+      
 
     
 
     
 
   .  
 
707 Immersion Oil 
0.05 
ml/sm+ 
     
 
     
 
     
 
   .  
 
711 Filter Paper Pieces 
100 pc/ 
clinic 
     
 
     
 
     
 
   .  
 
712 Request Form (TB 05) 
1 
pc/person 
     
 
     
 
     
 
   .  
 
713 Lab Register (TB 04)       
 
     
 
     
 
   .  
 
714 Diamond Pencil       
 
     
 
     
 
   .  
 
715 Slide Box       
 
     
 
     
 
   .  
 
716        
 
     
 
     
 
   .  
 
717        
 
     
 
     
 
   .  
 
718        
 
     
 
     
 
   .  
 
719        
 
     
 
     
 
   .  
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720        
 
     
 
     
 
   .  
 
721        
 
     
 
     
 
   .  
 
722        
 
     
 
     
 
   .  
 
            Quarter 3 (April 2016- June 2016) 
 
SL# 
Reagent/Lab supplies’ 
name 
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
Quantity purchased 
from market  (units) 
Total received in 
this quarter  
  F G H 
701 
Carbol fuchsin (1%) 
Solution 
     
 
     
 
     
 
702 
Methylene Blue 
(0.1%) 
     
 
     
 
     
 
703 Sulphuric Acid (25%)      
 
     
 
     
 
704 Burning Spirit      
 
     
 
     
 
705 Slides      
 
     
 
     
 
706 Sputum Containers      
 
     
 
     
 
707 Immersion Oil      
 
     
 
     
 
708 Filter Paper Pieces      
 
     
 
     
 
709 Request Form (TB 05)      
 
     
 
     
 
710 Lab Register (TB 04)      
 
     
 
     
 
711 Diamond Pencil      
 
     
 
     
 
712 Slide Box      
 
     
 
     
 
713 Filter Paper Pieces      
 
     
 
     
 
714       
 
     
 
     
 
715       
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716       
 
     
 
     
 
717       
 
     
 
     
 
718       
 
     
 
     
 
719       
 
     
 
     
 
720       
 
     
 
     
 
721       
 
     
 
     
 
722       
 
     
 
     
 
 
Quarter 2 (January 2016- March 2016) 
SL# 
Reagent/Lab supplies’ 
name 
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
Quantity purchased 
from market  (units) 
Total received in 
this quarter 
  I J K 
701 
Carbol fuchsin (1%) 
Solution 
     
 
     
 
     
 
702 
Methylene Blue 
(0.1%) 
     
 
     
 
     
 
703 Sulphuric Acid (25%)      
 
     
 
     
 
704 Burning Spirit      
 
     
 
     
 
705 Slides      
 
     
 
     
 
706 Sputum Containers      
 
     
 
     
 
707 Immersion Oil      
 
     
 
     
 
708 Filter Paper Pieces      
 
     
 
     
 
709 Request Form (TB 05)      
 
     
 
     
 
710 Lab Register (TB 04)      
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711 Diamond Pencil      
 
     
 
     
 
712 Slide Box      
 
     
 
     
 
713 Filter Paper Pieces      
 
     
 
     
 
714       
 
     
 
     
 
715       
 
     
 
     
 
716       
 
     
 
     
 
717       
 
     
 
     
 
718       
 
     
 
     
 
719       
 
     
 
     
 
720       
 
     
 
     
 
721       
 
     
 
     
 
722       
 
     
 
     
 
 
Quarter 1 (October 2016- December 2016) 
 
SL# 
Reagent/Lab supplies’ 
name 
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
Quantity purchased 
from market  (units) 
Total 
received in 
this 
quarter 
  L M N 
701 
Carbol fuchsin (1%) 
Solution 
     
 
     
 
 
702 Methylene Blue (0.1%)      
 
     
 
 
703 Sulphuric Acid (25%)      
 
     
 
 
704 Burning Spirit      
 
     
 
 
705 Slides      
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706 Sputum Containers      
 
     
 
 
707 Immersion Oil      
 
     
 
 
708 Filter Paper Pieces      
 
     
 
 
709 Request Form (TB 05)      
 
     
 
 
710 Lab Register (TB 04)      
 
     
 
 
711 Diamond Pencil      
 
     
 
 
712 Slide Box      
 
     
 
 
713 Filter Paper Pieces      
 
     
 
 
714       
 
     
 
 
715       
 
     
 
 
716       
 
     
 
 
717       
 
     
 
 
718       
 
     
 
 
719       
 
     
 
 
720       
 
     
 
 
721       
 
     
 
 
722       
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Section 8.0 Cost of Other Supplies 
Number of Supplies received by the facility last year (October 2015-September 2016) 
Quarter 4 (July 2016- September 2016) 
SL#  Supplies’ name 
Quantity 
measures  
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
Quantity purchased 
from market  (units) 
Total received in 
this quarter 
Market price of supplies 
per unit 
  A B C D E 
801 TB Register       
 
     
 
     
 
   .  
 
802 Treatment Card       
 
     
 
     
 
   .  
 
803 Pen       
 
     
 
     
 
   .  
 
804 Paper       
 
     
 
     
 
   .  
 
805 Box       
 
     
 
     
 
   .  
 
806 Soap       
 
     
 
     
 
   .  
 
807 Towel       
 
     
 
     
 
   .  
 
808 Boxes       
 
     
 
     
 
   .  
 
809 Tape       
 
     
 
     
 
   .  
 
810 Raincoat       
 
     
 
     
 
   .  
 
811 Torch light       
 
     
 
     
 
   .  
 
812 Umbrella       
 
     
 
     
 
   .  
 
813 Drug Baskets       
 
     
 
     
 
   .  
 
814 Kit Bag       
 
     
 
     
 
   .  
 
815 Poster       
 
     
 
     
 
   .  
 
816 Sticker       
 
     
 
     
 
   .  
 
817 Leaflet       
 
     
 
     
 
   .  
 
818 Flip chart       
 
     
 
     
 
   .  
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819 Flash Chart       
 
     
 
     
 
   .  
 
820 Brochure       
 
     
 
     
 
   .  
 
821        
 
     
 
     
 
   .  
 
822        
 
     
 
     
 
   .  
 
823        
 
     
 
     
 
   .  
 
824        
 
     
 
     
 
   .  
 
825        
 
     
 
     
 
   .  
 
826        
 
     
 
     
 
   .  
 
827        
 
     
 
     
 
   .  
 
828        
 
     
 
     
 
   .  
 
829        
 
     
 
     
 
   .  
 
830        
 
     
 
     
 
   .  
 
 
Quarter 3 (April 2016- June 2016) 
SL#  Supplies’ name 
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
Quantity purchased 
from market  (units) 
Total received in 
this quarter 
  F G H 
801 TB Register      
 
     
 
     
 
802 Treatment Card      
 
     
 
     
 
803 Pen      
 
     
 
     
 
804 Paper      
 
     
 
     
 
805 Box      
 
     
 
     
 
806 Soap      
 
     
 
     
 
807 Towel      
 
     
 
     
 
  
 
 
2
8
5
 
808 Boxes      
 
     
 
     
 
809 Tape      
 
     
 
     
 
810 Raincoat      
 
     
 
     
 
811 Torch light      
 
     
 
     
 
812 Umbrella      
 
     
 
     
 
813 Drug Baskets      
 
     
 
     
 
814 Kit Bag      
 
     
 
     
 
815 Poster      
 
     
 
     
 
816 Sticker      
 
     
 
     
 
817 Leaflet      
 
     
 
     
 
818 Flip chart      
 
     
 
     
 
819 Flash Chart      
 
     
 
     
 
820 Brochure      
 
     
 
     
 
821       
 
     
 
     
 
822       
 
     
 
     
 
823       
 
     
 
     
 
824       
 
     
 
     
 
825       
 
     
 
     
 
826       
 
     
 
     
 
827       
 
     
 
     
 
828       
 
     
 
     
 
829       
 
     
 
     
 
830       
 
     
 
     
 
 
  
 
 
2
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Quarter 2 (January 2016- March 2016) 
SL#  Supplies’ name 
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
Quantity purchased 
from market  (units) 
Total received in 
this quarter 
  I J K 
801 TB Register      
 
     
 
     
 
802 Treatment Card      
 
     
 
     
 
803 Pen      
 
     
 
     
 
804 Paper      
 
     
 
     
 
805 Box      
 
     
 
     
 
806 Soap      
 
     
 
     
 
807 Towel      
 
     
 
     
 
808 Boxes      
 
     
 
     
 
809 Tape      
 
     
 
     
 
810 Raincoat      
 
     
 
     
 
811 Torch light      
 
     
 
     
 
812 Umbrella      
 
     
 
     
 
813 Drug Baskets      
 
     
 
     
 
814 Kit Bag      
 
     
 
     
 
815 Poster      
 
     
 
     
 
816 Sticker      
 
     
 
     
 
817 Leaflet      
 
     
 
     
 
818 Flip chart      
 
     
 
     
 
819 Flash Chart      
 
     
 
     
 
820 Brochure      
 
     
 
     
 
  
 
 
2
8
7
 
821       
 
     
 
     
 
822       
 
     
 
     
 
823       
 
     
 
     
 
824       
 
     
 
     
 
825       
 
     
 
     
 
826       
 
     
 
     
 
827       
 
     
 
     
 
828       
 
     
 
     
 
829       
 
     
 
     
 
830       
 
     
 
     
 
 
Quarter 4 (October 2015- December 2015) 
SL#  Supplies’ name 
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
Quantity purchased 
from market  (units) 
Total received in 
this quarter 
  L M N 
801 TB Register      
 
     
 
     
 
802 Treatment Card      
 
     
 
     
 
803 Pen      
 
     
 
     
 
804 Paper      
 
     
 
     
 
805 Box      
 
     
 
     
 
806 Soap      
 
     
 
     
 
807 Towel      
 
     
 
     
 
808 Boxes      
 
     
 
     
 
809 Tape      
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810 Raincoat      
 
     
 
     
 
811 Torch light      
 
     
 
     
 
812 Umbrella      
 
     
 
     
 
813 Drug Baskets      
 
     
 
     
 
814 Kit Bag      
 
     
 
     
 
815 Poster      
 
     
 
     
 
816 Sticker      
 
     
 
     
 
817 Leaflet      
 
     
 
     
 
818 Flip chart      
 
     
 
     
 
819 Flash Chart      
 
     
 
     
 
820 Brochure      
 
     
 
     
 
821       
 
     
 
     
 
822       
 
     
 
     
 
823       
 
     
 
     
 
824       
 
     
 
     
 
825       
 
     
 
     
 
826       
 
     
 
     
 
827       
 
     
 
     
 
828       
 
     
 
     
 
829       
 
     
 
     
 
830       
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Section 9.0 Other Capital Items 
Number of Items used by the facility  
SL# Capital Items 
Quantity 
(Unit) 
Quantity 
received from 
National TB 
Control Program 
(NTP)  (units) 
Quantity 
purchased from 
market  (units) 
Total is being 
used 
 
Life time  
(In Years) Market price of item per unit 
  A B C D E F 
901 Microscope     
 
   
 
   
 
   
 
     
 
902 GeneXpert     
 
   
 
   
 
   
 
     
 
903 Weight Scale     
 
   
 
   
 
   
 
     
 
904 Signboard     
 
   
 
   
 
   
 
     
 
905 Computer     
 
   
 
   
 
   
 
     
 
906 Printer     
 
   
 
   
 
   
 
     
 
907 Smart Phone     
 
   
 
   
 
   
 
     
 
908 App development     
 
   
 
   
 
   
 
     
 
909 Motor Cycle     
 
   
 
   
 
   
 
     
 
910 Bicycle     
 
   
 
   
 
   
 
     
 
911 Car     
 
   
 
   
 
   
 
     
 
912 Ambulance     
 
   
 
   
 
   
 
     
 
913      
 
   
 
   
 
   
 
     
 
914      
 
   
 
   
 
   
 
     
 
915      
 
   
 
   
 
   
 
     
 
916      
 
   
 
   
 
   
 
     
 
917      
 
   
 
   
 
   
 
     
 
918      
 
   
 
   
 
   
 
     
 
919      
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Section 10.  Other Costs 
Section 10.1 Cost of Supervision (facility supervisory visits conducted in last year (October 2015-September 2016)  
SL # 
Title of person 
conducting 
supervisory visit 
Number of 
visits in 
last year 
(Oct 2015-
Sep 2016) 
Duration of visit 
(total for all visits 
in days) 
Per Diem (total) Travel expenses (total) Other expenses 
What % of 
costs paid by 
facility? 
 A B C D E F H 
1001    
 
   
 
    
 
    
 
   
 
   
 
1002    
 
   
 
    
 
    
 
   
 
   
 
1003    
 
   
 
    
 
    
 
   
 
   
 
1004    
 
   
 
    
 
    
 
   
 
   
 
Section 10.2 Travel cost for Drug /Attending Meeting/Training  
SL # 
Title of person 
conducting 
travel 
Number 
of travel 
in last 
year (Oct 
2015-Sep 
2016) 
Purpose of the 
travel 
(Use Code 
from below)^ 
Duration of 
visit (total for 
all visits in 
days) 
Per Diem (total) 
Travel expenses 
(total) 
Other 
expenses 
What % of 
costs paid by 
facility? 
 A B C D E F H I 
1005    
 
    
 
    
 
    
 
   
 
   
 
1006    
 
    
 
    
 
    
 
   
 
   
 
1007    
 
    
 
    
 
    
 
   
 
   
 
1008    
 
    
 
    
 
    
 
   
 
   
 
 ^Code: 1. Receiving drug 2. Attending Meetings 3. Training 4. Others (Please specify) 
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Section 10.3 Cost of Other Activities 
No Questions and Filters Coding categories Record Response Skip 
1009 
Was Health education on TB 
organized by the DOTS center?  
Yes………………………………….1 
No………………..…………………2 
    
 
If 2  
1011 
1010 
If Health education on TB was 
organized, How much money was paid 
for this activity in last year (October 
2015-September 2016)? 
IF THIS ACTIVITY WAS NOT 
ORGANIZED AND/OR NO MONEY 
WAS PAID, RECORD “00000” 
 
Taka      
 
 
1011 
Was DOTS committee meeting 
organized by the DOTS center? 
Yes………………………………….1 
No………………..…………………2 
    
 
If 2  
1013 
1012 
If DOTS committee meeting was 
organized, How much money was paid 
for this activity in last year (October 
2015-September 2016)? 
IF THIS ACTIVITY WAS NOT 
ORGANIZED AND/OR NO MONEY 
WAS PAID, RECORD “00000” 
 
Taka      
 
 
1013 
Were Contact Tracing activities 
organized by the DOTS center? 
Yes………………………………….1 
No………………..…………………2 
    
 
If 2  
1015 
1014 
If Contact Tracing activities were 
organized, How much money was paid 
for this activity in last year (October 
2015-September 2016)? 
IF THIS ACTIVITY WAS NOT 
ORGANIZED AND/OR NO MONEY 
WAS PAID, RECORD “00000” 
 
Taka      
 
 
1015 
Were Refresher training activities 
organized by the DOTS center? 
Yes………………………………….1 
No………………..…………………2 
    
 
If 2  
1017 
1016 
If Refresher training activities were 
organized, How much money was paid 
for this activity in last year (October 
2015-September 2016)? 
IF THIS ACTIVITY WAS NOT 
ORGANIZED AND/OR NO MONEY 
WAS PAID, RECORD “00000” 
 
Taka      
 
 
1017 
Were Other meetings organized by the 
DOTS center? 
Yes………………………………….1 
No………………..…………………2 
    
 
If 2  
1019 
1018 
If Other meetings were organized, 
How much money was paid for this 
activity in last year (October 2015-
September 2016)? 
IF THIS ACTIVITY WAS NOT 
ORGANIZED AND/OR NO MONEY 
WAS PAID, RECORD “00000” 
 
Taka      
 
 
1019 
Were Incentive payments were 
provided to the providers by the 
DOTS center? 
Yes………………………………….1 
No………………..…………………2 
    
 
If 2  
1021 
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1020 
If incentive payments were given to 
the providers, How much money was 
paid for this activity in last year 
(October 2015-September 2016)? 
IF THIS PAYMENT WAS NOT MADE 
AND/OR NO MONEY WAS PAID, 
RECORD “00000” 
 
Taka      
 
 
1021 
Were Incentive payments were 
provided to the patients by the DOTS 
center? 
Yes………………………………….1 
No………………..…………………2 
    
 
If 2  
1023 
1022 
If incentive payments were given to 
the patients, How much money was 
paid for this activity in last year 
(October 2015-September 2016)? 
IF THIS PAYMENT WAS NOT MADE 
AND/OR NO MONEY WAS PAID, 
RECORD “00000” 
 
Taka      
 
 
1023 
Were Incentive payments were 
provided to the community members 
by the DOTS center? 
Yes………………………………….1 
No………………..…………………2 
    
 
If 2  
END 
1024 
If incentive payments were given to 
the community members, How much 
money was paid for this activity in last 
year (October 2015-September 2016)? 
IF THIS PAYMENT WAS NOT MADE 
AND/OR NO MONEY WAS PAID, 
RECORD “00000” 
 
Taka      
 
 
 
Thank you for your cooperation! Is there anything you would like to ask or say? 
 
 
 
 
Comments by Interviewer: 
 
 
 
 
Date, Signature by Interviewer: 
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APPENDIX E – PROVIDER QUESTIONNAIRE (MDR-TB) 
IDENTIFICATION 
 
DIVISION _____________________________________________________ 
 
DISTRICT________________________________________________________________ 
 
UPAZILA   _________________________________________________ 
 
NAME OF THE FACILITY_________________________________________ 
 
TYPE OF THE FACILITY___________________________________________ 
(NIDCH =01, District Chest Hospital =02, Damien Foundation Hospital =03, Other=04, Please Specify) 
 
DRUG REGIMEN FOLLOWED__________________________ 
(21 Month Regimen=1, 9 Month Regimen=02) 
 
NAME OF THE MANAGER____________________________________ 
 
 
LOCATION OF FACILITY: RURAL=1, URBAN=2 
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INTERVIEWER VISITS 
 1 2 3 FINAL VISIT 
 
DATE 
           
INTERVIEWER’S NAME & 
CODE 
   CODE 
 
 
RESULT CODE* 
   RESULT CODE 
NEXT VISIT:         DATE     
TOTAL NO. OF VISITS 
                             TIME    
*RESULT CODES: 
 01 COMPLETED     
 02 NOT AVAILABLE 
03 POSTPONED  
  
04 REFUSED  
05 PARTLY COMPLETED 
96 OTHER_________________ 
                          (SPECIFY)  
SUPERVISOR FIELD EDITOR OFFICE EDITOR KEYED BY 
 
NAME____________________  
 
DATE _________________ 
 
 
NAME___________________  
 
DATE _________________ 
 
NAME____________ 
 
DATE ______________ 
 
NAME_________  
 
DATE __________ 
Section 1: Number of Personnel, their salary, and contribution to the MDR-TB Control Program 
Collect data based on each staff working on the day of data collection during day-shift (9:00am- 5:00pm). This table is for collecting information on TB clinics 
open on day of the interview.  
USE DECIMAL POINTS TO INDICATE PART-TIME WORK. FOR EXAMPLE, IF AN INDIVIDUAL WORKS IN TWO CLINICS, RECORD 0.5 FOR 
THIS PERSON IN BOTH 
 A  B C D E F G H 
SL# 
DESIGNATION 
Number 
Employed Monthly 
Salary 
Monthly 
Benefits 
TA/DA Overtime 
Incentive 
Payment 
Total 
% 
involvement 
with TB 
program 
101 Professor    
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
102 
Associate 
Professor 
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103 
Assistant 
Professor 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
104 Consultant     
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
105 Registrar    
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
106 
Assistant 
Registrar 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
107 Medical Officer     
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
108 HMO    
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
109 Staff Nurse    
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
110 
Program 
Organizer 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
111 
Medical 
Technologist 
(Laboratory) 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
112 Health Inspector    
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
113 
Assistant Health 
Inspector 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
114 
Family Planning 
Inspector 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
115 
Health Assistant 
(HA) 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
116 
Medical 
Assistant (MA) 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
117 
NGO 
Community 
Health Workers 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
118 
Leprosy and TB 
Conrol Assistant 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
119 
Statistical 
Assistant 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
120 
Gene Xpert 
Technician 
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121 
Community 
Health Worker 
(CHW)  
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
122 
 
 
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
123 
 
 
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
124 
 
 
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
125 
 
 
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
126 
 
 
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
127 
 
 
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
128 
 
 
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
129  
 
   
 
     
 
     
 
     
 
     
 
     
 
     
 
   
 
130  
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Section 2.0 Caseload (Number of New Patients Diagnosed, Number of Patients treated) last year (October 2015-September 
2016)  
 
PLEASE COMPLETE THIS TABLE FROM QUARTERLY REPORT ON DR TB CASE REGISTRATION (FORM DR TB 08) 
Sl.  Quarter I Quarter II Quarter III Quarter IV 
 M=Male 
F=Female 
M F Total M F Total M F Total M F Total 
  A B C D E F G H I J K L 
201 MDR             
202 XDR             
203 RR             
204 Other DR             
205 Total (Confirmed 
DR TB) 
            
206 Presumptive DR 
TB 
            
207 Grand Total             
 
PLEASE COMPLETE THIS TABLE FROM QUARTERLY REPORT ON DR TB CASE REGISTRATION (FORM DR TB 08) 
Sl. Patient registered in DR TB Register Quarter I Quarter II Quarter III Quarter IV 
 Confirmed DR TB A B C D 
208 New     
209 Failure after CAT I     
210 Failure after CAT II     
211 Relapse after CAT II     
212 Relapse after CAT I     
213 Treatment after lost to follow up CAT II     
214 Treatment after lost to follow up CAT I     
215 Delayed Converters CAT II     
216 Delayed Converters CAT I     
217 Close Contact of DR TB with S/S     
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218 Total     
 Pulmonary Diagnosed     
219 New     
220 Previously treated     
221 Unknown TB treatment history     
 Extrapulmonary     
222 New     
223 Previously treated     
224 Unknown TB treatment history     
225 Total     
 Grand Total     
 
Section 3.0 Xpert MTB/RIF Result  
Please enumerate the number of MDR-TB patients detected last year (October 2015-September 2016) USINF DR TB FORM 10A 
Sl. MDR-TB Patient Referral Month 
  1 2 3 4 5 6 7 8 9 10 11 12 
  A B C D E F G H I J K L 
301  Number of total presumptive DR VTB cases tested             
302 Number of MTB detected Rif resistance not detected (T)             
303 Number of MTB detected Rif resistance detected (RR)             
304 Number of MTB detected Rif resistance indeterminate (TI)             
305 Number of MTB not detected (N)             
306 Number of invalid/no result/ error (I)             
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Section 4.0 Treatment outcomes (MDR-TB Patients got treatment 24 to 36 months earlier) 
 
PLEASE COMPLETE THIS TABLE FOR MDR TB PATIENTS GOT TREATMENT 24 TO 36 MONTHS EARLIER USING DR TB 
FORM 09 
Quarter  |__|__|  Year  |__|__| 
Sl. Patient Group Total 
number 
of DR TB 
patients 
registered 
during 
the 
quarter 
Number 
of 
confirmed 
DR TB 
patients 
registered 
during 
the 
quarter 
Cured Treatment 
Completed 
Failure Died Lost to 
follow 
up 
Transferred 
Out 
Still on 
Treatment 
Not 
Evaluated 
Total 
  A B C D E F G H I J K 
401 MDR            
402 XDR            
403 RR            
404 Other            
405 Presumptive 
DR TB 
           
406 Total            
 
TREATMENT OUTCOME ACCORDING TO THE REGISTRATION GROUP 
Sl. Patient Group Total 
number 
of DR TB 
patients 
registered 
during 
the 
quarter 
Number 
of 
confirmed 
DR TB 
patients 
registered 
during 
the 
quarter 
Cured Treatment 
Completed 
Failure Died Lost to 
follow 
up 
Transferred 
Out 
Still on 
Treatment 
Not 
Evaluated 
Total 
  A B C D E F G H I J K 
   
 
 
3
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407 New            
408 Failure after CAT 
I 
           
409 Failure after CAT 
II 
           
410 Relapse after 
CAT II 
           
411 Relapse after 
CAT I 
           
412 Treatment after 
lost to follow up 
CAT II 
           
413 Treatment after 
lost to follow up 
CAT I 
           
414 Delayed 
Converters CAT 
II 
           
415 Delayed 
Converters CAT 
I 
           
416 Close Contact of 
DR TB with S/S 
           
 Pulmonary 
Diagnosed 
           
417 New            
418 Previously 
treated 
           
419 Unknown TB 
treatment history 
           
 Extrapulmonary            
420 New            
421 Previously 
treated 
           
422 Unknown TB 
treatment history 
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PLEASE COMPLETE THIS TABLE FOR MDR TB PATIENTS GOT TREATMENT 24 TO 36 MONTHS EARLIER USING DR TB 
FORM 09 
Quarter  |__|__|  Year  |__|__| 
Sl. Patient Group Total 
number 
of DR TB 
patients 
registered 
during 
the 
quarter 
Number 
of 
confirmed 
DR TB 
patients 
registered 
during 
the 
quarter 
Cured Treatment 
Completed 
Failure Died Lost to 
follow 
up 
Transferred 
Out 
Still on 
Treatment 
Not 
Evaluated 
Total 
  A B C D E F G H I J K 
401 MDR            
402 XDR            
403 RR            
404 Other            
405 Presumptive 
DR TB 
           
406 Total            
 
TREATMENT OUTCOME ACCORDING TO THE REGISTRATION GROUP 
Sl. Patient Group Total 
number 
of DR TB 
patients 
registered 
during 
the 
quarter 
Number 
of 
confirmed 
DR TB 
patients 
registered 
during 
the 
quarter 
Cured Treatment 
Completed 
Failure Died Lost to 
follow 
up 
Transferred 
Out 
Still on 
Treatment 
Not 
Evaluated 
Total 
  A B C D E F G H I J K 
407 New            
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408 Failure after CAT 
I 
           
409 Failure after CAT 
II 
           
410 Relapse after 
CAT II 
           
411 Relapse after 
CAT I 
           
412 Treatment after 
lost to follow up 
CAT II 
           
413 Treatment after 
lost to follow up 
CAT I 
           
414 Delayed 
Converters CAT 
II 
           
415 Delayed 
Converters CAT 
I 
           
416 Close Contact of 
DR TB with S/S 
           
 Pulmonary 
Diagnosed 
           
417 New            
418 Previously 
treated 
           
419 Unknown TB 
treatment history 
           
 Extrapulmonary            
420 New            
421 Previously 
treated 
           
422 Unknown TB 
treatment history 
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PLEASE COMPLETE THIS TABLE FOR MDR TB PATIENTS GOT TREATMENT 24 TO 36 MONTHS EARLIER USING DR TB 
FORM 09 
Quarter  |__|__|  Year  |__|__| 
Sl. Patient Group Total 
number 
of DR TB 
patients 
registered 
during 
the 
quarter 
Number 
of 
confirmed 
DR TB 
patients 
registered 
during 
the 
quarter 
Cured Treatment 
Completed 
Failure Died Lost to 
follow 
up 
Transferred 
Out 
Still on 
Treatment 
Not 
Evaluated 
Total 
  A B C D E F G H I J K 
401 MDR            
402 XDR            
403 RR            
404 Other            
405 Presumptive 
DR TB 
           
406 Total            
 
TREATMENT OUTCOME ACCORDING TO THE REGISTRATION GROUP 
Sl. Patient Group Total 
number 
of DR TB 
patients 
registered 
during 
the 
quarter 
Number 
of 
confirmed 
DR TB 
patients 
registered 
during 
the 
quarter 
Cured Treatment 
Completed 
Failure Died Lost to 
follow 
up 
Transferred 
Out 
Still on 
Treatment 
Not 
Evaluated 
Total 
  A B C D E F G H I J K 
407 New            
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408 Failure after CAT 
I 
           
409 Failure after CAT 
II 
           
410 Relapse after 
CAT II 
           
411 Relapse after 
CAT I 
           
412 Treatment after 
lost to follow up 
CAT II 
           
413 Treatment after 
lost to follow up 
CAT I 
           
414 Delayed 
Converters CAT 
II 
           
415 Delayed 
Converters CAT 
I 
           
416 Close Contact of 
DR TB with S/S 
           
 Pulmonary 
Diagnosed 
           
417 New            
418 Previously 
treated 
           
419 Unknown TB 
treatment history 
           
 Extrapulmonary            
420 New            
421 Previously 
treated 
           
422 Unknown TB 
treatment history 
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PLEASE COMPLETE THIS TABLE FOR MDR TB PATIENTS GOT TREATMENT 24 TO 36 MONTHS EARLIER USING DR TB 
FORM 09 
Quarter  |__|__|  Year  |__|__| 
Sl. Patient Group Total 
number 
of DR TB 
patients 
registered 
during 
the 
quarter 
Number 
of 
confirmed 
DR TB 
patients 
registered 
during 
the 
quarter 
Cured Treatment 
Completed 
Failure Died Lost to 
follow 
up 
Transferred 
Out 
Still on 
Treatment 
Not 
Evaluated 
Total 
  A B C D E F G H I J K 
401 MDR            
402 XDR            
403 RR            
404 Other            
405 Presumptive 
DR TB 
           
406 Total            
 
TREATMENT OUTCOME ACCORDING TO THE REGISTRATION GROUP 
Sl. Patient Group Total 
number 
of DR TB 
patients 
registered 
during 
the 
quarter 
Number 
of 
confirmed 
DR TB 
patients 
registered 
during 
the 
quarter 
Cured Treatment 
Completed 
Failure Died Lost to 
follow 
up 
Transferred 
Out 
Still on 
Treatment 
Not 
Evaluated 
Total 
  A B C D E F G H I J K 
407 New            
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408 Failure after CAT 
I 
           
409 Failure after CAT 
II 
           
410 Relapse after 
CAT II 
           
411 Relapse after 
CAT I 
           
412 Treatment after 
lost to follow up 
CAT II 
           
413 Treatment after 
lost to follow up 
CAT I 
           
414 Delayed 
Converters CAT 
II 
           
415 Delayed 
Converters CAT 
I 
           
416 Close Contact of 
DR TB with S/S 
           
 Pulmonary 
Diagnosed 
           
417 New            
418 Previously 
treated 
           
419 Unknown TB 
treatment history 
           
 Extrapulmonary            
420 New            
421 Previously 
treated 
           
422 Unknown TB 
treatment history 
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Section 5.0 Quantity and Cost of Drugs  
Number of TB Drugs received by the facility last year (January 2016- December 2016-PLEASE CONSULT LAST TWO REQUISITION 
FORM DR TB-09) 
Quarter  |__|__|  Year  |__|__| 
SL# Drug name 
Quantity 
measures  
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
CAT I Patients 
 
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
CAT II Patients 
 
Total received in 
this quarter  
Market price of drugs per 
unit 
  A B C D E 
501 
Pyrazinamide 500 mg 
Tab 
      
 
     
 
     
 
   .  
 
502 
Kanamycin 1 gm Vial 
(Only for IP) 
      
 
     
 
     
 
   .  
 
503 
Ethionamide 250 mg 
Tab 
      
 
     
 
     
 
   .  
 
504 Cycloserine 250 mg Tab       
 
     
 
     
 
   .  
 
505 Ofloxacin 400 mg Tab       
 
     
 
     
 
   .  
 
506 
Levofloxacin 250 mg 
Tab 
      
 
     
 
     
 
   .  
 
507 
Moxifloxacin 400 mg 
Tab 
      
 
     
 
     
 
   .  
 
508 
Clofazimine (Cfz 50 mg 
Tab) 
      
 
     
 
     
 
   .  
 
509 
Amox/Clav 500/125 mg 
Tab 
      
 
     
 
     
 
   .  
 
510 Linezolid (Lzd)       
 
     
 
     
 
   .  
 
511 
Capreomycin 1 gm Vial 
(Only for IP) 
      
 
     
 
     
 
   .  
 
512 PAS 4 gm sachet       
 
     
 
     
 
   .  
 
513 Omeprazole 20 mg Tab       
 
     
 
     
 
   .  
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514 
Domperidone 10 mg 
Tab 
      
 
     
 
     
 
   .  
 
515 Pyridoxine 25 mg Tab       
 
     
 
     
 
   .  
 
516 Multivitamin        
 
     
 
     
 
   .  
 
517 Alprazolam 0.5 mg       
 
     
 
     
 
   .  
 
518        
 
     
 
     
 
   .  
 
519        
 
     
 
     
 
   .  
 
520        
 
     
 
     
 
   .  
 
521       
522        
 
     
 
     
 
   .  
 
523 Others       
 
     
 
     
 
   .  
 
524 Syringe, 5 cc       
 
     
 
     
 
   .  
 
525 Distilled Water, 3 cc       
 
     
 
     
 
   .  
 
526        
 
     
 
     
 
   .  
 
527        
 
     
 
     
 
   .  
 
528        
 
     
 
     
 
   .  
 
529        
 
     
 
     
 
   .  
 
530        
 
     
 
     
 
   .  
 
531        
 
     
 
     
 
   .  
 
532        
 
     
 
     
 
   .  
 
533        
 
     
 
     
 
   .  
 
534        
 
     
 
     
 
   .  
 
535        
 
     
 
     
 
   .  
 
 
Quarter  |__|__|  Year  |__|__| 
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SL# Drug name 
Quantity received 
from National TB 
Control Program 
(NTP) (units) for 
CAT I Patients 
 
Quantity received from 
National TB Control 
Program (NTP) (units) 
for 
CAT II Patients 
 
Total received in 
this quarter  
  E F G 
501 
Pyrazinamide 500 mg 
Tab 
     
 
     
 
     
 
502 
Kanamycin 1 gm Vial 
(Only for IP) 
     
 
     
 
     
 
503 
Ethionamide 250 mg 
Tab 
     
 
     
 
     
 
504 Cycloserine 250 mg Tab      
 
     
 
     
 
505 Ofloxacin 400 mg Tab      
 
     
 
     
 
506 
Levofloxacin 250 mg 
Tab 
     
 
     
 
     
 
507 
Moxifloxacin 400 mg 
Tab 
     
 
     
 
     
 
508 
Clofazimine (Cfz 50 mg 
Tab) 
     
 
     
 
     
 
509 
Amox/Clav 500/125 mg 
Tab 
     
 
     
 
     
 
510 Linezolid (Lzd)      
 
     
 
     
 
511 
Capreomycin 1 gm Vial 
(Only for IP) 
     
 
     
 
     
 
512 PAS 4 gm sachet      
 
     
 
     
 
513 Omeprazole 20 mg Tab      
 
     
 
     
 
514 
Domperidone 10 mg 
Tab 
     
 
     
 
     
 
515 Pyridoxine 25 mg Tab      
 
     
 
     
 
516 Multivitamin       
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517 Alprazolam 0.5 mg      
 
     
 
     
 
518       
 
     
 
     
 
519       
 
     
 
     
 
520       
 
     
 
     
 
521       
 
     
 
     
 
522       
 
     
 
     
 
523 Others      
 
     
 
     
 
524 Syringe, 5 cc      
 
     
 
     
 
525 Distilled Water, 3 cc      
 
     
 
     
 
526       
 
     
 
     
 
527       
 
     
 
     
 
528       
 
     
 
     
 
529       
 
     
 
     
 
530       
 
     
 
     
 
531       
 
     
 
     
 
532       
 
     
 
     
 
533       
 
     
 
     
 
534       
 
     
 
     
 
535       
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Quarter  |__|__|  Year  |__|__| 
SL# Drug name 
Quantity received 
from National TB 
Control Program 
(NTP) (units) for 
CAT I Patients 
 
Quantity received from 
National TB Control 
Program (NTP) (units) 
for 
CAT II Patients 
 
Total received in 
this quarter  
  H I J 
501 
Pyrazinamide 500 mg 
Tab 
     
 
     
 
     
 
502 
Kanamycin 1 gm Vial 
(Only for IP) 
     
 
     
 
     
 
503 
Ethionamide 250 mg 
Tab 
     
 
     
 
     
 
504 Cycloserine 250 mg Tab      
 
     
 
     
 
505 Ofloxacin 400 mg Tab      
 
     
 
     
 
506 
Levofloxacin 250 mg 
Tab 
     
 
     
 
     
 
507 
Moxifloxacin 400 mg 
Tab 
     
 
     
 
     
 
508 
Clofazimine (Cfz 50 mg 
Tab) 
     
 
     
 
     
 
509 
Amox/Clav 500/125 mg 
Tab 
     
 
     
 
     
 
510 Linezolid (Lzd)      
 
     
 
     
 
511 
Capreomycin 1 gm Vial 
(Only for IP) 
     
 
     
 
     
 
512 PAS 4 gm sachet      
 
     
 
     
 
513 Omeprazole 20 mg Tab      
 
     
 
     
 
514 
Domperidone 10 mg 
Tab 
     
 
     
 
     
 
515 Pyridoxine 25 mg Tab      
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516 Multivitamin       
 
     
 
     
 
517 Alprazolam 0.5 mg      
 
     
 
     
 
518       
 
     
 
     
 
519       
 
     
 
     
 
520       
 
     
 
     
 
521       
 
     
 
     
 
522       
 
     
 
     
 
523 Others      
 
     
 
     
 
524 Syringe, 5 cc      
 
     
 
     
 
525 Distilled Water, 3 cc      
 
     
 
     
 
526       
 
     
 
     
 
527       
 
     
 
     
 
528       
 
     
 
     
 
529       
 
     
 
     
 
530       
 
     
 
     
 
531       
 
     
 
     
 
532       
 
     
 
     
 
533       
 
     
 
     
 
534       
 
     
 
     
 
535       
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Quarter  |__|__|  Year  |__|__| 
SL# Drug name 
Quantity received 
from National TB 
Control Program 
(NTP) (units) for 
CAT I Patients 
 
Quantity received from 
National TB Control 
Program (NTP) (units) 
for 
CAT II Patients 
 
Total received in 
this quarter  
  K L M 
501 
Pyrazinamide 500 mg 
Tab 
     
 
     
 
     
 
502 
Kanamycin 1 gm Vial 
(Only for IP) 
     
 
     
 
     
 
503 
Ethionamide 250 mg 
Tab 
     
 
     
 
     
 
504 Cycloserine 250 mg Tab      
 
     
 
     
 
505 Ofloxacin 400 mg Tab      
 
     
 
     
 
506 
Levofloxacin 250 mg 
Tab 
     
 
     
 
     
 
507 
Moxifloxacin 400 mg 
Tab 
     
 
     
 
     
 
508 
Clofazimine (Cfz 50 mg 
Tab) 
     
 
     
 
     
 
509 
Amox/Clav 500/125 mg 
Tab 
     
 
     
 
     
 
510 Linezolid (Lzd)      
 
     
 
     
 
511 
Capreomycin 1 gm Vial 
(Only for IP) 
     
 
     
 
     
 
512 PAS 4 gm sachet      
 
     
 
     
 
513 Omeprazole 20 mg Tab      
 
     
 
     
 
514 
Domperidone 10 mg 
Tab 
     
 
     
 
     
 
515 Pyridoxine 25 mg Tab      
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516 Multivitamin       
 
     
 
     
 
517 Alprazolam 0.5 mg      
 
     
 
     
 
518       
 
     
 
     
 
519       
 
     
 
     
 
520       
 
     
 
     
 
521       
 
     
 
     
 
522       
 
     
 
     
 
523 Others      
 
     
 
     
 
524 Syringe, 5 cc      
 
     
 
     
 
525 Distilled Water, 3 cc      
 
     
 
     
 
526       
 
     
 
     
 
527       
 
     
 
     
 
528       
 
     
 
     
 
529       
 
     
 
     
 
530       
 
     
 
     
 
531       
 
     
 
     
 
532       
 
     
 
     
 
533       
 
     
 
     
 
534       
 
     
 
     
 
535       
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Section 7.0 Quantity and Cost of Laboratory Reagents/Supplies/Equipment 
Number of Laboratory reagents/ supplies received by the facility last year (October 2015-September 2016- Laboratory Request Form) 
Quarter 4 (July 2016- September 2016) 
SL# 
Reagent/Lab supplies’ 
name 
Quantity 
measures 
per 
patient  
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
Quantity purchased 
from market  (units) 
Total received in 
this quarter 
Market price of reagents 
per unit 
  A B C D E 
601 Basic fuchsin 1 gm/sm+      
 
     
 
     
 
   .  
 
602 Phenol crystals 5 gm/sm+      
 
     
 
     
 
   .  
 
603 
Methanol (or 
denatured ethanol) 
10 ml/sm+      
 
     
 
     
 
   .  
 
604 Methylene Blue 
0.1 
gm/sm+ 
     
 
     
 
     
 
   .  
 
605 Sulphuric Acid conc. 33 ml/sm+      
 
     
 
     
 
   .  
 
606 Burning Spirit 50 ml/sm+      
 
     
 
     
 
   .  
 
607 Slides 
36 
pcs/sm+ 
     
 
     
 
     
 
   .  
 
608 Sputum Containers 
36 
pcs/sm+ 
     
 
     
 
     
 
   .  
 
609 Bamboo Sticks 
36 
pcs/sm+ 
     
 
     
 
     
 
   .  
 
610 Immersion Oil 2 ml/sm+      
 
     
 
     
 
   .  
 
611 Xylene 25 ml/sm+      
 
     
 
     
 
   .  
 
612 Toilet Paper Rolls 
3 
rolls/clinic 
     
 
     
 
     
 
   .  
 
613 Filter Paper Pieces 
20 pcs/ 
clinic 
     
 
     
 
     
 
   .  
 
614 Culture Media (Solid)       
 
     
 
     
 
   .  
 
615 
Culture Media 
(Liquid) 
      
 
     
 
     
 
   .  
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616        
 
     
 
     
 
   .  
 
617        
 
     
 
     
 
   .  
 
618        
 
     
 
     
 
   .  
 
619        
 
     
 
     
 
   .  
 
620        
 
     
 
     
 
   .  
 
621        
 
     
 
     
 
   .  
 
622        
 
     
 
     
 
   .  
 
            Quarter 3 (April 2016- June 2016) 
 
SL# 
Reagent/Lab supplies’ 
name 
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
Quantity purchased 
from market  (units) 
Total received in 
this quarter  
  F G H 
601 Basic fuchsin      
 
     
 
     
 
602 Phenol crystals      
 
     
 
     
 
603 
Methanol (or 
denatured ethanol) 
     
 
     
 
     
 
604 Methylene Blue      
 
     
 
     
 
605 Sulphuric Acid conc.      
 
     
 
     
 
606 Burning Spirit      
 
     
 
     
 
607 Slides      
 
     
 
     
 
608 Sputum Containers      
 
     
 
     
 
609 Bamboo Sticks      
 
     
 
     
 
610 Immersion Oil      
 
     
 
     
 
611 Xylene      
 
     
 
     
 
612 Toilet Paper Rolls      
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613 Filter Paper Pieces      
 
     
 
     
 
614       
 
     
 
     
 
615       
 
     
 
     
 
616       
 
     
 
     
 
617       
 
     
 
     
 
618       
 
     
 
     
 
619       
 
     
 
     
 
620       
 
     
 
     
 
621       
 
     
 
     
 
622       
 
     
 
     
 
 
Quarter 2 (January 2016- March 2016) 
SL# 
Reagent/Lab supplies’ 
name 
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
Quantity purchased 
from market  (units) 
Total received in 
this quarter 
  I J K 
601 Basic fuchsin      
 
     
 
     
 
602 Phenol crystals      
 
     
 
     
 
603 
Methanol (or 
denatured ethanol) 
     
 
     
 
     
 
604 Methylene Blue      
 
     
 
     
 
605 Sulphuric Acid conc.      
 
     
 
     
 
606 Burning Spirit      
 
     
 
     
 
607 Slides      
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608 Sputum Containers      
 
     
 
     
 
609 Bamboo Sticks      
 
     
 
     
 
610 Immersion Oil      
 
     
 
     
 
611 Xylene      
 
     
 
     
 
612 Toilet Paper Rolls      
 
     
 
     
 
613 Filter Paper Pieces      
 
     
 
     
 
614       
 
     
 
     
 
615       
 
     
 
     
 
616       
 
     
 
     
 
617       
 
     
 
     
 
618       
 
     
 
     
 
619       
 
     
 
     
 
620       
 
     
 
     
 
621       
 
     
 
     
 
622       
 
     
 
     
 
 
Quarter 1 (October 2016- December 2016) 
 
SL# 
Reagent/Lab supplies’ 
name 
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
Quantity purchased 
from market  (units) 
Total 
received in 
this 
quarter 
  L M N 
601 Basic fuchsin      
 
     
 
 
602 Phenol crystals      
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603 
Methanol (or denatured 
ethanol) 
     
 
     
 
 
604 Methylene Blue      
 
     
 
 
605 Sulphuric Acid conc.      
 
     
 
 
606 Burning Spirit      
 
     
 
 
607 Slides      
 
     
 
 
608 Sputum Containers      
 
     
 
 
609 Bamboo Sticks      
 
     
 
 
610 Immersion Oil      
 
     
 
 
611 Xylene      
 
     
 
 
612 Toilet Paper Rolls      
 
     
 
 
613 Filter Paper Pieces      
 
     
 
 
614       
 
     
 
 
615       
 
     
 
 
616       
 
     
 
 
617       
 
     
 
 
618       
 
     
 
 
619       
 
     
 
 
620       
 
     
 
 
621       
 
     
 
 
622       
 
     
 
 
   
 
 
3
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Section 8.0 Cost of Other Supplies 
Number of Supplies received by the facility last year (October 2015-September 2016) 
Quarter 4 (July 2016- September 2016) 
SL#  Supplies’ name 
Quantity 
measures  
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
Quantity purchased 
from market  (units) 
Total received in 
this quarter 
Market price of supplies 
per unit 
  A B C D E 
701 TB Register       
 
     
 
     
 
   .  
 
702 Treatment Card       
 
     
 
     
 
   .  
 
703 Pen       
 
     
 
     
 
   .  
 
704 Paper       
 
     
 
     
 
   .  
 
705 Box       
 
     
 
     
 
   .  
 
706 Soap       
 
     
 
     
 
   .  
 
707 Towel       
 
     
 
     
 
   .  
 
708 Boxes       
 
     
 
     
 
   .  
 
709 Tape       
 
     
 
     
 
   .  
 
710 Raincoat       
 
     
 
     
 
   .  
 
711 Torch light       
 
     
 
     
 
   .  
 
712 Umbrella       
 
     
 
     
 
   .  
 
713 Drug Baskets       
 
     
 
     
 
   .  
 
714 Kit Bag       
 
     
 
     
 
   .  
 
715 Poster       
 
     
 
     
 
   .  
 
716 Sticker       
 
     
 
     
 
   .  
 
717 Leaflet       
 
     
 
     
 
   .  
 
718 Flip chart       
 
     
 
     
 
   .  
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719 Flash Chart       
 
     
 
     
 
   .  
 
720 Brochure       
 
     
 
     
 
   .  
 
721        
 
     
 
     
 
   .  
 
722        
 
     
 
     
 
   .  
 
723        
 
     
 
     
 
   .  
 
724        
 
     
 
     
 
   .  
 
725        
 
     
 
     
 
   .  
 
726        
 
     
 
     
 
   .  
 
727        
 
     
 
     
 
   .  
 
728        
 
     
 
     
 
   .  
 
729        
 
     
 
     
 
   .  
 
730        
 
     
 
     
 
   .  
 
 
Quarter 3 (April 2016- June 2016) 
SL#  Supplies’ name 
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
Quantity purchased 
from market  (units) 
Total received in 
this quarter 
  F G H 
701 TB Register      
 
     
 
     
 
702 Treatment Card      
 
     
 
     
 
703 Pen      
 
     
 
     
 
704 Paper      
 
     
 
     
 
705 Box      
 
     
 
     
 
706 Soap      
 
     
 
     
 
707 Towel      
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708 Boxes      
 
     
 
     
 
709 Tape      
 
     
 
     
 
710 Raincoat      
 
     
 
     
 
711 Torch light      
 
     
 
     
 
712 Umbrella      
 
     
 
     
 
713 Drug Baskets      
 
     
 
     
 
714 Kit Bag      
 
     
 
     
 
715 Poster      
 
     
 
     
 
716 Sticker      
 
     
 
     
 
717 Leaflet      
 
     
 
     
 
718 Flip chart      
 
     
 
     
 
719 Flash Chart      
 
     
 
     
 
720 Brochure      
 
     
 
     
 
721       
 
     
 
     
 
722       
 
     
 
     
 
723       
 
     
 
     
 
724       
 
     
 
     
 
725       
 
     
 
     
 
726       
 
     
 
     
 
727       
 
     
 
     
 
728       
 
     
 
     
 
729       
 
     
 
     
 
730       
 
     
 
     
 
 
   
 
 
3
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Quarter 2 (January 2016- March 2016) 
SL#  Supplies’ name 
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
Quantity purchased 
from market  (units) 
Total received in 
this quarter 
  I J K 
701 TB Register      
 
     
 
     
 
702 Treatment Card      
 
     
 
     
 
703 Pen      
 
     
 
     
 
704 Paper      
 
     
 
     
 
705 Box      
 
     
 
     
 
706 Soap      
 
     
 
     
 
707 Towel      
 
     
 
     
 
708 Boxes      
 
     
 
     
 
709 Tape      
 
     
 
     
 
710 Raincoat      
 
     
 
     
 
711 Torch light      
 
     
 
     
 
712 Umbrella      
 
     
 
     
 
713 Drug Baskets      
 
     
 
     
 
714 Kit Bag      
 
     
 
     
 
715 Poster      
 
     
 
     
 
716 Sticker      
 
     
 
     
 
717 Leaflet      
 
     
 
     
 
718 Flip chart      
 
     
 
     
 
719 Flash Chart      
 
     
 
     
 
720 Brochure      
 
     
 
     
 
   
 
 
3
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721       
 
     
 
     
 
722       
 
     
 
     
 
723       
 
     
 
     
 
724       
 
     
 
     
 
725       
 
     
 
     
 
726       
 
     
 
     
 
727       
 
     
 
     
 
728       
 
     
 
     
 
729       
 
     
 
     
 
730       
 
     
 
     
 
 
Quarter 4 (October 2015- December 2015) 
SL#  Supplies’ name 
Quantity received 
from National TB 
Control Program 
(NTP)  (units) 
Quantity purchased 
from market  (units) 
Total received in 
this quarter 
  L M N 
701 TB Register      
 
     
 
     
 
702 Treatment Card      
 
     
 
     
 
703 Pen      
 
     
 
     
 
704 Paper      
 
     
 
     
 
705 Box      
 
     
 
     
 
706 Soap      
 
     
 
     
 
707 Towel      
 
     
 
     
 
708 Boxes      
 
     
 
     
 
709 Tape      
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710 Raincoat      
 
     
 
     
 
711 Torch light      
 
     
 
     
 
712 Umbrella      
 
     
 
     
 
713 Drug Baskets      
 
     
 
     
 
714 Kit Bag      
 
     
 
     
 
715 Poster      
 
     
 
     
 
716 Sticker      
 
     
 
     
 
717 Leaflet      
 
     
 
     
 
718 Flip chart      
 
     
 
     
 
719 Flash Chart      
 
     
 
     
 
720 Brochure      
 
     
 
     
 
721       
 
     
 
     
 
722       
 
     
 
     
 
723       
 
     
 
     
 
724       
 
     
 
     
 
725       
 
     
 
     
 
726       
 
     
 
     
 
727       
 
     
 
     
 
728       
 
     
 
     
 
729       
 
     
 
     
 
730       
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Section 8.0 Other Capital Items 
Number of Items used by the facility  
SL# Capital Items 
Quantity 
(Unit) 
Quantity 
received from 
National TB 
Control Program 
(NTP)  (units) 
Quantity 
purchased from 
market  (units) 
Total is being 
used 
 
Life time  
(In Years) Market price of item per unit 
  A B C D E F 
801 Microscope     
 
   
 
   
 
   
 
     
 
802 GeneXpert     
 
   
 
   
 
   
 
     
 
803 Weight Scale     
 
   
 
   
 
   
 
     
 
804 Signboard     
 
   
 
   
 
   
 
     
 
805 Computer     
 
   
 
   
 
   
 
     
 
806 Printer     
 
   
 
   
 
   
 
     
 
807 Smart Phone     
 
   
 
   
 
   
 
     
 
808 App development     
 
   
 
   
 
   
 
     
 
809 Motor Cycle     
 
   
 
   
 
   
 
     
 
810 Bicycle     
 
   
 
   
 
   
 
     
 
811 Car     
 
   
 
   
 
   
 
     
 
812 Ambulance     
 
   
 
   
 
   
 
     
 
813 LPA     
 
   
 
   
 
   
 
     
 
814 LJ     
 
   
 
   
 
   
 
     
 
815 MGIT     
 
   
 
   
 
   
 
     
 
816      
 
   
 
   
 
   
 
     
 
817      
 
   
 
   
 
   
 
     
 
818      
 
   
 
   
 
   
 
     
 
819      
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Section 9.  Other Costs 
Section 9.1 Cost of Supervision (facility supervisory visits conducted in last year (October 2015-September 2016)  
SL # 
Title of person 
conducting 
supervisory visit 
Number of 
visits in 
last year 
(Oct 2015-
Sep 2016) 
Duration of visit 
(total for all visits 
in days) 
Per Diem (total) Travel expenses (total) Other expenses 
What % of 
costs paid by 
facility? 
 A B C D E F H 
901    
 
   
 
    
 
    
 
   
 
   
 
902    
 
   
 
    
 
    
 
   
 
   
 
903    
 
   
 
    
 
    
 
   
 
   
 
904    
 
   
 
    
 
    
 
   
 
   
 
 Section 9.2 Travel cost for Drug /Attending Meeting/Training  
SL # 
Title of person 
conducting 
travel 
Number 
of travel 
in last 
year (Oct 
2015-Sep 
2016) 
Purpose of the 
travel 
(Use Code 
from below)^ 
Duration of 
visit (total for 
all visits in 
days) 
Per Diem (total) 
Travel expenses 
(total) 
Other 
expenses 
What % of 
costs paid by 
facility? 
 A B C D E F H I 
905    
 
    
 
    
 
    
 
   
 
   
 
906    
 
    
 
    
 
    
 
   
 
   
 
907    
 
    
 
    
 
    
 
   
 
   
 
908    
 
    
 
    
 
    
 
   
 
   
 
 ^Code: 1. Receiving drug 2. Attending Meetings 3. Training 4. Others (Please specify) 
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Section 9.3 Cost of Other Activities 
No Questions and Filters Coding categories Record Response Skip 
909 
Was Health education on TB 
organized by the DOTS center?  
Yes………………………………….1 
No………………..…………………2 
    
 
If 2  
911 
910 
If Health education on TB was 
organized, How much money was paid 
for this activity in last year (October 
2015-September 2016)? 
IF THIS ACTIVITY WAS NOT 
ORGANIZED AND/OR NO MONEY 
WAS PAID, RECORD “00000” 
 
Taka      
 
 
911 
Was DOTS committee meeting 
organized by the DOTS center? 
Yes………………………………….1 
No………………..…………………2 
    
 
If 2  
913 
912 
If DOTS committee meeting was 
organized, How much money was paid 
for this activity in last year (October 
2015-September 2016)? 
IF THIS ACTIVITY WAS NOT 
ORGANIZED AND/OR NO MONEY 
WAS PAID, RECORD “00000” 
 
Taka      
 
 
913 
Were Contact Tracing activities 
organized by the DOTS center? 
Yes………………………………….1 
No………………..…………………2 
    
 
If 2  
915 
914 
If Contact Tracing activities were 
organized, How much money was paid 
for this activity in last year (October 
2015-September 2016)? 
IF THIS ACTIVITY WAS NOT 
ORGANIZED AND/OR NO MONEY 
WAS PAID, RECORD “00000” 
 
Taka      
 
 
915 
Were Refresher training activities 
organized by the DOTS center? 
Yes………………………………….1 
No………………..…………………2 
    
 
If 2  
917 
916 
If Refresher training activities were 
organized, How much money was paid 
for this activity in last year (October 
2015-September 2016)? 
IF THIS ACTIVITY WAS NOT 
ORGANIZED AND/OR NO MONEY 
WAS PAID, RECORD “00000” 
 
Taka      
 
 
917 
Were Other meetings organized by the 
DOTS center? 
Yes………………………………….1 
No………………..…………………2 
    
 
If 2  
919 
918 
If Other meetings were organized, 
How much money was paid for this 
activity in last year (October 2015-
September 2016)? 
IF THIS ACTIVITY WAS NOT 
ORGANIZED AND/OR NO MONEY 
WAS PAID, RECORD “00000” 
 
Taka      
 
 
919 
Were Incentive payments were 
provided to the providers by the 
DOTS center? 
Yes………………………………….1 
No………………..…………………2 
    
 
If 2  
921 
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920 
If incentive payments were given to 
the providers, How much money was 
paid for this activity in last year 
(October 2015-September 2016)? 
IF THIS PAYMENT WAS NOT MADE 
AND/OR NO MONEY WAS PAID, 
RECORD “00000” 
 
Taka      
 
 
921 
Were Incentive payments were 
provided to the patients by the DOTS 
center? 
Yes………………………………….1 
No………………..…………………2 
    
 
If 2  
923 
922 
If incentive payments were given to 
the patients, How much money was 
paid for this activity in last year 
(October 2015-September 2016)? 
IF THIS PAYMENT WAS NOT MADE 
AND/OR NO MONEY WAS PAID, 
RECORD “00000” 
 
Taka      
 
 
923 
Were Incentive payments were 
provided to the community members 
by the DOTS center? 
Yes………………………………….1 
No………………..…………………2 
    
 
If 2  
END 
924 
If incentive payments were given to 
the community members, How much 
money was paid for this activity in last 
year (October 2015-September 2016)? 
IF THIS PAYMENT WAS NOT MADE 
AND/OR NO MONEY WAS PAID, 
RECORD “00000” 
 
Taka      
 
 
 
 
 
Thank you for your cooperation! Is there anything you would like to ask or say? 
 
 
 
 
Comments by Interviewer: 
 
 
 
 
Date, Signature by Interviewer: 
 
